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Abstract 
Despite worldwide concern about the consumption of psychoactive substances during earlier 
development, the long-term behavioural effects of many have remained largely unexplored.  
By the mid 2000’s there was a public epidemic declared on the escalating rate of individuals 
consuming New Zealand’s form of methamphetamine (MA), called ‘P’ (short for 'pure' 
methamphetamine).  Within this environment the emergence of new unregulated psychoactive 
compounds appeared.  These were known and marketed as “legal or herbal highs’.  N-
benzylpiperazine (BZP) became the main ingredient in the legal highs and was marketed as a 
safe alternative to “P”, however there was no research to support this claim. The present study 
investigated the long-lasting effects on anxiety-like behaviour in rats, after BZP or MA 
administration during early to late adolescent development, examining variables: drug; age; 
sex; dose; and whether differences remained over time. Rats were either administered saline, 
BZP (5.0, 10.0, or 20.0 mg/kg) or MA (0.5, 1.0, 2.0 mg/kg) at three different ages of 
adolescence (Post Natal Day [PND]: PND31-40, PND41-50, PND51-60) for a period of ten 
days.  After a thirty day wash-out period rats were tested in four different rodent tests of 
anxiety: Y-maze, Elevated Plus Maze, Light/dark Emergence Box and a Social Interaction 
Test. Behavioural testing occurred again at PND 120 and PND 200 to assess behavioural 
change over time.  Daily BZP or MA treatment across the three different ages of adolescence 
increased anxiety-like behaviours in all behavioural measures and this was maintained over 
time.  In summary, rats treated with BZP or MA during PND31-40 and PND41-50 displayed 
more anxiety-related behaviour comparative to control rats and this effect increased with drug 
dose, primarily for male-treated rats. The general pattern of results was more complex for 
PND51-60 treated rats, with MA-treated female rats displaying increased anxiety-like 
behaviours as the dose of MA increased and rats treated with the highest dose of BZP 
displaying decreased emotionality.  There were more similarities between BZP and MA than 
differences, yet adolescent BZP treatment appeared to have greater impact on adult behaviour 
than adolescent MA treatment.  Additionally, male rats exposed to both BZP and MA 
displayed increased anxiety-like behaviours compared to female-treated rats.  The implications 
are far reaching, as there is currently a cohort of the population that consumed BZP legally as 
adolescents who may have a greater risk for the development of increased anxiety with 
developing age. In sum, the effect of adolescent exposure to psychostimulant drugs affected 
anxiety-like behaviours that were observable into middle adulthood, suggesting that the 
vulnerability to anxiety may be shaped by drug use in adolescence.         
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Chapter 1: Introduction 
General Overview 
Adolescence is the transition period from childhood to adulthood.  Typically, adolescence is a 
time when the individual initiates multiple risk taking behaviours namely, 
sensation/novelty/reward seeking and impulsivity (Ernst, Pine & Hardin, 2005).  These 
behaviours can be observed in increased delinquency, high risk sexual behaviours and 
substance use. It is well established that early substance use is associated with a number of 
functioning difficulties in later life (Rohde, Lewinsohn, Seeley & Klein, 2007).  For example, 
initial consumption of an illicit substance before the age of 15 years is a strong predictor of 
later drug dependence (Meyer & Neale, 1992; Laviola, Adriani, Terranova & Gerra, 1999; 
Estelles, Lluch, Rodriguez-Arias, Aguilar & Minarro 2007).  Many studies have attempted to 
explain how drug use or experimentation during adolescence can lead to dependence. Drug 
experimentation is perceived to be a natural aspect of human behaviour (Smith, 2003) and 
although substance use occurs across the lifespan, adolescence is proposed to be a time of 
when long term changes can occur in brain functioning which in turn is manifested in 
problematic behaviours that further predispose the young person to seek out drugs (Labonte et 
al., 2012). However, large numbers of individuals experiment with substances for variable 
periods of time, yet only a few go on to develop an addiction (Piazza & LeMoal, 1998). For 
example, it is suggested that only 15 to 17 percent of individuals experimenting with drugs 
become substance- dependent or addicted to the substance (Deroche-Gamonet, Belin, & 
Piazza, 2004).   
Substance Use  
Although substance abuse and dependency is documented throughout history, public concern 
has markedly increased since the 1960’s.  Substance use can be defined as a harmful or 
hazardous use of psychoactive substances.  Problematic use of these substances causes 
significant health and social problems for the individual using them.  Likewise the impact on 
the families of the user and community is significant.  In 2008, it was reported that 
approximately 3.5% to 5.7% of the world’s population aged 15 to 64 years used psychoactive 
substances.  Globally cannabis is the most common, followed by amphetamine-type stimulants 
(ATS), then cocaine and opioids (UNODC, 2012; Labonte et al., 2012).    It is reported that 10 
to 15 percent of Australian and New Zealand individuals aged between 15 and 64 had smoked 
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cannabis in the past year, and 2.8 percent had ingested, injected or inhaled ATS (Degenhardt & 
Hall, 2012).    
To assist in the understanding of the increasing worldwide substance abuse problem (Everitt, 
Dickinson, & Robbins, 2001; Stansfield & Kirstein, 2005), the diagnosis of a substance use 
disorder is presented. The complex and controversial aetiology of substance use itself is briefly 
explored. Additionally, before individuals are diagnosed with a substance use disorder (SUD), 
they must make the transition from experimentation to dependency. A broader construct of the 
“stage” theory of addiction sheds some light on the possible consequences of earlier drug use. 
Substance Use Disorder 
For individuals presenting with SUD, The Diagnostic and Statistical Manual of Mental 
Disorders, fifth edition (DSM-V) is the leading tool used to diagnose substance use disorders 
(American Psychiatric Association, [APA], 2013).  To meet a diagnosis of a SUD, an 
individual must meet two or more of the eleven criteria during the previous 12 months, with 
two to three criteria considered to be a mild SUD, four to five criteria moderate and six to 
seven criteria met a severe SUD (APA, 2013 provides a full description). The defined criteria 
include: taking the substance in larger amounts or for longer than intended, wanting to cut 
down but not managing to, spending a long time getting, using or recovering from use, 
cravings and urges to use, not managing at work, home or school, continuing to use, even when 
it causes problems in relationships, giving up important social, occupational or recreational 
activities, using the substance even when it puts the individual in danger, continuing to use 
even when the individual has a physical or psychological problem that was caused by or made 
worse by the substance, needing more of the substance to get the desired effect (tolerance) and 
development of withdrawal symptoms, which can be relieved by taking more of the substance.   
These criteria are supported by animal drug research.  Rats given extended access to self-
administered cocaine showed three well-established symptoms of substance dependence, that 
is: an escalation in drug use, continued drug seeking and an increased motivation to self-
administer cocaine (Ferrario, Gorny, Crombag, Li, Kolb & Robinson, 2005).  Yet, despite 
mounting evidence showing detrimental consequences of substance use, individuals still 
experiment with drugs of abuse (DOA). However, the question of why people use or 
experiment with substances is complex.  As already mentioned, substance use is generally 
initiated during adolescence, however not all individuals make the transition from recreational 
or experimental use to dependence or addiction.  
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Theoretical Frameworks of Addiction 
Two principal theoretical frameworks help to explain the transition from drug experimentation 
to SUD: The first is the individual-centred concept of addiction, namely, that drug abuse is a 
pre-existing pathological condition in which certain individuals are biologically predisposed to 
be vulnerable to the rewarding properties of drugs. For example, some individuals may have 
increased or sensitised corticosterone levels that induce stress, which in turn increases 
vulnerability to drugs via the enhancement of the dopamine (DA) reward pathways, resulting in 
drug dependence (Piazza & LoMoal, 1996). The second theoretical framework is the drug-
centred concept of addiction, in which the changes are thought to result from drug use (for 
example, tolerance, sensitization and conditioning, (see Robinson & Berridge, 2001 or Wolf, 
1998) and are primarily responsible for the transition from use to dependency (Ferrario et al., 
2005; Robinson & Berridge, 2001). The present study seeks to address this drug-centred 
concept of addiction, by suggesting that changes in the developing brain during vulnerable 
windows of time can cause long-term changes in adult behaviour. Regardless of which view is 
correct, the stage theory of addiction raises important issues that must be considered in relation 
to young people experimenting with substances.  
Stage Theory of Addiction   
In the stage theory of addiction, the development of SUD is considered to follow a lawful 
progression from legal to illegal drug use. The key predictions of this theory are that 
individuals using illegal drugs will have previously used legal drugs, and that not all 
individuals who use legal drugs will move on to illegal drugs (MacCoun, 1998). The common 
developmental sequence of SUD generally starts with alcohol and/or tobacco, and then moves 
through inhalants and marijuana to illicit drugs (Smith, 2003; Walker, Venner, Hill, Meyer, & 
Miller, 2004). These substances have been deemed “gateway” drugs (Fergusson & Horwood, 
2000), because the taking of these substances may lead onto use of harder drugs.  
Support for the stage theory of addiction comes from the Christchurch Health and 
Development Study (CHDS). This is a 21 year follow up study of 990 New Zealand children 
born in mid-1977. The authors measured frequency of cannabis use and other illegal drugs in 
the cohort of individuals when they were aged between 15 and 21 years.  They controlled for 
family, social, behavioural and educational backgrounds prior to the age of 15 and additionally 
controlled for differences in adolescent lifestyle variables. By the age of 21, nearly 70% of the 
total cohort of individuals had used cannabis and 26% of the cohort had used other illegal 
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drugs. This suggests that not all earlier cannabis users went on to using other illicit drugs.  
Astonishingly though, for the 246 individuals who reported using other illicit drugs, cannabis 
in all but three of the cases preceded the use of illegal drugs.  However 63% of the cannabis 
users did not progress to use of other illicit drugs.  The authors also assessed the frequency of 
use, using five different levels, from did not use cannabis over the past year to using cannabis 
over 50 times in the past year.  They found a clear dose/response relationship with those who 
had consumed over 50 times to be 143 times more likely to have progressed to illicit drug use 
than those that had not consumed any cannabis over the past year.  The authors concluded that 
cannabis in New Zealand may act as a gateway drug, supporting the stage theory of addiction 
(Fergusson & Horwood, 2000). Proponents of the stage theory of addiction conclude that there 
is a general progression from legal to illegal drugs. 
Research on addiction trajectories has shown that, while initial experimentation with drugs of 
abuse is largely a voluntary behaviour, continued drug use gradually impairs neural function, 
eventually impacting the very capacity to exert free will. In persons with genetic 
vulnerabilities, suffering from chronic stress or comorbid psychiatric conditions, or who have 
been exposed to drugs, these processes can eventually turn drug use into the automatic and 
compulsive behaviours that characterize addiction. 
Aetiology of Addiction 
The aetiology of addiction is complicated because of interactions among many psychological, 
environmental and biological risk factors related to drug use (Crombag & Robinson, 2004; 
Gilvarry, 2000). Examples of internal psychological risk factors include underlying mood 
disorders (Armstrong & Costello, 2002), sensation seeking (Barnea, Teichman & Rahau, 1992) 
or impulsivity (Jentsch & Taylor, 1999). Environmental risk factors are one or more of the 
following: use of the drug in a drug-associated environment, use of drug paraphernalia; 
individual expectations of the drug being used; and peer pressure or the expectations of the 
social circle to which the individual belongs (Crombag & Robinson, 2004). Examples of 
biological risk factors are genetic predispositions (Merikangas et al., 1998) and differences in 
the structure or biochemistry of the brain (Carlson, 2001).  
Addiction can be defined as a chronic, relapsing disorder that has been characterized by a 
compulsion to seek and take drugs, loss of control over drug intake, and emergence of a 
negative emotional state (e.g., dysphoria, anxiety, and irritability) that defines a motivational 
withdrawal syndrome when access to the drug is prevented. Individuals continue to use drugs 
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despite the negative consequences (Joffe, Grueter & Grueter, 2014; Pierce & Kumaresan, 
2006).  Addicted individuals typically progress through periods of binging (high level 
consumption of a short time frame), withdrawal (abstinence, in the presence of negative affect 
and or anxiety), and preoccupation (craving and anticipation of next use).  The occasional, 
limited, recreational use of a drug is clinically distinct from escalated drug use, the loss of 
control over drug intake, and the emergence of compulsive drug-seeking behaviour that 
characterise addiction (Koob, 2005).   
Several theories have been proposed for the phenomenon of addiction.  Bechara (2005) 
proposes that addiction is an imbalance between two separate but interacting neural systems 
controlling decision making.  On the one hand the impulsive amygdala system for signalling 
pleasure or pain of the immediate choice compared to the reflective prefrontal cortex for 
signalling pleasure or pain of future consequences. Blum and colleagues (2012) suggest that 
addiction occurs due to "reward deficiency syndrome", in that behaviours associated with 
addiction are due to low DA functioning. However, Berridge (2007) argues that DA's 
contribution is more to cause "wanting" for hedonic rewards, more than liking or learning for 
those rewards.  Alternatively Koob and colleagues (1989) suggest that addiction occurs 
through the development of an adaptive process that is initiated to counter the acute effects of 
the drug (opponent processes).  Redish, Jenson and Johnson (2008) propose addicted 
individuals have vulnerabilities in their decision process.  They suggest ten key vulnerabilities 
that differ for different drugs, different behaviours and different individuals can lead to 
addiction (see Redish et al., 2008 for a review).  Belin, Jonkman, Dickinson, Robibs and 
Everitt (2009) propose that addiction is a maladaptive compulsive habit that has dominance 
over goal-directed behaviours and highly influenced by Pavlovian incentive mechanisms. 
Although mentioned, it is beyond the scope of this research to critically analyse different 
theories of addiction, however it appears sufficient to mention the complexities of addiction 
will be modulated not only by brain changes but also by genetic, developmental, experiential 
and environmental factors. The literature also suggests there are differences between 
individuals and within the same individual at different stages of development.  
Neurodevelopment 
Neurodevelopment and neurotransmission play a critical role in the mechanisms of action of 
addictive drugs.  There is evidence indicating differences in development between adolescence 
and adulthood in brain regions thought to be important in drug abuse (Spear, 2000).  After the 
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synaptic pruning and myelination that typically occurs during adolescence and young 
adulthood, brain development reaches completion (Andersen, 2005; Rezvani & Levin, 2004; 
Spear, 2000).  Therefore, exposure to drugs during adolescence can have long-lasting 
implications for brain structure and function (Stansfield & Kirstein, 2005).  The adult brain can 
generally compensate for drug-induced changes within the synaptic clefts, whereas more 
permanent changes can occur in the immature developing neural systems (Laviola et al., 1999; 
Stanwood & Levit, 2004).  The transition from recreational experimentation to the compulsive 
patterns of drug use and abuse is understood to arise from changes in the neurotransmitter 
systems (Robinson & Kolb, 2004).   
 Most drugs of abuse directly or indirectly target the brain’s reward system by flooding the 
circuit with DA. DA is a neurotransmitter present in regions of the brain that regulate 
movement, memory formation, retention and extinction, motivation, reward, predispositions 
for drug abuse and feelings of pleasure. When activated at normal levels, this 
system rewards the user's natural behaviours. Over stimulating the system with drugs, however, 
produces euphoric effects, which strongly reinforce the behaviour of drug use (Julien, 2001).  
The rewarding effects of drugs that are responsible for continuing use are mediated by the 
mesolimbic DA system (Piazza & LeMoat, 1998), especially DA projections to the nucleus 
accumbens (NAc) (Robinson & Berridge, 2001) The NAc is implicated not only in levels of 
self-administration with stimulant drugs (White & Kalivas, 1998) but also in the rewarding 
properties of all addictive substances (Andersen, 2005).  In the human brain, during 
adolescence DA is overproduced and then subsequently reduced as the brain develops to its 
mature state (Bolanos, Glatt, & Jackson, 1998).  Additionally, DA may play a critical role in 
shaping neural responses to drugs during this period and these responses might be quite 
different in adolescence from those of the same receptors in adulthood (Penner, McFadyen, 
Pinaud, Carrey, Robertson, & Brown, 2002).  However, there is evidence that the neurons 
containing DA and serotonin (5-HT) do not necessarily die after drug use.  Instead, it is more 
likely that their nerve terminals are damaged and further development is limited (Fukami, 
Hashimotot, Koike, Okamura, Shimizu, & Iyo, 2004).  Although there is conclusive evidence 
of the involvement of DA and the reward pathways in drug abuse, the same does not 
characterise 5-HT.  
The 5-HT system is involved in the regulation of emotion.  Emotion consists of stress, sexual 
behaviour, memory, cognition, mood arousal, pituitary hormone secretion and satiety (Carlson, 
2001).  Additionally, 5-HT integrates complex brain functions such as motor activity, sensory 
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processing and cognition (Lesch & Merschdorf, 2000).  Like the DA system, during 
adolescence the 5-HT system undergoes substantial reorganization.  For example, it has been 
reported that in a rat's hippocampus, the 5-HT levels are five times higher at puberty than at 
either the juvenile or adult ages (Chen, Turiak, Galler, & Volicer, 1997).  The decrease of 5-
HT uptake after puberty is suggested to be important for the modulation and attenuation of the 
rewarding properties of stimulant-like drugs (Hashimoto, Harumi, & Guromaru, 1992).  It 
appears safe to suggest that the exposure to psychoactive substances while neurons operated by 
DA and 5-HT are not fully matured, may have long-lasting implications.  As 5-HT is known to 
be involved in the regulation of mood and the expression of emotions, it is therefore, connected 
to the development and continuation of many mental illnesses such as anxiety, depression, 
obsessive-compulsive disorder and panic disorder (Naughton, Mulrooney & Leonard, 2000).  
As the brain (primarily the pre frontal cortex; PFC), is not fully developed in adolescence and 
the 5-HT and DA systems are still undergoing changes, stimulant substances administered 
during this period may affect the regulation of emotion.  
The PFC is the last area of the human brain to mature (Smith, 2003; Spear, 2000) and 5-HT is 
known to be involved in its functioning.  The PFC is implicated in impulsive control, attention 
and executive functioning (Andersen, 2005).  There is conclusive evidence that there are 
difference in executive functioning between adolescents and adults (Spear, 2000); for example, 
the underdeveloped PFC in adolescence assists to explain impulsivity, risk taking behaviours 
and use of addictive substance that adolescents engage in (Smith, 2003).  Research has also 
shown that rats with PFC lesions are at a greater risk for the development of SUDs (Chambers, 
Taylor & Potenza, 2003) because of loss of control over behaviour, or increased impulsivity 
(Ferrario et al., 2005).  Therefore, any alteration to the PFC when it is not fully matured could 
have long-term negative implications for the normal development of behaviour (Stansfield & 
Kirstein, 2005).     
 Neuronal imprinting    
Research is suggesting that exposure to psychoactive substances in early stages of life could 
affect brain neuroplasticity processes, which may produce long-lasting abnormal behavioural 
responses (Estelles et al., 2007).   Neuroplasticity occurs as a function of experience, through 
learning and memory and is thought to be due to the re-organization of synaptic connections in 
brain functioning (Robinson & Kolb, 2004).  Most research to date has focused on how 
learning, stress, environments, recovery of function and pathological states impact on synaptic 
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or dendrite structure.  There is limited research into the impact of how experience at one point 
in life can change behaviour and an individual's psychological functioning thereafter.  The 
neuronal imprinting hypothesis suggests that long-term effects of drug exposure can be delayed 
and expressed once the vulnerable brain system reaches maturation.  Neuronal imprinting 
assists to explain the phenomenon of why addicts relapse even years after the discontinuation 
of drug use and long after withdrawal symptoms have subsided (Andersen & Navalta, 2004).  
Neuronal imprinting occurs when the effects of the earlier drug exposure outlast the drug itself.  
Increasingly, evidence is suggesting that long-term effects of drug exposure in adolescence are 
delayed and expressed typically during adulthood (Aarons et al., 1999).  McFadyen, Brown 
and Carrey (2002) state that neural development may continue until approximately 20-25 years 
of age.  Therefore, throughout adolescence, the plasticity of the brain continues and also 
hormonal levels change drastically (Laviola et al., 1999; Smith, 2003).  Aarons and colleagues 
(1999) have researched alcohol and drug use in human adolescents and suggest that even 
limited or infrequent use may be associated with adulthood depression, lack of a sense of 
purpose in life and lower self-esteem.   
Studies of both adolescent and adult animals suggest that the adolescent brain is more sensitive 
to the lasting effects of substances than adult brains (Smith, 2003).  The most conclusive 
support for this theory comes from studies with methylphenidate (MP).  MP is a stimulant drug 
used to treat childhood Attention Deficit Hyperactivity Disorder (ADHD).   Studies 
administering MP to adolescent animals have shown behavioural changes long after the drug 
was withdrawn.  For example, after adolescent MPH exposure, adult animals showed 
depression in a forced swim task (Carlezon, Mague, & Andersen, 2003),  reduced 
responsiveness to response to natural rewards (Bolanos, Barrot, Berton, Wallace-Black, & 
Nestler, 2003), increased vulnerability to substance abuse (Brandon, Marinelli, Baker, & 
White, 2001) and increased anxiety-like behaviour (Balanos, et al., 2003).   
 It is therefore conceivable that both BZP and MA (stimulants) administrated during 
adolescence might affect the developing brain and consequently later behaviour, consistent 
with MPH research, and the neuronal imprinting theory.   
In summary, the sensitivity of adolescence brain development may be related to extensive 
pruning of synapses and of reorganisation of many neurotransmitter systems (Jacobson-Pick, 
Audet, Nathoo  & Anisman, 2011).  The behaviourally activating effects of stimulants have 
long been thought to be due to its actions on the DA system (Labonte., et al., 2012; 
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Vanderschuren & Everitt, 2005), although recent evidence suggests 5-HT and norepinephrine 
(NE) may contribute also (Rothman & Baumann, 2006).  As already mentioned drug abuse is a 
major global health problem and over the last decade there has been a rise in the consumption 
of new unregulated psychoactive compounds. These substances are often marketed as ‘legal or 
herbal highs’ and mimic the psychoactive effects of illicit drugs, and evidence suggests that 
both male and female adolescents in New Zealand have consumed them. 
Sex Differences 
There is evidence to suggest that there are also differences in brain functioning between sexes 
(Bridges & Starkey, 2004; Crick & Zahn-Waxler, 2003; Dominguez, Cruz-Morales, Carvalho, 
Xzvier, & Brandao, 2003; Hallfors, Waller, Bauter, Ford & Halpern, 2005; Koenig, et al., 
2005; Opland, Winters, & Stinchfield, 1995) and, as anxiety is predominately diagnosed in 
females (Baranyi, Bakos, & Haller, 2005; Palanza, 2001) and adolescent stimulant drug users 
are more likely to be female (Rawson, Gonzales, Obert, McCann & Brethen, 2005), sex 
differences must be also considered.     
The rate that females report MA as their drug of choice is twice the rate for males (Cretzmeyer, 
Sarrazin, Huber, Block & Hall, 2003).  Therefore is appears safe to suggest that there are 
differences between sexes in their drug of choice. The Iowa Case Management Project sought 
to identify reasons for and the consequences of MA among rural users and their results 
suggested that females were more likely than males to use drugs to escape, to deal with 
emotional and family problems, to be more productive, to lose weight, improve their strength 
and because of the easy availability.  Males reported initiating MA use because their parents 
use drugs and out of curiosity (Cretzmeyer et al., 2003). Females tend to initiate MA use earlier 
than males, become more dependent on it but are suggested to respond better to treatment than 
males (Embry, Hankins, Biglan & Boles, 2009).  Rawson et al. (2005) reports that different 
from other DOA, adolescent MA users are more likely to be female.  
Anxiety disorders appear to be predominantly exhibited by women (Baranyi et al., 2005; 
Palanza, 2001).  However, hardly any animal models use female animals: although this 
discrepancy is lessening, the majority of research still involves only males animals.  
Consequently, there are few investigations of sex differences (Bridges & Starkey, 2004). A 
literature review investigating anxiety and 5-HT by Blanchard and collegues (1995), revealed 
that in 750 published studies (ranging from 1991 to 1994) 90% used only male animals, 9% 
only females and 1% used both sexes (Blanchard, Griebel, & Blanchard, 1995).  However, the 
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generally acknowledged higher frequencies of depression and anxiety are more common in 
women (Palanza, 2001), and one explanation can be attributed to different socialization 
practices.  Females are more strongly discouraged from engaging in risk taking activities than 
males (Guilamo-Ramos, Litardo, & Jaccard, 2005).  Nevertheless, the similarities between the 
sexes are more prevalent than differences between them (Armstrong & Costello, 2002).  
With the exception of MA, males tend to use a wider variety of drugs and initiate drug use 
earlier than females; however, in terms of clinical severity females obtain higher scores than 
males on physical symptoms and the emotional consequences of drug use.  Additionally, 
female drug users scored higher on the emotional scales because they stated that they were 
using the drug as a way of alleviating emotional unease (Embry et al., 2009; Opland et al., 
1995).  It is, however, questionable whether this is a true sex (as opposed to gender) difference 
because males may not readily admit to having any emotional issues or problems as openly as 
females.  Adolescent women are almost equally likely to drink, smoke or take illegal drugs as 
adolescent men, but are also at a greater health risk (Sarigiani, Ryan, & Petersen, 1999).  
Therefore the common assumption that drug use is more common in boys than in girls fails to 
address the current cultural context.  Evidence is mounting that there is a growing problem of 
substance abuse in adolescent females (Litt, 2003).  As discussed below, differences between 
sexes may be due to differences in plasticity during maturation of the brain.  
As mentioned, adolescence is an intense period of development of the brain, characterised by 
extensive pruning of synapses and receptors, and reorganization of many neurotransmitter 
systems (Spear, 2000).  This usually starts earlier for females than for males (Andersen, 2005).  
There is also a greater over-expression of DA receptors in the Nac and the striatum in males 
than in females (Andersen, & Teicher, 2000; McCormick, Robarts, Gleason, & Kelsey, 2004).  
This over-expression may make the male brain more susceptible to stimulation of the DA 
pathways implicated in addiction (Teicher, Andersen, & Hostetter, 1995).  The most common 
transmitter involved in sex differences in brain development is DA.  Male rats have higher 
levels of D1 receptors in the NAc than female rats and female rats have a greater rate of DA 
release and reuptake (Andersen, & Teicher, 2000) and higher DAT levels in the striatum than 
male rats (Spear, 2000).  Additionally, the literature on sex differences in psychomotor 
behaviour suggests that females exhibit more robust sensitization to stimulant substances than 
males and this is not due to metabolism of the drug, as it is reported to be similar between the 
sexes (Becker, 1999).  Also, it is suggested that drug use by both sexes is initiated increasingly 
earlier than it has been in previous decades.  Notwithstanding, there is conflicting evidence in 
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regards to sex differences in initiation and prevalence of MA use among adolescents, with 
some researchers suggesting that prevalence is higher for males (Embry et al., 2009) and others 
higher for females (Rawson et al. 2005).   Simply, as there is evidence of sex differences in the 
brain during the transition from adolescence to adulthood, exposure to BZP or MA during this 
period might be expected to affect the two sexes differently.  
Age 
Drug use is estimated to start from the ages ranging from 11-12 to 17-18 years of age and 
typically starts with tobacco smoking, followed by cannabis and alcohol, and then stimulants 
and opiates (Adrianai, Macri, Pacifici & Loviola, 2002).  The age of the first use of 
psychoactive substances appears to be critical, since it impacts on subsequent patterns of drug-
related behaviour. The earlier the exposure to psychoactive substances the higher the 
probability of moving from use to abuse and then to dependence (Labonte et al., 2012).  The 
most commonly used drug prior to the age of 16 years (other than alcohol or tobacco) is 
cannabis and, although not as prevalent, many users report starting stimulant use prior to 16 
years of age also (Cretzmeyer et al, 2003). This is important as Rawson et al. (2005) found that 
adolescents in treatment for MA use show increased rates of depression and suicide ideation 
compared to adolescents in treatment for other DOA's.  
Preadolescence is the stage of human development following early childhood and prior to 
adolescence, generally ending at the beginning of puberty.  However, there is no exact 
agreement as to when this period starts or ends but general consensus is from the ages of nine 
until puberty which is different for each individual based on heredity and environmental factors 
(e.g. diet and exercise).  Adolescence is the transitional period from puberty to legal adulthood 
and again chronological age only provides a rough marker as each individual is different.  
Early adulthood is the phase of life span between adolescence and adulthood and Arnett (2000) 
suggested this to be the period between 18 and 25 years of age.    Similarly, in rats these 
developmental periods are difficult to define.  Spear (2000) suggests that that PND28-60 is the 
periadolescent equivalent to adolescence in humans and Smith (2003) suggests that research 
needs to incorporate the entire adolescent phase.  However, as development is defined by 
critical periods or timing, it is noted that no critical period ends suddenly rather it gradually 
tapers off (Herlenius & Lagercrantz, 2004).  
 This thesis endeavours to capture the periadolescent period in rats and for convenience has 
defined PND31-40 as early adolescence, PND41-50 as adolescence and PND51-60 as late 
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adolescence (Vorhees et al., 2005).  Additionally, as the research topic involves differences or 
similarities between two psychoactive substances which are considered to be central nervous 
system stimulant drugs, prior research conducted during these developmental periods will be 
briefly examined.       
It has not been until the last decade that researchers have reported using animal models to 
analyse different developmental periods in relation to possible effects of substance use.  
Importantly, there are limited studies that compare the effects of equivalent treatment regimens 
under identical conditions at different adolescent developmental stages.    
Drug Classifications  
Drugs of abuse are commonly grouped into three large categories defined by their most 
prominent effects.  For example central nervous system stimulants (cocaine, methamphetamine 
[MA], amphetamine [AMP], caffeine, nicotine, methylphenidate [MP]) produce wakefulness 
and enhanced alertness, whereas central nervous system depressants (alcohol, benzodiazepines, 
opioids) induce sedation and drowsiness. The third group is known as hallucinogens 
(marijuana, mescaline, d-lysergic acid diethylamide [LSD], psilocybin [magic mushrooms], 
phencyclidine [PCP]) and include a wide variety of plant-derived and synthetic substances.  
Hallucinogens alter perception and enhance emotional responsiveness so that images are 
distorted in ways that may be interpreted to the user as interesting or frightening.  3,4-
methlenedioxy-methamphetamine (MDMA, commonly known as 'ecstasy') is a combination of 
a stimulant and a hallucinogen (Julien, 2001) and is mentioned here due to its well-known  use 
in research and its central nervous system (CNS) stimulation ability, similar to AMP and MA 
(Teixeria-Gomes, Costa, Feio-Azevedo, Bastos, Carvalho & Capels, 2015).   However, this 
thesis will focus on the stimulant category of substances due to the introduction of 
benzylpiperazine (BZP) as an alternative for individuals experiencing MA dependence in New 
Zealand.     
Benzylpiperazine 
Benzylpiperazine (BZP) is a piperazine derivative which comes as either a hydrochloride salt 
or a free base and is seen by some as an alternative to amphetamine drugs, as it produces 
similar behavioural and neurochemical effects (Baumann, Clark, Budzynski, Partilla, Blough 
& Rothman, 2005; Bishop, McCord, Gratz, Loeliger, & Witowski, 2005; Bye, Munro-Faure, 
Peck, & Young, 1973; Campbell, Cline, Evans, Lloyd & Peck, 1973; De Boer, Bosman, 
Hidvegi, Manzoni, Benko, Dos Reys, & Maes, 2001, Fantegrossi, Winger, Woods, Woolverton 
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& Coop, 2005; Nicholson, 2006; Peters, Schaefer, Staack, Kraemer, & Maurer, 2003; Staack & 
Maurer, 2005; Wikstrom, Holmgren & Ahlner, 2004).  Research suggests that BZP has 
approximately 10 percent the potency of dexamphetamine (Bye et al., 973; Campbell et al., 
1973). 
Benzylpiperazine was first developed in 1944, as an antihelminthic agent for livestock 
However, because of its lack of efficacy and side effects (namely seizures) it was removed 
from the market (Gee, Richardson, Woltersdorf & Moore, 2005; Johnstone, Lea, Brennan, 
Schenk, Kennedy & Fitzmaurice, 2007).    In 1970, BZP’s potential as an antidepressant was 
evaluated as it was found to reverse the effects of tetrabenazine in rats and mice (Tekes, 
Tothfalusi, Malomvolgyi, Herman & Magyer, 1987). Campbell et al., (1973) reported potential 
antidepressant activity, yet it was never marketed as an antidepressant because studies in 
rodents showed it to have similar effects to AMP: animals administered BZP displayed 
hyperactivity and stereotypic behaviour (Campbell et al., 1973), involuntary head movements, 
and reduced reaction time in shock avoidance studies (Miller, Green & Young., 1971). Any 
therapeutic effects of BZP were therefore dismissed, as it was concluded that BZP may have 
the potential to be abused (Bishop et al., 2005). Although aware of the previous findings and 
warnings, in 1980, BZP was marketed as an anti-depressant named Trebilet® by a 
pharmaceutical company in Hungry.  However, it was withdrawn during phase II of its clinical 
trials due to its amphetamine-like properties (EMCDDA, 2007a).   
Benzylpiperazine has also been trialled in human populations, comparing its effects with that 
of amphetamine. In a double blind study by Campbell and colleagues (1973), it was reported 
that former AMP addicts could not distinguish between the effects of 100mg of BZP and 10 
mg of AMP, and both were self-reported to be liked by the participants. The subjects reported 
that the subjective effects of BZP were more enjoyable than AMP (Campbell et al., 1973). The 
authors concluded that BZP is a compound with a potential for abuse and recommended that it 
be placed under statutory control similar to that regulating the use of AMP. A similar double-
blind study was conducted by Bye and colleagues (1973), in which 12 healthy volunteers were 
orally administered either AMP (1 mg to 7.5 mg) or BZP (20 to 100 mg). They were scored on 
performance tests (namely, tapping, addition and hand steadiness tests, and auditory vigilance 
tests), cardiovascular responses and self-reported subjective effects.  The results suggested that 
both BZP and AMP similarly produced tachycardia and increases in systolic blood pressure. 
The authors concluded that BZP was an indirectly acting sympathomimetic amine similar to 
AMP (Bye et al 1973).  
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The principal mechanisms of action are largely unclear.  Brennan et al. (2007) suggested that 
BZP’s abuse potential and self-administration is dependent on DA mechanisms. However, 
Tekes et al (1987) suggest that BZP has a complex mode of action working directly and 
indirectly on central monoamine receptors causing stimulation independent release of 
noradrenaline as well as blocking synaptic uptake.  Oberlander, Euvrard, Dumont and Boissier 
(1979) observed BZP effects similar to AMP and MA, by contralateral circling behaviour in 
rats that had undergone destruction of the nigrostriatal DA pathway by means of unilateral 
administration of 6-hydroxydopamine.  Recently, Baumann et al (2005) found that in in vivo 
microdialysis studies that BZP administration caused a parallel rise in extracellular DA and 5-
HT dialysate levels in the nucleus accumbens, with the DA effect predominant.  However, 
Simmler, Rickli, Schramm, Hoener and Liechti (2014) investigated BZP's pharmacological 
mechanism on human transporters and found that BZP inhibited human monoamine 
transporters and released DA.  They concluded that BZP is an indirect DA and NE agonist 
without 5-HT properties. Overall, the pharmacology and mechanism of action remains 
inconsistent, however it appears to have similar addiction potential of other stimulant 
substances (Baumann et al., 2005; Johnstone et al., 2007; Yarosh, Katz, Coop, & Fantegrossi, 
2007).    
Fantegrossi et al. (2005) found that BZP may be addictive and through their research with 
rhesus monkeys found that BZP can cause deficits in both the DA and 5-HT systems. 
Additionally, Fantegrossi et al. (2005) investigated the reinforcing effects of BZP and 
trifluoromethylphenylpiperazine (TFMPP) in rhesus monkeys previously trained to self-
administer cocaine and found that the monkeys would self-administer BZP at rates as high as 
or higher than they would for cocaine.  TFMPP was found in Fantegrossi et al’s (2005) study 
to not be a reliable re-inforcer.  TFMPP mimics the effects of MDMA and is often combined 
with BZP to enhance the subjective effects.  Baumann, Clark, Budzynski, Partilla, Blough and 
Rothman (2004) were concerned with recent accounts of drug users ingesting combinations of 
BZP and TFMPP. The combinations of these two substances were thought to mimic the 
subjective effects of MDMA. Therefore, Baumann et al (2004) investigated the effects of BZP 
and TFMPP on monoamine neurotransmission in the rat brain and reported evidence 
supporting an increase in extracellular 5-HT and DA similar to MDMA.  Additionally, adverse 
behavioural effects (for example, seizures) were observed in five out of the seven rats that 
received the higher dose (10 mg/kg) combination of BZP and TFMPP. The drug-induced 
seizures occurred at a dose that was just 3-times greater than the threshold dose for biological 
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activity. Baumann et al. (2004), suggest that BZP and TFMPP are potentially dangerous, even 
life-threatening, and that there appears to be a very narrow window of safety. For example, a 
single i.p. dose of 200 mg/kg given to a guinea pig caused death through tetanic convulsive 
seizures and BZP is also suggested to lower the threshold for seizures in human epileptics 
(National Chemicals Inspectorate, 2004). 
In 1999, “party pills’ containing 1-benzlpiperazine were introduced into the New Zealand 
market (Sheridan & Butler, 2010).  Party pills were promoted as a safe and legal alternative to 
illicit drugs and reflected a harm minimisation approach to the escalating MA use being 
observed in New Zealand (Bowden, 2004). However, there was no research to support these 
claims and BZP and similar products were unregulated until 2005 and marketed primarily for 
young people, under the legislation of ‘herbal and dietary supplements’.  Collins (2007) 
reported that 16 percent of the population of individuals aged 15-45 had used BZP in the last 
year as it was legal and available. BZP was sold at liquor outlets, service stations and corner 
dairies without advice, sold to any age group without any safety measures or quality control 
(The Expert Advisory Committee on Drugs [EACD], 2004). The effects of BZP are similar to 
those of other stimulants, arising from stimulation of the central nervous system, namely, 
euphoria, a heightened sense of awareness, wakefulness, and increased vigilance. The average 
duration of these effects is 6 -8 hours (EACD, 2004). Because of the misconception that party 
pills were “natural” or “herbal”, people appeared to take many times the recommended dose, 
aiming for stronger effects (Allan, 2005).  
In New Zealand, from 2000 a legal market for BZP-based products developed rapidly.  An 
estimated eight million doses were sold in New Zealand (Allan, 2005; Wilkins, Sweetsur & 
Girling, 2008) and aimed primarily at a youth market.  A household survey in 2006 found that 
out of 2010 individuals, aged between 15 and 45 years of age, the prevalence was higher 
among those aged 18-29 years and use was greater among males than females (Wilkins, 
Sweetsur, Huckle & Huakau, 2006).    It was not until 2005, when legislation was introduced in 
a new schedule within the Misuse of Drugs Amendment Act 2005 that BZP was classified as a 
Class C drug.  BZP was the first substance to be regulated this way and made the selling of it 
illegal (Sheridan & Butler, 2010). In April 2008, BZP and related substances were classified as 
Class C1 substances under the Misuse of Drugs Act 1975 thereby making the manufacture, 
exporting, importing or supply of BZP illegal.  A six month amnesty period followed, and on 
30th September 2008 the purchase, possession and use of BZP became illegal (Sheridan & 
Butler, 2010).  A household self-report survey conducted prior to BZP's illegal status, among 
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people aged 15 to 64 (n = 6784), showed that BZP was the second most used drug over the past 
12 months, at 5.6 percent, after cannabis at 14.6% (Ministry of Health, 2010).  Since BZP’s 
prohibition, Wilkins and Sweetsur (2013) reported a decline in its use from 15.3% in 2006 to 
3.2% in 2009.  The self-reported reasons for stopping BZP use were its illegal status (43%), 
just an experimental phase (26%), non-availability (24%) and ‘bad hangover effect’ (18%).    
At Waikato Hospital, during the mid-2000’s Dr Tania Nicholson (2006) surveyed 125 random 
users of party pills admitted to hospital. She reported that one third of the users were between 
the ages of 14 and 24 and one third of the individuals had not read the instructions.  Likewise, 
Jamieson (2005) reports that one third of individuals that he had contacted; one third of them 
had taken more pills than the recommended dose. In 2005, Gee et al. (2005) collected five 
months of data from 61 patients who had presented at Christchurch Hospital’s Emergency 
Department with BZP toxicity.  Sixty one patients attended on a total of 80 occasions with 
adverse effects following ingestion of party pills. The ratio of male to female was 1:1.3, age 
range was 15-36 years and the average number of pills consumed was 4.5.  The authors 
concluded that seizures (grand mal type) occurred in 14 patients and these patients had not 
taken more pills than the non-seizure patients.  Mild symptoms included insomnia, anxiety, 
nausea, and heart palpitations. Serious cases in addition to toxic seizures included epileptic 
attacks and severe respiratory and metabolic acidosis. Two cases were admitted to the 
hospital’s intensive care unit. Females presented with more adverse effects more frequently 
than males. Gee et al. (2005) concluded that BZP products had a narrow safety margin possibly 
due to intrinsic pharmodynamic properties, dosage variability, and/or genetic factors.  A 
literature search found 82 scientific articles related to BZP (Cohen & Butler, 2011), with only 
nine of these examining the psychoactive effect in humans.  Cohen and Butler reported limited 
social and health harm associated with BZP and were undecided about whether or not BZP 
serves as a gateway to illegal drugs.  They concluded that the lack of long-term effects of BZP 
use was a significant gap in the literature.    
In Ireland a 48 year old male diagnosed with schizophrenia presented with acute onset of 
unexplained confusion.  He was speaking incoherently and behaving in a ‘bizarre’ manner.  He 
had been stable for a number of years and was treated with clozapine 300mg twice daily.  It 
was discovered that he had developed an acute delirium secondary to BZP use (Tully, 
Hallahan, & McDonald, 2011). Additionally, Gee et al. (2005) stated that there have been 
numerous reports of BZP causing either a toxic paranoid psychosis or exacerbating an existing 
mental illness. With the exception of the clinical trials mentioned (Bye et al., 1973; Cambell et 
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al., 1973), there has been limited research into the subjective effects of BZP in human 
populations.  Thompson and colleagues (2010) conducted a randomised double-blind placebo-
controlled trial looking at the clinical effects of BZP/TFMPP alone and in combination with 
alcohol in 35 healthy adults.  The outcome measures were driving performance, cardiovascular 
effects, psychological function and sleep. However, the study was terminated early on because 
of severe adverse events in four of the 10 BZP/TFMPP-only subjects and three of the 
combined BZP/TFMPP and alcohol subjects.  None of the control participants experienced the 
severe agitation, anxiety, hallucinations, vomiting, insomnia and migraines experienced by the 
experimental groups.  The authors concluded that BZP/TFMPP either alone or in combination 
with alcohol carried a significant risk of severe adverse events even when taken in doses 
recommended by manufactures (Thompson et al., 2010).  Curley, Kydd, Kirk and Russell 
(2013) looked at the effects of a single acute dose of BZP or BZP and TFMPP on reward 
circuitry in healthy adults.  From an fMRI result recorded during an event-related gambling 
task, they concluded that BZP alone decreased the activation of the inferior frontal gyrus, 
insula and occipital regions in comparison to placebo.  This suggested that BZP increased 
positive arousal and subsequently reduced the response to uncertainty. 
Research with rats has provided similar findings.  Herbert and Hughes (2009) compared the 
acute effects of either BZP or MA on several measures of activity and unconditioned choice in 
rats.  They found that both BZP and MA increased open field rearing and ambulation, and 
possible anxiety-related novelty avoidance in a Y-maze.  They concluded that there were more 
similarities between the two drugs than differences.  Brennan et al. (2007) investigated the 
effects of acute and repeated BZP and MA exposure, to determine whether there was 
sensitization and cross-sensitization between the two drugs. Both MA and BZP produced dose-
dependent hyperactivity and sterotypy and repeated use of both drugs resulted in a potentiated 
locomotor but not sterotypy response.  The researchers concluded that repeated exposure to 
BZP results in sensitization and cross-sensitization to MA.  Meririnne, Kajos, Kankaanpaa and 
Seppala (2006) administered BZP (1.25, 5 & 20 mg/kg) to rats for three days and tested them 
in a place preference paradigm the following day.  They concluded that BZP induced dose-
dependent place preference and suggested that BZP possesses rewarding properties in the rat, 
possibly due to adaptations to DA and 5-HT.  They concluded that BZP may be susceptible to 
human abuse.   
In summary, even though prior to regulation many people in New Zealand were taking herbal 
highs, little is known about their possible long-term effects.  BZP was initially marketed as an 
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alternative to illicit and poor quality MA available in New Zealand (Bowden, 2004; 
EMCDDA, 2007a). Consequently, many individuals were under the impression that BZP was a 
safe and legal alternative to illegal drugs.  Evidence to date suggests that, although BZP is seen 
by some as an alternative to other stimulant drugs, it produces very similar effects (Baumann et 
al., 2005; Bishop et al., 2005; Bye et al., 1973; Campbell et al., 1973; De Boer et al., 2001; 
Fantegrossi et al., 2005; Peters et al., 2003; Wistrom et al., 2004). General consensus has 
emerged that BZP’s potency is one-tenth that of amphetamines (Robinson & Kolb, 2004), yet 
no research has addressed whether there are differences in long-term outcomes between BZP 
and other stimulant drugs, especially methamphetamine.      
Methamphetamine 
Methamphetamine is a potent psychomotor stimulant drug with strong physiological effects on 
peripheral and central systems.  Its use has increased significantly over the last few decades, 
fast becoming a world-wide problem that is now recognised by the public, the criminal system 
and researchers (Sheridan, Bulter & Wheeler, 2009; Wu, Pilowsky, Schlenger & Galvin, 
2007).  Initially, developed as an amphetamine derivative, methamphetamine quickly became a 
popular medication during the 1940s and 1950s, prescribed for a variety of concerns, including 
obesity, narcolepsy, depression and sinus inflammation. MA's chemical structure is similar to 
AMP, but it has a more potent effect on the central nervous system.  That is, MA is the N-
methylated analogue of AMP and it metabolizes into amphetamine in the body (Julien, 2001).  
Moreover, it is commonly accepted that MA is more addictive and preferred to AMP by drug 
users.  By the 1960's, the easy availability of MA resulted in its use becoming popular by 
students and truck drivers to stay awake and athletes as a diet aid.  In the 1970's the U.S 
government made MA illegal resulting in 'black market' manufacturing and distribution 
primarily by motor cycle gangs.  In the 1990's large clandestine laboratories appeared, and over 
the past 30 years the illicit manufacture and use of MA has increased substantially.  
MA is popular as a “street drug” because of its ease and cost-efficiency of manufacturing and 
low price compared to heroin or cocaine (Slamberova, Pometlova and Charousova, 2006).  MA 
is produced, or “cooked” quickly, reasonably simply, and cheaply by using legal and readily 
available ingredients.  In New Zealand, these include ephedrine or pseudoephedrine (available 
in cold and flu tablets), red phosphorous (used in matches), iodine (health food retailers), 
ammonia (supermarket), paint thinner and lye (hardware stores), methylated spirits and drain 
cleaner (McFadden & Matuszewich, 2007, New Zealand Police, 2009; Volkow et al., 2001; 
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Wilkins, Griffiths & Sweetsur, 2009).  Recipes’ for “cooking” MA can be found on the 
Internet.  It is known in New Zealand by the street names of “P”, meth, ice, pure and crack, and 
is generally smoked or injected. Over the past two decades the purity of available MA has 
increased with new technology and manufacturing techniques.  A higher risk of dependency 
and compulsive patterns of use are associated with users that smoke or inject purer forms of 
MA (McKetin, Kelly & McLaren, 2006).    
Immediately after use of MA, the individual experiences a number of sensations arising from 
the interaction of the drug with various neurotransmitter systems, primarily the dopaminergic 
but also the epinephrine and norepinephrine systems.  The greatest subjective effect is the 
sense of euphoria, increasing productivity, experiencing heightened attentiveness and curiosity, 
hypersexuality, decreased anxiety, and increased energy (Cretzmeyer et al., 2003).  These 
pleasurable feelings may vary in intensity and duration, depending on the mode of 
administration, with intravenous injection or smoking the preferred options. The MA 
subjective effects are estimated to last between four and 24 hours (Panenka, Procyshyn, 
Lecomte, MacEwan, Flynn, Honer, & Barr, 2013) and even after just one dose of MA, it 
persists in the body for nearly one day (Cook et al., 1993). The effects on the body are long-
lasting due to the relatively slow rate at which MA is metabolized.  MA has a half-life of 8 to 
24 hours with 50 percent still remaining in the body after 24 hours, whereas cocaine is 
metabolized rapidly and has a half-life of approximately 30 minutes (National Institute on 
Drug Abuse: NIDA).  Despite the short-term desirable effects the long term use of MA has 
significant negative implications for the psychological, physiological and social wellbeing of 
the individual (McKetin et al., 2006).  
Psychological effects include decreased sleep, depression, paranoia, hallucinations and 
irritability (Sommers, Baskin & Baskin-Sommers, 2006), decreased appetite, increased libido 
increased confidence and elevated mood (Panenka et al., 2013).  Higher doses can cause 
dysphoria which can be evident as restlessness and anxiety and associated with tremors and 
dyskinesia (Panenka et al., 2013). With prolonged methamphetamine use, consumers may 
experience nutritional and sleep deprivation, which can result in a number of mood and/or 
cognitive problems including fatigue, anxiety and depression (Cretzmeyer et al., 2003).    
Disorganized lifestyle, poor coping abilities and unprovoked incidents of violence are 
common.  MA users tend to indulge in a 'binge-crash' cycle of 1 to 3 weeks duration, which 
intensifies the negative effects as the binge period progresses.  The crash symptoms include 
irritability, depression, fatigue, anxiety, impaired social functioning, aggression and suicidal 
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and homicidal ideation.  Binge users can exhibit highly focused and repetitive behaviours, 
known as “punding” which is the most severe form of Repetitive Reward-Seeking Behaviours 
(Fasano, Barra, Nicosia, Rinaldi, Bria, Bentivoglio & Tonioni, 2008).  This is where an 
individual may have an intense fascination with complex, excessive, non-goal orientated, 
repetitive activities like manipulation of technical equipment, examining or sorting through 
common objects, writing lists, grooming or hoarding objects.  These behaviours are reported to 
be calming or soothing. However the individual can become irritable when distracted from 
their chosen task (Fasano et al., 2008).      
Physiological effects include increased heart rate, elevated blood pressure, vasoconstriction, 
strokes, heart attacks, irreversible damage to blood vessels, tooth decay (meth mouth), loss of 
appetite, malnutrition, anorexia, self-inflicted wounds, bone and hair loss, dry mouth, 
respiratory failure, chest pain, liver damage, kidney and lung disorders and permanent nerve 
damage (Panenka et al., 2013).  These effects are attributed to continuous use rather than 
occasional or recreational use of MA.  The rates of infectious disease, including human 
immunodeficiency virus (HIV) and hepatitis C are increased by intravenous MA use and the 
engagement in more risky sexual behaviours (Paneka et al., 2013).   Also, certain individuals 
who use MA experience compulsive scratching which results in skin lesions or delusional 
parasitosis, in that the individual believes that bugs are crawling under their skin (Hinkle, 
2011).  The common street term for this is ‘P worms’ in New Zealand.   
Social implications are far reaching. The relationship between violence and aggressive 
behaviour related to MA is not well understood.  Sleep deprivation and paranoia may be a 
factor related to violence while under the influence, yet social and biological factors, namely 
gang and other culture affiliation may also be a contributing factor (Cretzmeyer et al., 2003).  
The Methamphetamine Treatment Project examined the history of abuse and violence in a 
sample of 1016 MA users in treatment for MA dependence. Cohen and colleagues (2003) 
report that history of abuse and violence experienced by the individuals was extensive, with 
80% of women reporting violence or abuse from a partner.  Men were more likely to 
experience violence from friends and others. The researchers concluded that current and past 
interpersonal violence is a characteristic of the lifestyle of MA users.  Children of MA users 
can suffer neglect and abuse and the use of MA by pregnant women can cause growth 
retardation, premature birth, and long-term cognitive deficits in children (Anglin, Burke, 
Perrochet, Stamper & Dawnd-Noursi, 2000).  Risky sexual behaviour and practices increases 
the likelihood of HIV and other sexually transmitted diseases.  Lifetime costs of MA exposure 
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to adults and their children are estimated to exceed $1.5 million per user when considering 
child-protection services, special education, criminal justice, healthcare, mental health and 
other domains (McDaniel & Embry, 2001).  
MA interacts with nerve terminals that use DA and NE (catecholamines) or 5-HT 
(indoleamine), as neurotransmitters.  Regardless of route of administration (swallowed, 
snorted, smoked or taken intravenously), MA crosses the blood-brain barrier and enters these 
terminals, inducing a non-exocytoxic transmitter ‘release’ (Marshall and O’Dell, 2012).  
Acutely this accounts for the initial euphoric and other stimulatory actions of MA.  In addition 
to acute effects, MA is cable of inducing long-lasting brain changes. Volkow et al. (2001) and 
McCann et al. (1998) found DA transporter binding reductions persisting for at least eleven 
months after last MA use in human subjects.    
MA affects neuronal functioning through the continuous overstimulation of the neural 
transmitters DA, epinephrine, and norepinephrine (NE). NE is released first, followed by DA 
then 5-HT.  Panenka and colleagues (2013) reviewed the reported mechanism of action of MA 
and concluded that the acute effects of MA modulate DA release by acting at two main 
molecular substrates on DA neuronal terminals: the vesicular monoamine transporter-2 
(VMAT-2) and the plasmalemmal DAT. According to the ‘exchange-diffusion model” 
(Fleckenstein, Volz, Riddle, Gibbs & Hanson, 2007), MA competes with synaptic DA at the 
extracellular site on the DAT.  Because the DAT can transport DA in a bi-directional manner, 
and concentrations of DA are greater inside the cell, the binding of MA on the extracellular 
side causes cytosolic DA to be reverse-transported outside of the cell.  Additionally, MA is 
taken up into the presynaptic terminal where it binds to and inhibits vesicular monoamine 
transporter 2 (VMAT2).  This mechanism of action prevents cytosolic DA from being re-
vascularised, leaving more DA (and 5-HT in 5-HT terminals) in the cytosol where it is either 
pumped back out into the synaptic cleft by MA-induced reversal of DAT and SERT or escapes 
by passive diffusion.  Through these interactions individuals can experience psychotic states, 
such as paranoia and hallucinations, which in turn can lead to extremely irrational behaviours 
as well as suicidal and homicidal ideation (Zweben, Cohen, Christian, Galloway, Salinardi, 
Parent & Iguchi, 2004).  Chronic long-term use is associated with alterations to the DA system, 
including depletion of DA, a decrease in the number of DAT neurons, and a degeneration of 
nerve endings (De Vito & Wagner, 1989).   Behaviourally a reduction in DA transported is 
associated with poor motor activity, decreased memory performance, and reduced verbal 
learning.  
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Kalechstein and colleagues (2003) found that former MA users continued to demonstrate 
impairments across a variety of neurocognitive domains (attention, psychomotor speed and 
executive functioning) even after a short period of abstinence.  The impact of MA on executive 
functioning has been well documented (Paulus, Hozack, Zauscher, Frank, Brown, Braff & 
Schuckit, 2002). Block, Erwin, and Ghoneim (2002) compared the cognitive functioning of 
adult drug users in treatment, and non-using controls on achievement tests. Two to three weeks 
after last use, drug users scored lower than non-drug users on all four achievement tests and 
could be classified according to their primarily drug dependence, namely stimulant, alcohol or 
polydrug users.  The same tests were administered 11 to 15 weeks after last use and non 
relaspers were compared to relapsers.  Only one test showed relative improvement for the 
abstinent drug users and there was no difference in improvements among the stimulant, alcohol 
and polydrug users.  They concluded that the greater cognitive impairment was greater for 
stimulant users then other classes of drugs.  Overall, it appears that humans who use MA, 
similar to rats exposed to this drug can suffer long-lasting brain injury (Marshall & O’Dell, 
2012).  
Among adolescents, MA is now the second most used illicit substance after marijuana in over 
36 countries, and this age group is now identified as the key group at risk of MA use (New 
Zealand Police, 2009; Wu et al., 2007).  A United Nations Survey found that New Zealand and 
Australia were second only to Thailand for MA use in 2001, with 3.4% of the population using 
MA (Degenhardt & Hall, 2012).  New Zealand experienced what was termed a 'P' epidemic 
(McCrone, 2008) and under the harm reduction umbrella BZP was proposed to be a safe and 
legal alternative for MA use.  It appears there is sufficient evidence to suggest that BZP and 
MA share similar mechanisms of action and have the same potential for abuse.  However, with 
the exception of one study the long term effects of BZP are largely unknown.  Aitchison and 
Hughes (2006) found that BZP treatment during adolescence led to heightened anxiety in later 
development possibly because of interference with the maturation of anxiety-associated 
forebrain mechanisms operated by 5-HT.    
Long-term effects of Stimulant exposure  
Psychostimulant drugs such as MA, AMP or cocaine have profound and long-lasting 
neurobiological effects, which may affect anxiety or social behaviours.  There is evidence that 
use of any stimulant drug leads to similar long-term consequences.  Although, many other 
neurotransmitters are involved in and contribute to substance abuse, Figure 1 simplifies the 
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roles of stimulant drug use on both DA and 5-HT neurotransmitters. Deficits in these 
neurotransmitters can lead to a range of negative outcomes that can constitute withdrawal 
symptoms and mood disturbances.  To alleviate these negative outcomes, the individual may 
continue to use the drug, leading to escalating drug use and a circular pattern that may 
eventually constitute a SUD.  Additionally, a number of behavioural, cognitive and 
psychological consequences can occur.  The DA deficits produce predominantly psychomotor 
deficits, whereas, 5-HT deficits may produce cognitive behavioural dysregulation and 
emotional changes.  In other words, fundamental aspects of pleasurable human behaviour and 
survival are compromised by continued use of the stimulant drugs (Rothman & Bauman, 
2003). 
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Figure 1:  Stimulant use and/or abuse and the corresponding deficits in dopamine and serotonin transmission.  
Dopamine deficits underlie psychomotor disturbances, whereas, serotonin deficits causes mood disturbances and lack of 
impulse control, characteristic of withdrawal symptoms, in turn, contributing to increased drug craving and mood 
disorders.  (Adapted from Rothman & Baumann, 2003).   
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Evidence from long-term studies of human MA abuse suggests that detrimental effects occur in 
tests of memory, mental flexibility and abstract thinking (Simon, Dacey, Glynn, Rawson, & 
Ling, 2004) and these deficits continue for periods lasting for five days to several years.  
Additionally, there is evidence that abusers of stimulant drugs may develop abnormalities in 
brain regions implicated in mood disorders.  London et al. (2004), found that human abusers of 
MA provided higher self-ratings of anxiety and depression than controls.  In addition, social 
withdrawal, paranoia and anxiety are well documented occurrences in human MA users 
(Rawson, Gonzales, & Brethen, 2002).  King, Alicata, Cloak and Chnag (2010) found in 
adolescent abstinent MA users that even after 11 months of not using MA, that MA had 
induced psychological and behavioural alterations displayed as increased depression and 
anxiety scores and increased cortisol secretion following a social stressor compared to non-MA 
users, with female MA-users having the most symptoms.  
The ability to quickly respond to objects, events and threats in the environment is essential for 
the survival of humans and animals alike (Gawronski & Cesario, 2013).  Fear and anxiety are 
behaviourally very similar, however anxiety is defined as a long-lasting state of apprehension 
that can become pathological if it becomes extreme, whereas, fear is prompted by imminent 
and potential real danger and serves to activate the individual to respond.  Anxiety is a future-
oriented mood state that is associated with arousal and vigilance (Davis, Wlaker, Miles & 
Grillon, 2010) and behavioural avoidance is a central feature of anxiety disorders.  In rats, 
anxiety is an avoidance behaviour that is considered to reflect fear of novelty, whereas 
approach behaviour (e.g. exploration) reflects motivation to explore novelty. In the current 
research, the conflict between approach and avoidance was used, however, it is proposed that 
they do not represent ends of a continuum, but instead are independent biological functions 
(Green, Barnes & McCormick, 2012).   
 Commencing early in life, anxiety disorders are one of the most common mental disorders 
with an estimated one in fourteen people meeting diagnostic criteria at any one point in time 
(Baxter, Scott, Vos and Whiteford, 2012). No one single brain structure or neurotransmitter 
controls the anxiety response system.  It is reported that several interrelated systems operate 
together in complex ways to induce anxiety.  The hypothlamic-pituitary-adrenal (HPA) axis 
and the limbric system (particularly the amygdala) act as a mediator between the brain stem 
and the cortex, the PFC and other cortical and subcortical structures to evoke a behavioural 
responses to potential threats and fear (Chaby, Cavigelli, Hirrlinger, Caruso & Braithwaite, 
2015). The HPA axis is the central factor of the brain's neuroendocrine response to stress. The 
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hypothalamus, when stimulated, secretes the corticotropin-releasing hormone (CRH), which 
stimulates the pituitary gland to secrete the andrenocorticotropic hormone (ACTH) into the 
bloodstream.  In order to prepare the body to meet a challenging situation, ACTH then causes 
the adrenal gland to release cortisol.  This system works on a feedback loop and it is reported 
that damage or disruption to this feedback loop can effect normal responses to stress and 
abilities to regulate emotions, such as anxiety or mood disorders (Chaby et al., 2015).   
There are three possible views concerning the association between substance use and anxiety 
disorders.  One of these is based on a causal link between anxiety disorders and substance use 
in order to alleviate the anxiety symptoms.  This is described as the "self-medication 
hypothesis" (Harris & Edlund, 2005).  For example, an individual will use stimulants to 
decrease inhibition and increase confidence, or conversely will use depressants to decrease 
tension or anger.  A second opposing view is that the causality runs from substance use to 
anxiety disorders (Chilcoat & Breslau, 1998); specifically that substance use may advance the 
onset of anxiety symptoms.  The final view is that there is a shared etiology or a third variable, 
such as a genetic predisposition.  Merikangas et al. (1998), suggest that genetic factors, 
environmental risk factors and/or prenatal environment may predispose an individual to both 
substance use disorders and anxiety disorders.  The present study was influenced by the view 
that causality progresses from substance use to anxiety disorders.  However, neither of the 
other two approaches should necessarily be discounted because animals used in the present 
study were normal rats, without genetically increased anxiety or any differences in 
environmental or prenatal manipulations.  Therefore, it would be likely that if BZP or MA 
induces behavioural changes in adulthood, these would have arisen purely from earlier 
exposure to the stimulant substances, relatively independent of other influences.   
Another long-term outcome of earlier stimulant abuse is behavioural sensitization. Behavioural 
sensitization occurs after the repeated administration of a substance and cross-sensitization 
occurs when an increased behavioural response occurs to a different drug after previous 
repeated administration of another drug (Landa, Machalova and Sulcova, 2014).  The 
expression of sensitization is associated with the reinstatement of self-administration of the 
substance after a long period of abstinence (Everitt & Wolf, 2002) and is thought to underlie 
certain aspects of addiction and drug-induced psychosis (Vanderschuren, Schmidt, Vries, Van 
Moorsel, Tilders & Schoffelmeer, 1999).  Psychostimulant sensitization is characterised by 
progressive increases in locomotor response after repeated drug administration and is thought 
to result from experience-induced plasticity in brain regions involved in mediating motivation 
 27 
 
for drugs (Clark & Bernstein, 2004).  Behavioural sensitization is well documented in humans 
(see Leyton, 2007 for a review) and animals models suggest this occurs through sensitized 
activations of the DA system.  In rodents,  sensitization from BZP to BZP (Brennan et al., 
2007; Meririnne et al., 2006), AMP to AMP (McPherson & Lawrence, 2006; Vanderschuren et 
al., 1999) and cocaine to cocaine (Snyder, Katovic & Spear, 1998) has been documented, and 
cross-sensitization from BZP to MA (Brennan et al., 2007), AMP to nicotine (Santos, Marin, 
Cruz, DeLucia & Planeta, 2009) and cocaine (Vanderschuren et al., 1999), MP to AMP 
(Valvassori et al., 2007) and cocaine (Brandon et al., 2001) and MDMA to cocaine (Fone, 
Beckett, Topham, Sweetenham, Ball & Maddocks, 2002) to name a few.  In the few studies 
that look at long-term behavioural change, these effects appear to more prominent with 
increasing abstinence (Vanderschuren et al., 1999).  Behavioural sensitization is important, as 
there may be a cohort of young people who consumed BZP (as a legal substance) that are now 
more sensitive to the effects of other stimulants and Wilkins et al. (2006) reported that 13.5% 
of individuals they  surveyed reported using BZP-based pills prior to any other illicit substance.          
 Long-term Outcomes of Adolescent Exposure to Amphetamine (AMP) in Animals   
Amphetamine effects result from elevation of the extracellular DA and prolonging DA 
signaling in the striatum. Three mechanisms have been proposed, first AMP is a substrate for 
DAT that inhibits DA uptake; secondly, AMP facilitates the movement of DA out of the 
vesicles into the cytoplasm; and third, AMP promotes DAT-mediated reverse-transport of DA 
into the synaptic cleft independently of action-potential-induced vesicular releases 
(Fleckenstein et al., 2007). Low doses of AMP (1 mg/kg) are suggested to be therapeutically 
enhancing, yet high doses (10 mg/kg) can produce a behavioural profile similar to the positive 
symptoms associated with schizophrenia (Daberkow et al., 2013).  McPherson and Lawrence 
(2006) administered either a low (2 mg/kg) or high (10 mg/kg) dose of AMP to male rats, 
during PND33-41. After a 4-week period of abstinence, rats received either AMP or saline and 
their locomotor activity was assessed for 60 minutes, then anaesthetized. The researchers 
concluded that exposure to AMP during the periadolescence period in rats, established 
behavioural sensitization to an AMP re-challenge in adulthood. Rats previously treated with 10 
mg/kg of AMP had a higher Fos expression compared with rats treated with 2 mg/kg, however 
the locomotor activity displayed was similar between the two groups. The researchers 
concluded that adolescent exposure to AMP led to a neuronal sensitisation in adulthood and 
this was accompanied by widespread neuronal activation.    
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As most studies of the effects of adolescent stimulant exposure in adulthood, follow a re-
challenge with the drug,  Labonte et al. (2012) were interested in the subsequent altered 
emotionality of the rodents in a drug-free condition. They treated male rats during PND30 and 
PND50 with either saline, 0.5, 1.5 or 5.0 mg/kg of AMP.  After a 20 day wash-out period the 
rats were either randomly assessed in an open-field test and EPM or used for 
electrophysiological analysis. 5-HT and DA firing was increased for rats treated with 1.5 
mg/kg AMP but not NE firing, in contrast with the rats treated with 5 mg/kg, in which NE 
firing was increased but not 5-HT or DA firing. Similarly, the rats treated with the middle dose 
of AMP significantly increased the total distance travelled in the EPM, while this effect did not 
occur for the other two doses.  All three doses of AMP increased the time spent in the open 
arms and central platform, as well as the number of stretch-attend postures made.  Labonte et 
al. (2012) concluded that AMP exposure during the adolescence developmental stage, in rats, 
may promote long-lasting neurophysiological alterations that influence their future behaviour.   
Sherrill, Stanis and Gulley (2013) administered 1 or 3 mg/kg of AMP, every other day to 
adolescent rats (PND37 to PND55) and adult rats (PND98 to 116). The authors were interested 
in the long-lasting effects of repeated AMP exposure on locomotor sensitisation and cognition 
in groups of rats treated during adolescence or adulthood.  The rats were tested at adulthood on 
cognitive performance (delayed matching-to-position and delayed nonmatching-to-position).  
Adolescent treated rats were less sensitive the psychomotor effects of AMP and more 
vulnerable to exposure-induced cognitive impairment, compared to adult-treated rats.  The 
authors suggested that adolescent rats are more susceptible to AMP-induced neurobehavioral 
deficits than adult AMP treated rats. They proposed that the cognitive impairment is possibly 
due to the adolescent brain still undergoing neural development and tentatively suggested that 
the PFC may be an important mediating factor in their results.  A study assessing sustained 
attention after 1.0, 2.0 or 3.0 mg/kg of AMP administered to male PND54 rats, for five 
alterative days, found that after sensitisation had occurred, the effects of AMP treatment led to 
attention consequences. Deller & Sarter (1998) reported that treated rats had increased false 
alarms, like "claims" for hits in non-signal trails, suggestive of hyperattentional dysfunctions 
that may contribute to the development of psychostimulant-induced psychotic symptoms.   
Overall, it appears that exposure to AMP during adolescence leads to long-lasting 
neurophysiological alterations, which contributes to changes in the rats’ behaviour in 
adulthood. The cognitive impairments displayed after AMP treatment seem to be dependent on 
the age of exposure and possibly due to complex neural mechanisms.     
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Long-term Outcomes of Adolescent Exposure to Cocaine in Animals   
Cocaine is an indirect agonist at the DA receptors by inhibiting DAT in neuron terminals, 
causing an increase of concentration and intensity of DA action on postsynaptic receptors 
(Pereira, Andrade and Valentao, 2015).  Estelles et al. (2007) treated both PND26 (defined as 
adolescent) or PND46 (defined as early adult) male mice to either daily injections of 25 mg/kg 
of cocaine for nine days, or the same total amount of cocaine over a three day period (defined a 
binge administration).  Three variables were examined: age; pattern of drug administration and 
the housing conditions (either isolated or in groups).  15 days later they were evaluated in 
measures of cocaine-induced motor activity; anxiety, using the Elevated plus maze (EPM) and 
their social profiles using the social interaction test (SI).  The mice treated with cocaine from 
PND26 and housed individually displayed increased avoidance and flee in the social 
interaction measure, and the same age treated mice that had been housed in groups displayed 
decreased social contacts.  The binge-treated PND26 mice increased the time spent on the open 
arms of the EPM.  Both PND26 and PND46 mice daily treated with cocaine displayed an 
increase in cocaine-induced motor activity when challenged with 6 mg/kg of cocaine two 
weeks after drug treatment.  Similarly, Snyder et al. (1998) administered 30 mg/kg cocaine to 
PND14 male and female rats for a period of seven days.  The drug treatment was paired with 
placement in a novel test context.  The rats were then challenged with a 15 mg/kg of cocaine in 
the same environment either 1, 3, 7, 14 or 21 days after the administration phase.  They 
concluded that behavioural sensitization was evident in terms of squares crossed in the test 
environment and stereotypy behaviours and suggested that behavioural sensitisation can be 
expressed for weeks following chronic treatment during late pre-weaning period.  Santucci & 
Rosario (2010), administered daily 10 mg/kg or 20 mg/kg cocaine to PND30 male rats for 
eight days and measured their anxiety-like behaviour twice following a ten to 11 day 
withdrawal period.  Group differences of both cocaine-treated rats were displayed only on the 
second test day, whereas the control animals increased the amount of time spent in the open 
arms of a zero maze, relative to the cocaine-treated rats. The authors concluded that an anxiety-
like response produced by adolescent treatment with cocaine emerges after a relatively short 
abstinence period.  The results of Santucci and Rosario's (2010) research are supported by 
Santucci and Maderia (2008) study, which found the same anxiogenic response after an 
abstinence period of eight and thereafter twelve weeks. Overall, it appears that adolescent 
exposure to cocaine largely affects anxiety-related behaviours in the treated mice and rats 
tested in adulthood.         
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Long-term Outcomes of Adolescent Exposure to 3,4-methylenedioxymethamphetamine 
(MDMA) in Animals   
Methylenedioxymethamphetamine (MDMA) is a ring-substituted amphetamine derivative that 
acts by increasing the release of 5-HT, noradrenaline and DA from their respective axon 
terminals.  MDMA does not act by directly releasing 5-HT but rather by binding to SERT and 
preventing the re-uptake (Kalant, 2001). Piper and Meyer (2004) administered (PND35-60) 
with MDMA (10 mg/kg) twice daily for six days, to male rats, and observed a significant 
weight loss over this period.  Five days after the last doses of MDMA the rats were assessed in 
an open field (OF), an object recognition task and the EPM.  The results suggested that 
MDMA did not affect ambulatory behaviour in the OF. However the MDMA rats showed 
impairment on the object recognition test and reduced anxiety in the EPM.  These results 
suggest that MDMA exposure during adolescence can alter subsequent cognitive and affective 
function, and Piper and Meyer (2004) reported that this occurred in the absence of severe 
damage to the 5-HT. Similarly, Gurtman, Morley, Li, Hunt and McGregor (2002) and Morley, 
Gallate, Hunt, Mallet and McGregor (2001) found deficits in working memory but also 
reported increased anxiety-like behaviour in adult rats treated with MDMA in adolescence.   
However, Kolyaduke and Hughes (2013) administered MDMA (10 mg/kg) daily to PND35 
(defined as early adolescence) and PND45 (defined as late adolescence) male and female rats 
for ten days.  Rats were subsequently tested in an OF, Y-maze, light/dark box and a novel 
object test at PND90 in a drug-free state.   Female rats that had been treated with MDMA 
during early adolescence were heavier than saline controls at PND90, whereas male rats treated 
with MDMA during late adolescence were heavier than saline treated rats at PND90.  MDMA 
treated rats displayed decreased OF ambulation (for male treated rats only), increased 
defecation, plus fewer entries into the light compartment of the light/dark box and entries into 
both arms of the Y-maze.  Of note, there was no evidence for any effects on spatial or working 
memory. Overall, Kolyaduke and Hughes (2013) suggested that rats exposed to MDMA during 
adolescence, especially late adolescence had increased anxiety in adulthood.    
Piper, Fraiman and Meyer (2005) administered MDMA (5 mg/kg) four times daily for six days 
to male rats during PND35-60 and tested them on a variety of anxiety and memory tests at 
PND64-70.  They reported that MDMA altered habituation to an OF, increased motor activity 
in the EPM, decreased attention in a novel-object recognition test and reduced transporter 
binding in the neocortex.  They concluded that repeated exposure to MDMA during 
adolescence produced later changes in behaviour and neurochemistry.  Similarity, Fone et al. 
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(2002) found that rats tested in a SI paradigm 12 days after the last dose of a 7 day regime of 
MDMA, showed decreased rearing in the OF and a SI reduction of 41%.  Additionally on a 
cocaine challenge, the MDMA-treated rats showed significant conditioned place preference 
compared to control rats. Some immediate effects of MDMA given to PND39 male and female 
rats included the females displaying significantly greater locomotor activation than males at a 
later MDMA challenge. However males showed greater hyperlocomotion at the second 
challenge and all of the ten male rats died at the third challenge (Koenig et al., 2005).  
Morley and colleagues (2001) administered moderate (1x5 mg/kg) or high dose (4 x 5 mg/kg) 
of MDMA or AMP (4 x1 over four hours)  for a two day period and, 12 weeks later, tested the 
animals on three anxiety-provoking measures (emergence box, SI test and the EPM) and a test 
of object recognition memory.  They reported that high MDMA treated rats displayed greater 
anxiety on all three anxiety measures compared to saline- or AMP-treated rats.  The moderate 
dosed rats showed increased anxiety, but not to the extent of the high MDMA treated rats and 
the AMP animals did not differ from control animals.  However, Clemens, van 
Nieuwenhuyzen, Li, Cornish, Hunt & McGregor (2004) found that after an acute dose of either 
MDMA (2.5 or 5 mg/kg x 4), or MA (2.5 or 5 mg/kg x 4) or MDMA and MA (1.25 + 1.25 or 
2+2 mg/kg) combined, four to five weeks later the MDMA/MA- treated rats, MA and high 
dose MDMA rats displayed less social interaction in a SI test.  A lower dose of MDMA also 
produced increased anxiety on the emergence test. Seven weeks after the last drug 
administration, these researchers conducted a neurochemical analysis and concluded that 
MDMA caused 5-HT and 5-HIAA depletion in several brain regions (PFC, striatum, 
hippocampus and amygdala) whereas MA pre-treatment reduced DA in the PFC.  McGregor, 
Gurtman, Morley, Clemens, Blokland, Li, Cornish and Hunt (2003) administered 5 mg/kg 
MDMA every four hours for two days to late adolescent rats and tested them in a variety of 
anxiety measures (SI, emergence test and forced swim) eight to ten weeks after last drug use.  
Two to 4 months later MDMA pre-treatment resulted in increased anxiety in the SI test and 
emergence test and reduced escape attempts and increased immobility in the forced swim test. 
Cox, Shah, Cichon, Tancer, Galloway, Thomas and Perrine (2014) were interested in how the 
effects of MDMA (5.0 or 10 mg/kg) administered once daily for four days to rats during 
PND38-41, would affect place conditioning to MDMA, anxiety-like behaviour and their 
subsequent monoamine levels once abstinent from the drug.   Rats treated with 5 mg/kg of 
MDMA during adolescence were similar to saline-treated rats on all measures.  However, rats 
treated with 10 mg/kg displayed place aversion one day after the last exposure to MDMA and 
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similar to Kolyaduke and Hughes (2013) study, avoidance behaviours in the light/dark box and 
increased anxiety-like behaviours in the OF after a five day absence period. Cox et al. (2014) 
found a opposing result to Clemens et al. (2004) on 5-HT alteration due to adolescent MDMA 
treatment. Whereas, Clemens et al. (2004) reported a depletion of 5-HT and 5-HIAA in the 
brain regions mentioned above, Cox et al. (2014) found decreased 5-HT in the dorsal raphe, 
and increased 5-HT and 5-HIAA in the amygdala and no change in the hippocampus.  It is 
noted though that Clemens et al. (2004) administered MDMA to adult male rats, whereas Cox 
et al. (2014) treated adolescent male rats, suggestive of different 5-HT receptor functioning 
possibly due to age of treatment.  Similarly, Bull et al. (2004) treated PND28 male rats with 
MDMA (5 mg/kg) hourly for four hours on two consecutive days.  Social interaction occurred 
on PND84 in a drug free state, and Bull et al. (2004), found that social interaction was reduced 
by 27% in the pre-treated rats compared to control rats.  On PND86, rats received MDMA (5 
mg/kg) followed by either saline or 5-HT2A/2C  receptor agonist, 1-(2,5-dimethoxy-4-
iodophenyl)-2-aminopropane (DOI, 1 mg/kg) and locomotor activity, wet-dog shakes and back 
muscle contractions were monitored, followed by an EPM test.   On the EPM, pre-treatment 
with MDMA prevented the anxiogenic effect of DOI.  On PND92, neurochemical analysis 
showed significant reductions in hippocampal 5-HT and 5-HIAA concentrations, and 5-HT 
levels were also depleted in the frontal cortex and striatum.  The researchers concluded that the 
inability of DOI to decrease anxiety-like responses suggests that the 5-HT2A receptor may have 
mediated the observed behaviour in the MDMA pre-treated rats.    
Kelly, Ritchie, Quate, McBean & Olverman (2002) treated pregnant female rats on gestational 
day 15 (E15) with MDMA (20 mg/kg), twice daily for four consecutive days, neonatal male 
rats (from untreated dams) with the same MDMA treatment on PND10, 15, 20, 25 or 30 and 
another group of rats with the same MDMA treatment on PND90.  This study investigated the 
toxicity induced by MDMA in the perinatal rat brain and its relation to 5-HTT sites and 
whether early exposure to MDMA alters subsequent brain functions in adulthood. Kelly et al. 
(2002) found no difference in the density of [³H]-paroxetine binding sites, measured at PND40, 
in the brains of MDMA treated rats from E15 to PND20, compared to controls.  However, 
MDMA treatment from PND25 onwards resulted in significant reductions in [³H]-paroxetine 
binding, with decreases of 46% at PND25, 63% at PND30, and 90% at PND90, compared to 
control rats.  They concluded that MDMA-induced neurotoxicity is absent in the perinatal 
period and increases markedly from PND25 onwards, although not to the same extent as what 
is found in the adult rat brain. Klomp, den Hollander, de Bruin, Booij and Reneman (2012) 
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investigated the effects of MDMA on the 5-HT system and whether MDMA effects in 5-HT 
densities were dependent on the age of first exposure. They treated male rats from PND27 or 
PND63 with 10 mg/kg MDMA twice daily, for four consecutive days, and following a seven 
day wash-out period, were injected with [¹²³I]ß-CIT and then anesthesiatised.  MDMA 
treatment produced significant reductions in 5-HTT binding in several brain regions and this 
was more pronounced in the PND63 rats (ranging from 35% to 75%) compared to the PND27 
treated rats (ranging from 20% to 69%).  The effect of age and treatment was observed in the 
frontal cortex of rats and not in the midbrain.  They concluded that the difference on the 
developing and mature brain of MDMA effects may be due to the different maturational stages 
of the 5-HT projections at the age of first exposure.    
In summary, it appears that MDMA-induced neurotoxicity to the 5-HT system occurs from 
PND25 and is largely absent in during gestation or the perinatal period. Adult rats seem to be 
more susceptible to neurotoxic effects than adolescent rats.  Notwithstanding, the literature 
suggests long-term decreases in 5-HT, 5-HIAA and 5-HTT binding sites within the adolescent 
rat brain due to MDMA administration, however further research is required into the effects of 
MDMA exposure on other neurotransmitter functions.  
Long-term Outcomes of Adolescent Exposure to Methylphenidate (MPH) in Animals   
Methylphenidate (MPH, commonly known as Ritalin®) is the prominent pharmacological 
treatment in the management of attention deficit hyperactivity disorder (ADHD) and the 
pharmacological pathways and psychotropic effects are similar, although not identical to those 
produced by other stimulant substances.  MPH acts mainly through the modification of the DA 
system, by blocking DAT, and consequently by increasing meso-corticolimbic DA levels 
(Volkow et al., 2001). The majority of published research into the effects of MP on later 
behaviour largely exposes juvenile animals (<PND40), due to MPH's abilities to treat 
childhood ADHD, and the prominent area of investigation focuses on the potential increased 
risk of drug addiction in adulthood following MPH earlier use.   
Brandon et al. (2001) found that MPH (2 mg/kg) administered to PND14 male rats, enhanced 
the rewarding effects of cocaine administration at PND56, without inducing locomotor 
sensitisation.  However, Carlezon et al. (2003) treated male rats aged PND20 until PND35 with 
MPH (2 mg/kg) or cocaine (15 mg/kg twice daily) for 15 days and then tested them as adults 
on PND60.  These authors were interested in how early exposure to either MPH or cocaine 
would affect sensitivity to the rewarding and aversive properties of cocaine using a place 
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preference paradigm.  They reported that early exposure to MPH or cocaine made moderate 
doses of cocaine aversive and high doses less rewarding in adulthood. Early MPH use also 
caused depressive-like effects in a forced swim test.  They concluded that earlier exposure to 
MPH caused long-term behavioural changes enduring into adulthood, some of these changes 
were considered to be beneficial (reduced sensitivity to reward) whereas others (increases in 
depression) may be detrimental. Andersen et al. (2002) found similar results with earlier MPH 
treatment reducing self-administration of cocaine and rewarding properties. Additionally, 
Bolanos et al. (2003) found the MPH-treated animals were significantly less responsive to 
rewards such as sucrose, novelty and sex compared with control animals.  They also found that 
the earlier MPH-exposed animals were significantly more sensitive to stressful situations and 
showed increased anxiety-like behaviours and these effects lasted well into adulthood, 
compared to the saline-exposed group (Balanos, et al., 2003).  They concluded that this effect 
was because of deficits in the mesolimbic DA system induced by early exposure to stimulants. 
Likewise, Crawford, Der-Ghazarian, Britt, Varela & Kozanian (2013) investigated juvenile 
male and female (PND11-PND20) treatment with MPH (2 or 5 mg/kg) and the effects in 
adulthood (PND60) on novelty-induced conditioned place preference, sucrose preference and 
the EPM.  They found that early MPH exposure altered the rats' preference for the white 
compartment of the of the placement chamber.  Crawford et al. (2013) suggested that the MPH 
pre-treated rats displayed an anxiolytic response to novelty, behaviourally expressed as 
decreased fear or anxiety.  However, the MPH-treated rats displayed a long-term increase in 
anxiety, as observed by reduced time in the open arms of the EPM, with no significant sex 
effects, yet female-treated rats spent more time in the open arms, compared to male treated rats. 
Overall, they reported that the results of changes in anxiety-like behaviour may be dependent 
on the type of anxiety-provoking stimulus.  
As mentioned above, the published research on MPH’s ability to increase or decrease an 
animal’s vulnerability to later substance abuse is conflicting.  However, there appears to be 
increasing evidence of the use of MPH to treat young children with ADHD does not effect the 
risk of substance abuse in adulthood.  For example, Biederman et al. (2008) conducted a 10-
year follow-up study on 140 male children with ADHD (ages 6 to 17 years) and found no 
association between earlier stimulant treatment and alcohol, drug or nicotine use disorders 
(Biederman, Monuteaux, Spencer, Wilens, MacPherson & Faraone, 2008). Similarly, 
Mannuzza et al. (2008) were interested in the age of initiation of MPH treatment of ADHD 
children (ages 6 to 12 years) on the later development of substance use and concluded that 
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treatment prior to the age of eight years of age did not increase the risk of later substance use 
and possibly had benefical long-term effects (Mannuzza, Klein, Truong, Moulton, Roizen, 
Howell & Castellanos, 2008).  Additionally, Mannuzza et al. did not find any association 
between age of MPH treatment and mood or anxiety treatments in adulthood.         
Another study of MPH treatment in rats during adolescence, on subsequent anxiety-like 
behaviours, investigated sex differences (Vendruscolo, Izidio, Takahashi, & Ramos, 2008).  
From PND23 to PND38 male and female rats were treated with MPH (2.0 mg/kg x 2 daily) for 
16 days and tested in the OF, an EPM and a protocol of ethanol consumption, four weeks after 
last drug exposure. Earlier treatment elicited anxious-like behaviour in the open-field but not 
the EPM, regardless of sex, and enhanced ethanol intake in female treated rats.  Male treated 
rats made fewer crossings of the centre of the OF than female treated rats, and all treated rats 
made less crossings of the centre of the OF than control rats and female rats were significantly 
more active than male rats.  There were significant sex effects in the EPM, with female rats 
spending more time in the open arms and making more closed arm entries than male rats. 
Similarly, female treated rats had higher ethanol intake than saline-treated females, and female 
rats had a higher ethanol preference than male rats.  Overall, Vendruscolo et al. (2008) 
concluded that MPH treatment during adolescence induced persistent changes on emotionality, 
but these effects were dependent on the sex and behavioural tests utilised.     
In addition to the above mentioned behavioural changes, cognitive processes may also be 
effected by adolescent MPH exposure. Scherer, Cunha, Matte, Schmitz, Netto and Wyse 
(2010) treated male rats (PND15-45) daily for 30 days with 2.0 mg/kg of MPH.  At PND45, 
treated rats displayed impairment in spatial learning/memory, as assessed in the Morris water 
maze and a reduced efficiency for finding the platform position in a working memory task.  
These impairments were reported to have occurred in absence of any motor deficits, as 
revealed by an open field measure and swim speeds. LeBlanc-Duchin and Taukulis (2009) 
found similar impairment in recognition (14 days after drug exposure) and spatial memory (21 
days after drug exposure) in adult rats treated with MPH (5 mg/kg and 10 mg/kg).  However, 
Zhu, Weedon & Dow-Edwards (2007) found improved spatial learning and memory in MP-
treated male and female rats treated with 3.0 mg/kg from PND22 to PND39 as displayed in a 
radial arm maze, seven days after drug exposure. Using similar doses to Zhu et al. (2007) and 
the radial arm maze, Dow-Edwards, Weedon & Hellmann (2008) found improved performance 
on the maze during the first week of testing, however prolonged dosing did not continue to 
improve performance.  They concluded that 3 mg/kg MPH treatment (PND22 to PND59) 
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improved performance on a spatial cognitive task, only early in treatment, with female rats 
only displaying this improvement under conditions of increased motivation.  In a recent 
investigation on sequential learning in adulthood, after adolescent (PND25) MPH exposure 
(20.0 mg/kg, 5 x a week for 5 weeks), Rowan et al. (2015) found adolescent treated rats had 
impaired learning for some aspects of the pattern learning in the training phase and learning for 
the violation element in the transfer phase.  They concluded that earlier MPH treatment 
produced multiple cognitive impairments in male rats that persisted into adulthood.  
Bethancourt, Camarena and Britton (2009) found transient effects on object recognition 
memory and contextual fear memory after adolescent exposure (PND27 to PND71) in rats 
tested 18 days after drug exposure, yet no cognitive impairment. They concluded that MPH 
treatment had modified the hippocampal-sensitive learning and Gray et al. (2007) found MPH 
chronically administered to juvenile rats affected brain areas involved in cognition, motivated 
behaviour, appetite and stress.   
Research into the long-term effects of MPH treatment on the developing brain has focused on 
alterations to the PFC (Arnsten & Dudley, 2005), the caudate putamen, nucleus accumbens 
(Adriani, Canese, Podo & Laviola, 2007), and hippocampus (Bethancourt et al. 2009). (See 
Marco, Adriani Ruocco, Canese, Sadile and Laviola, 2011, for a full review).  Ruocco et al. 
(2010) was interested in the long-term effects of MPH treatment on later adult behaviour and 
forebrain neurochemical functioning. They administered MPH (1.0 mg/kg) once daily to male 
rats from PND29 to PND42.  Behavioural testing in a Lat maze (a measure of 'behavioural 
arousal to a novel environment) and radial maze occurred at PND70-75 and the neurochemical 
results were subsequently conducted.  MPH exposure reduced horizontal activity, although to a 
different extent in the two behavioural measures (i.e. 39% in the Lat maze and 16% in the 
radial maze) and increased non-selective attention as assessed by higher duration of wall 
rearing.  The neurochemical results found decreased DA, 5-HT and their metabolites in the 
PFC and dorsal striatum, decreased NE in the PFC, decreased DA and its metabolites in the 
ventral striatum and decreased NE, 5-HT and its metabolite, 5-HIAA in the hippocampus. They 
hypothesised that the reduction in 5-HT and NE in both the PFC and hippocampus may affect 
mood control in adulthood after adolescent MPH exposure. Overall, the published research into 
long-term effects of MPH treatment during earlier development suggests numerous complex 
behavioural and brain adaptations, that endure into adulthood.        
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Long-term Outcomes of Adolescent Exposure to Methamphetamine (MA) in Animals  
There is evidence that the adolescent brain is protected against the neurotoxic effects of MA on 
the DA systems compared to adult brains.  Miller, O'Callaghan and Ali (2000) treated PND30 
mice with MA (4 x 10 mg/kg) and found a 50% reduction in striatal DA levels 72 hours after 
drug exposure, whereas mice treated to the same dose at 12 months had a 80% reduction in 
striatal DA levels. Similarly, PND40  rats exposed to the same treatment regime displayed no 
changes in DA uptake, DAT binding, DAT activity, and tyrosine hydroxylase activity in the 
striatum 7 days after drug treatment, whereas the same doses administered to PND90 rats had 
reduced DA measures (Kokosha, Fleckenstein, Wilkins & Hanson, 2000; Riddle, Kokoshka, 
Wilkins, Hanson & Fleckenstein, 2002). However, Kokosha et al. (2000) did find reductions in 
striatal DA uptake and DAT activity one hour after MA exposure in both adolescent and adult 
treated rats, yet this effect mitigated more rapidly in adolescent brain.  
Thuong et al. (2005) found high doses of MA (4 x 10 mg/kg) administered at PND40, 
moderately reduced vesicular DA uptake one hour after exposure, whereas the reduced 
vesicular DA uptake was considered to be severe in PND90 MA treated rats, with the PND40 
administration effects not evident one week later yet still present in the PND90 treated rats. 
Absence of significant DA alterations have also been found in rats treated with neurotoxic MA 
(10 mg/kg or 20 mg/kg x 4, 2 hour apart)  at PND20 (Pu & Vorhees, 1993) and prior to PND21 
(Vorhees et al. 2005), which may be attributed, in part, to the immature thermoregulatory 
system.  Cappon, Morford and Vorhees (1997) suggest that from PND40 hyperthermia is 
required to exhibit neurotoxicity in MA treated rats.  However, although early adolescent MA 
treated rats may not have the same depletion of the DA system as seen in older animals (Iman 
& Ali, 2001) they still display hyperthermia induced from MA treatment.  To summarise, it 
appears that after PND40, is the transaction age, where rats' become susceptible to MS-induced 
hyperthermia, monoamine reductions and glial fibrillary acidic protein increases.  On PND40 
they are still resistant to MS-induced neurotoxicity, however if they are administered MA in a 
warmed environment then they can display adult-like MA neurotoxicity..        
Serotonin depletion has also been implicated in MA affects in adolescent animals (Cappon et 
al., 1997). Kokoshka et al's (2000) study showed that the effect of earlier MA exposure on the 
5-HT system (measured by reductions in tryptophan hydroxtlase) were present in both the 
adolescent and adult rats at one hour after drug exposure and these reductions remained seven 
days later.  Similarly, Zombeck, Lewicki, Patel & Rhodes (2010) found MA exposure to 
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PND30-35 and PND69-74 resulted in comparable increases in cFos activity in a variety of 
brain regions between the adolescent and adult treated mice.  Overall these findings suggest 
adolescent MA exposure causes indiscriminate impairments in 5-HT functional activation, in 
contrast to potential age-specific effects displayed by MA on the DA system.         
MA administered to adult rats has resulted in a broad array of learning and memory 
impairments; however there is little published work on the effects of MA on later cognitive 
functioning when administered to an adolescent brain.  Ye, Pozos, Phillips and Izquierdo 
(2014) investigated the long-term effects of MA exposure in adolescent rats on visual 
discrimination and reversal learning and whether MA exposure in adolescence affected later 
MA use in adulthood.  Rats were administered either MA (0.3 mg/kg, escalating in 0.3 mg/kg 
increments per day) or saline from PND41 -50.  Behavioural testing occurred on PND55 
(Visual discrimination and reversal learning) and a drug choice of either saline, MA or a bitter 
substance was conducted during adulthood.  The authors reported that low escalating exposure 
to MA during “late” adolescence period led to a generalised learning impairment which was 
correlated with the degree of MA intake in adulthood.  They concluded that this period may 
serve as a critical temporal window in which the adolescent brain is vulnerable to the 
neuroplastic alterations caused by MA exposure. Additionally, they found that adolescent 
treated rats consumed significantly more MA during adulthood than adult-treated rats  
Williams, Morford, Wood, Wallace, Fukumura, Broening and Vorhees, (2003) administered 
MA (5.0, 10.0, 15.0 mg/kg) four times daily, to male and female rats from PND11 until 
PND20.  Significant weight loss was later observed in both sexes from PND16 until PND59. 
Thereafter, these were no significant changes.  However, six out of the eight animals in the 
highest dose treatment group died between PND14 and PND16.  Rats were then tested from 
PND50 in a variety of spatial learning tasks.  They concluded that all MA groups showed 
impaired spatial memory but not deficits in working memory. However, Moenk and 
Matuszewich (2012) found male rats treated with a low dose (2 mg/kg) of MA for 15 days, 
from PND20 to PND34 displayed improved spatial performance in the Morris water maze 
when tested 45 days after treatment, compared to rats treated with MA from PND70-84.  Using 
the same drug dosing and developmental age period as Moenk and Matuszewich (2012), 
McFadden and Matuzewich (2007), found MA exposed rats had long-term effects on spatial 
memory in a gender specific manner.  Female rats displayed improved acquisition and 
performance in the Morris water maze compared to control females.  The male treated rats also 
displayed improved acquisition compared to control male rats, but this improvement was only 
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observed during the first day of acquisition.  Female rats also located the hidden platform in a 
novel quadrant more efficiently than control females. It is possible that the improved spatial 
performance seen after PND20 MA treatment may be due to confounded by sex differences.     
Vorhees et al. (2005) administered MA (1.25 – 10.0 mg/kg) for ten days to either PND21-30, 
PND31-40, PND41-50 or PND51-60 to male and female rats and tested them in a variety of 
measures after a thirty day abstinence period.  Rats treated with MA (2.5, 5, or 10 mg/kg x 4 
dose per day), PND31-40 (1.25, 2.5, 5, or 7.5 mg/kg x 4 doses per day), or PND51-60 (1.25, 
2.5, 3.75, or 5 mg/kg x 4 doses per day) did not show any changes in spatial learning/reference 
memory and sequential learning compared to saline- treated rats.  However, the highest dose of 
MA (6.25 mg/kg) administered to PND41-50 rats, displayed impairment in spatial and 
sequential memory as observed in the Morris water maze and Cincinnati water maze. They 
concluded that PND41-50 is the vulnerable stage of brain development in rodents and a period 
of susceptibility for MA-induced cognitive deficits.  
However,  Joca and colleagues (2014) treated male and female mice with 2 days of 4 x 7.5 
mg/kg MA on PND30 and 31, and then tested them either at PND41-52 or PND62-73 in an 
open field, novel object recognition, social interaction, a forced swim test and the Morris water 
maze. The researchers reported that MA exposure increased depression-like behaviour in the 
forced swim test for both male and female adolescent-treated mice.  Additionally, the 
researchers found that male-treated mice displayed a decrease in the number of vasopressin-
immunoreactive neurons in the paraventricular neucleus compared to sex-matched saline-
treated rats, yet no impairment of memory in either the novel object recognition, Morris water 
maze test or social interaction measures for either male or female mice (Joca, Zuloaga, Raber 
& Siegel, 2014). North et al. (2013) treated male mice (PND28-42) to daily 24 mg/kg MA for 
14 days and after a 7, 14 and 21 day wash-out period, were tested in a novel object recognition 
and spatial recognition memory tasks.  These researchers found no change in short-term 
memory when measured 14 days after last drug administration, however at all three later 
testing periods they found a deficit in spatial memory. They concluded that the cognitive 
consequences of earlier MA exposure may manifest and persist long after drug abstinence.    
Although, there is research into the long-term effects of MA when administered in adulthood, 
on later anxiety-like behaviour (Clemens et al., 2004), there is limited studies into the long-
term effects on emotionality after adolescent treatment.  Although,  Joca et al's., (2014), found 
increased depression-like behaviour, most studies on earlier adolescent exposure of MA focus 
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on neurotoxicity of high doses and/or subsequent cognitive functioning in adulthood. This gap 
in the literature is important to address, as there is evidence of human adolescent MA users 
experiencing anxiety long after discontinuation (London et al., 2004; Rawson et al., 2002) and 
an animal model is not contaminated by genetic or environmental variables that a human 
population presents with.        
Long-term Outcomes of Adolescent Exposure to Benzylpiperazine (BZP) in Animals  
There is one published study into subsequent behavioural effects following adolescent BZP 
treatment.  Aitchison and Hughes (2006) treated male and female rats on PND45, with 10 
mg/kg of BZP, for ten days.  Behavioural testing in a Y-maze, SI test and a light/dark 
emergence box began on PND72.  In the Y-maze, BZP treated rats entered the novel arm less, 
spent less time in it and also entered both arms significantly less than control rats.  Female rats 
entered both arms significantly more than male rats.  In the social interaction test, BZP-treated 
rats reared less in both the outer and inner squares of the open-field than saline-treated rats.  
Female rats entered significantly more squares than male rats.  BZP-treated rats spent less time 
engaged in social interactions than control rats and female BZP treated rats spent a longer time 
restraining a partner rat than saline-treated females.  In the light/dark box BZP-treated rats took 
a longer time to emerge into the illuminated arena than control animals, and deposited fewer 
fecal boluses in the darkened start box.  Aitchison and Hughes (2006) concluded that that BZP 
treatment in adolescent rats led to higher levels of anxiety-like behaviour in adulthood.  They 
proposed that this may have occurred from interference with the development of anxiety-
related forebrain mechanisms operated by 5-HT.      
In summary, the published research suggests that adolescent animals are less susceptible to 
neurotoxic effects of stimulant drugs, than adult animals.  However, PND40 appears to be a 
transitional period when detrimental effects become more pronounced.  5-HT is affected earlier 
in development than the DA system and may account for later changes in emotionality.  
Female rats are generally more active than male rats and appear to not be as susceptible to 
learning deficits as male adolescent treated rats.  Adolescent exposure to most stimulants 
results in sensitization and cross sensitization in adulthood, however low doses of AMP and 
MP are reported to improve performance in learning tasks.  Overall there are many 
discrepancies within the different stimulant treated rats and between the different stimulant 
drugs.  This may reflect differences in the stimulant treatment doses, duration, the exposure 
period during development, time between treatment and behavioural testing and behavioural 
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measures used.   To add to the limited long-term studies on later anxiety behaviours, one of the 
aims of this thesis is to supplement the work of Vorhees et al. (2005) by expanding behavioural 
testing into old age (PND200), and Aitchison and Hughes (2006) research by further 
examining the effects of BZP comparable to MA, using three different non-toxic doses of each 
drug and both male and female animals.  
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Chapter 2: Aims and Method 
Aims 
Since there is limited research on any long-term effects of adolescent BZP and MA exposure 
on subsequent adulthood behaviour, the main aim of this study was to compare possible 
differences in long-term outcomes between saline-, BZP- and MA-treated groups of rats. 
Anxiety (or emotionality) was principally investigated because, as in addition to affecting DA 
transmission, BZP may affect 5-HT levels in the brain, which are implicated in anxiety 
disorders (Carlson, 2001). Primarily, the current study sought to expand on the results of 
Aitchison and Hughes (2006) research, which found increased emotionally in adult rats who 
had been treated with BZP during adolescence.  Additionally, long-term behavioural effects of 
MA was included as a comparative stimulant drug, and on the assumption that BZP was a safe 
alternative for MA use.  As it is unclear whether any neurochemical changes that may occur at 
different developmental stages continue or redeem themselves over-time, this study measured 
the rats’ emotionality at three different developmental stages up until middle age.  Finally, 
since, both male and female humans take stimulant-based drugs, the study aimed to determine 
whether exposure to a psychoactive substance at different developmental periods affected the 
sexes differently.  
Method 
Subjects 
The subjects were 210 male and 210 female PVG/C Hooded rats, from the breeding colony at 
the University of Canterbury, New Zealand.  When 30 days old, the pups were weaned and 
housed in 525 x 330 x 230mm plastic cages, in groups of three or four of the same sex, for the 
duration of the experiment.  They were housed in a controlled environment (rh 22°C ± 2° and 
48% ± 10% humidity), and maintained on a 12 hour light/dark cycle (lights on at 8.00am) with 
free access to food (commercial rat pellets) and water.  Two females and one male rat died of 
unknown causes, prior to behavioural testing. All procedures were approved by the Animal 
Ethics Committee of the University of Canterbury.  
The subjects were randomly allocated to one of 21 experimental groups.  Each group had 10 
males and 10 females.  In the drug treatment phase animals were i.p exposed daily (for 10 
consecutive days) to either saline, BZP (5 mg/kg, 10 mg/kg or 20 mg/k) or MA (0.5 mg/kg, 1.0 
mg/kg or 2.0 mg/kg). All doses were administered at approximately 09.00 hours.  To 
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encompass the total adolescent stage of development in rats (Spear, 2000), rats were treated 
during either between PND31-40, PND41-50 or PND51-60.  Subsequently, all rats were tested 
at three different developmental periods, firstly; 30 days after last drug dose, secondly at 
PND120 and finally at PND200.  Test phase one (30 day wash-out period) was to ensure no 
drug effect was evident and occurred when all animals were adults (Spear, 2000).  Test phase 
two occurred when all animals were 120 old and test phase three occurred when all rats were 
200 days old. See Figure 2 for a comparison between stages of rat versus human development 
and experimental procedure.       
 
 
Experimental  
Procedure 
 
RATS 
(PND) 
 
 
HUMANS 
(Develop- 
ment) 
 
 
  
Figure 2: Experimental procedure and a relative comparison of ages and stages of rat versus human development (Adapted from 
Andersen, 2003)  
Drugs and Rationale for Doses 
1-Benzylpiperazine (BZP) was purchased from ABCR Gmbh & Co (Karlsruhue, Germany), 
and mixed daily in sterile 0.9% saline to produce doses of 5 mg/kg, 10 mg/kg and 20 mg/kg, 
and administered in a volume of 1 ml/kg.  MA had been donated as a pure crystal form of the 
drug by Environmental Science & Research Ltd (ESR, Wellington, New Zealand). It was 
crushed and then dissolved in 0.9% saline to give doses of 0.5 mg/kg, 1.0 mg/kg and 2.0 
mg/kg. Previous research had demonstrated that these doses of both drugs were behaviourally 
effective in rats (Brennan et al., 2007a [BZP]; Hughes and Greig, 1976 [MA]) and Campbell et 
al., (1973) reported that AMP is approximately ten times more potent than BZP.   All animals 
received a daily intraperitoneal injection (i.p.) of saline, BZP or MA for ten consecutive days 
either on PND31-40, PND41-50 or PND51-60 (See Table 1 below).  Although human users 
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typically take BZP orally, or MA intranasally, an i.p route of administration was chosen for 
ease of drug delivery.  According to the allometric scaling principles ("dose human [mg/kg] = 
dose animal [mg/kg] x animal weight/human weight¼) and the suggestion that a dose of 10 
mg/kg MA in an adolescent rat is approximately equivalent to 117 mg in a 50 kg adolescent 
human, the doses used in this study can be considered small. The rationale for this was to 
examine long-term effects following adolescent recreational substance use as opposed to acute 
neurotoxic effects.  The body weights and health of animals were monitored throughout drug 
treatment and all behavioural testing.   
Table 1: Days of treatment with saline (S), BZP, or MA for a total of 210 male and 210 
female hooded rats 
 
Juvenile  
(PND 31-40) 
Adolescence 
(PND 41-50) 
Early Adult 
(PND 51-60) 
Control S S S 
Dose 1 BZP 5 mg/kg BZP 5 mg/kg BZP 5 mg/kg 
Dose 2 BZP 10 mg/kg BZP 10 mg/kg BZP 10 mg/kg 
Dose 3 BZP 20 mg/kg BZP 20 mg/kg BZP 20 mg/kg 
Dose 1 MA 0.5 mg/kg MA 0.5 mg/kg MA 0.5 mg/kg 
Dose 2 MA 1.0 mg/kg MA 1.0 mg/kg MA 1.0 mg/kg 
Dose 3 MA 2.0 mg/kg MA 2.0 mg/kg MA 2.0 mg/kg 
 
National Chemicals Inspectorate (2004) report that BZP’s LD50 in both male and female rats 
is 2,600 mg/kg, therefore the BZP doses used in this study can be considered small.  A typical 
‘small’ dose of amphetamine for rats is 1 mg/kg (Robinson & Kolb, 2004). As there are no 
longitudinal studies looking at earlier administration of BZP this study used three different 
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doses of each drug to assess any differences within the class of drug and between BZP and 
MA.   
The three periods of administration of the two different drugs took into account that, in rats, 
adolescence can endure from 28 to 55 days after birth (Spear 2007). However, for ease of 
comprehension, the PND31-41 period was called "juvenile", the PND41-50 period was called 
"adolescent" and the PND51-60 period was called "early adult", as suggested by Vorhees et.al. 
2005.  Rats are usually regarded as adults from PND 60 onwards (Marco, Macri, & Laviola, 
2011), therefore this study spanned the adolescent developmental period of male and female 
animals.      
Behavioural Testing Rationale 
All rats were tested in a drug-free state on a battery of anxiety tests at three independent time 
periods.  Firstly, 30 days after the last dose of saline, BZP or MA, secondly at PND 120 and 
finally at PND 200.  Ideally, the first behavioural testing phase would be at PND60, when the 
adolescent brain had matured to adult levels, however in this study that would mean the 
behavioural testing would begin straight after drug treatment for PND51-60 and twenty days 
after treatment for the PND31-40 treated rats.  The 30-day washout period was chosen to 
ensure all rats had the same recovery interval before behavioural testing (Vorhees et al., 2005).  
Therefore, PND31-40 treated rats were 70 days old, PND41-50 were 80 days old and PND51-
60 were 90 days old, at the first testing phase.  It is proposed that sex differences occur from 
PND60 (Imhof, Coelho, Schmitt, Morato and Carobrez, 1993) and most research suggests that 
performance on behavioural measures does not differ as a function of age after PND50.  The 
second behavioural measures occurred when all rats had reached PND120 and the third 
measure at PND200.       
Apparatus and Behavioural Measures 
Emotionality, or emotional reactivity, in the rat is regarded as the animal equivalent to human 
anxiety.  The experience of anxiety in humans is a normal phenomenon and has been suggested 
to be valuable in improving performance (Andrews, Creamer, Crino, Hunt, Lampe & Page, 
2003). However when anxiety impacts on everyday functioning it can be detrimental to the 
individual experiencing it. There are different clinical classifications of different types of 
anxiety, such as generalized anxiety GAD), phobias, social anxiety, panic and post-traumatic 
stress disorders (Graeff, Netto, & Zangrossi, 1998). Anxiety in humans is characterized by 
unrealistic, unfounded fear and emotion (Andrews et al., 2003), typically exhibited as escape, 
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avoidance, non-verbal vocalisation and/or hypervigilance, whereas anxiety in animals is 
defined by changes in behaviour (Handley, 1995) and it is now recognised that both species 
may share common affective states (Palanza, 2001). This is important, as the assessment of 
anxiety in animals is based on the assumption that human and animal anxiety is similar (Ohl, 
2003).     
Four sets of apparatus were used and the behaviour measured probably reflect the equivalent of 
human GAD (Morley et al., 2001; Ohl, 2003; Samyai, Sibille, Pavlides, Fenster, McEwen, & 
Toth, 2000).  All apparatus are empirically supported measures of anxiety-like behaviour (File 
& Seth, 2003; Millan, 2003; Ohl, 2003).  In the Y-maze a more anxious animal will enter a 
novel arm less, spend less time in it and make fewer entries of both the novel and familiar 
arms, than a less anxious animal. In the social interaction test a more anxious animal will 
display less rearing behaviour (outer squares and inner unprotected squares) and spend less 
time in social interaction compared with a less anxious animal and this apparatus may also 
measure social anxiety (File & Seth, 2003).  In the light/dark box more anxious animals will 
take longer to emerge from the start chamber than less anxious animals, and in addition to 
GAD may measure the human equivalent of panic disorder (Graeff, et al., 1998). In the EPM a 
more anxious animal will avoid the open arms more readily than a non-anxious animal 
(Pellow, Chopin, File & Briley, 1985).  All four types of apparatus were present in the same 
experimental room and these ethologically appropriate tests are based on a rodent's innate 
curiosity to explore novel areas (Samyai et al., 2000) and do not require learning or any 
positive or negative reinforcers..  
The experimental room was kept at 20°C, with 38% humidity and dim (47 lux) fluorescent 
room lighting.  All testing took place between 10.00 and 15.00 hours during the light phase of 
the rats’ light/dark cycle. At each of the three different testing periods each animal was tested 
in the Y-maze four times, elevated plus maze once or social interaction test once (randomly 
determined), and then placed in the light/dark box (times six trials per testing period).  The 
order of trials was random, however every animal completed six separate trials per testing 
phase and the averages of all of their trials in each test setting were determined.  There was a 
break of at least two days between each series of tests, to control for habituation effects.   
1. Responsiveness to Change in the Y-Maze 
The Y-maze taps into rats’ innate tendency to explore novel areas (Hughes, 2001; Hughes & 
Neeson, 2003; Samyai, et al., 2000) and normal animals will enter the novel arm more than the 
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familiar arm, whereas anxious animals will show less of a preference for novelty.  
Additionally, the Y-maze is a test of short-term spatial memory for brightness change (Gray & 
Hughes, 2015).  The clear Perspex enclosed clear-varnished wooden Y-maze sat on a 700mm-
high table.  The maze consisted of two 45-cm long arms and a 30-cm stem.  The arms and the 
stem were 10cm wide and 14cm high, and the angle between them was 120°.  One arm of the 
maze contained a removable black insert, and the other contained a white insert.  Each insert 
occupied the width, height and 40-cm of the length of the arm.  The animals were placed in the 
first 15cm of the stem and allowed to freely roam the entire maze for 6 minutes (acquisition 
trial).  The rat was then removed and kept in a covered holding cage (530 x 330 x 230) while 
the white and black inserts were replaced with two clean black inserts, and the entire maze 
cleaned with a solution of 20% Powerquat blue and 80% water.  The rat was then returned to 
the first 15 cm of the stem and allowed to freely roam the entire maze for 3 minutes (retention 
trail). 
Arm entries were recorded by the experimenter using a PC keyboard, computer and suitably 
developed event recording software.  The dependent variables measured in the retention trials 
were: (1) percentage of time spent in the novel arm for three minutes (novel arm time/ in 
seconds/ [novel + familiar arm time in seconds] x 100); (2) the percentage of entries made into 
the novel arm for three minutes (novel arm entries/ [novel + familiar arm entries] x 100); and 
(3) the total entries of both changed arms for the three minute trials. The entry to an arm was 
defined as all four paws in the arm.   
At the three periods of testing all animals were tested in this maze four times.  The novel arm 
was on the left for half the trails and the right for the other half (randomly determined).  The 
average of the four trials became the representative score for each rat on each measure.  
2. Light/dark Emergence Test 
After testing in either the Y-maze, social interaction test or the EPM all animals were then 
observed in the light/dark emergence apparatus.  This test is based on rodents’ innate aversion 
to bright illuminated areas.  In response to mild stressors, that is, bright light and a novel 
environment, a rodent faces a natural conflict between the tendency to explore and the innate 
tendency to avoid the unfamiliar (Bourin & Hascoet, 2003).  This apparatus is quick and easy 
to use and does not require food or water deprivation, shock administration or prior training.  
The apparatus comprised a 20 x 15 x 20-cm high darkened start box, which was painted flat 
black inside and could be opened (via a sliding wooden door) to a larger 50 x 40 x 20-cm 
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illuminated arena.  It was constructed from wood apart from the floor and the ceiling of the 
arena.  The floor consisted of translucent white Perspex that was illuminated from underneath 
by two 16-lux fluorescent tubes.  The light measurements were, 80 lux in the centre of the 
illuminated area at the roof level and 172 lux on the Perspex floor.  The roof of the arena was 
made of fine wire mesh. 
The animals were placed in the smaller darkened box for 60 seconds, and then a sliding door to 
the illuminated arena was opened.  By means of a hand-held stopwatch the experimenter timed 
how long it took for the animal to fully emerge (all four paws) into the illuminated arena.  If 
the animal did not emerge within five minutes, the trial was terminated and the rat assigned a 
score of 300 seconds.  All animals were tested this way seven times with an interval of at least 
two to three days in between each test.  The average emergence time was calculated for each 
rat on each of the three testing periods.  
3. Elevated Plus Maze (EPM) 
The EPM is currently one of the most popular in vivo animal tests of anxiety (Carobrez & 
Bertoglio, 2005). There are two underlying assumptions for the EPM; firstly that it is an 
‘ethological’ animal model of anxiety (Rodger, 1997) that has ecological meaning for the rat, 
and secondly, that anxiety (which can be regarded as agoraphobic) is induced by the 
unfamiliarity of the test (Carobrez & Bertoglio, 2005). Research suggests that rats prefer the 
secure closed arms of the maze to the more threatening open arms (Pellow, et al., 1985; Flint, 
2003).  This preference would be greater in more anxious animals. The EPM does not require 
any training procedures or the use of shock, or food or water deprivation.  
The apparatus was elevated from the floor, consisted of two open arms (with 25 cm high clear 
Perspex walls) and two closed arms constructed of black painted wood. Each arm was 50 cm 
long and 15 cm across. Similar arms were opposite each other and there was a central zone (15 
cm x 15 cm), in which the rat was placed facing a closed arm. 
The animals were placed in the centre of the enclosure facing one of the closed arms and 
allowed to roam freely for five minutes.  An infared camera was mounted on the ceiling (200 
cm) above the EPM and connected to a video recorder to record the animals’ behaviour for 
later analysis. The measures recorded were (1) percentage of time spent in the open arms for 
the five minutes (open arm time in seconds/ [open + closed arm time] x 100); (2) percentage of 
entries made into the open arms (open arm entries/ [open and closed arm entries] x 100; and (3) 
the total entries of the closed arms over the five minute testing phase. Flint (2003) suggests that 
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these measures give a better indication of anxiety-like behaviour in the rat than the more 
sophisticated measures (i.e. grooming, rearing or stretch-attend postures).  Cruz, Frei & Graeff 
(1994) suggests that entries of the closed arms is the most appropriate measure of activity in 
the EPM as it is not contaminated by anxiety. The entry to an arm was defined as all four paws 
in the arm.  Animals were tested once at each of the three different periods as research suggests 
the EPM can produce habitation effects if tested within two weeks after first trial (Bessa, 
Oliveira, Cerqueira, Almeida & Sousa, 2005)  
4. The Social Interaction Test (SI) 
At all three testing periods pairs of unfamiliar animals were tested once in the social interaction 
test, which is a test of anxiety and curiosity (Wills, Wesley, Moore & Sismore, 1983).  As with 
the other tests, it does not require training and thus the use of shock or deprivation.  The 
animals were weighed on the day of the social interaction test and the weights of each pair did 
not differ by more than 10 grams. The apparatus consisted of a wooden open field (OF) 60 x 60 
x 25-cm, that was placed on a table 700mm high in the same experimental room described 
above.  The apparatus floor was painted flat black and divided into a 4 x 4 grid of 16 identical 
squares (twelve peripheral and four central), each measuring 15 x 15-cm.  The wooden walls 
were 25-cm high and painted flat black.  Uncertainty (and thus anxiety) is increased by placing 
animals in an unfamiliar environment, and by altering the light levels (Garau, Marti, SL& 
Balada, 2000). In this case, the light level was low (47 lux) and the test arena was unfamiliar, 
producing low to moderate anxiety (File & Seth, 2003).  An infrared video camera was 
mounted on a single wooden arm 85-cm above the OF.  The camera was connected to a video 
recorder, to record the animals’ behaviour for later analysis.  The tests were videotaped for 5 
minutes and all testing was carried out between 10.00 and 15.00 hours.  The OF was washed 
(20% Powerquat blue and 80% water) and dried between each pair of animals. Behaviour was 
scored manually by a research assistant blind to the conditions of the experiment.  
Unfamiliar same-sexed rat pairs, matched on the basis of body weights and treatment 
conditions were placed in the middle of the OF facing each other for the start of the social 
interaction test.  They were allowed to freely roam the entire OF together for five minutes.  The 
animals were assessed for both their individual behaviours and their social interaction 
behaviours.  The individual measures in the OF for each animal for the recorded five minutes 
were: (1) the total number of lines crossed (locomotion) defined as all four paws crossing the 
line;  (2) the total rearing in the outside 12 squares (outer rearing); (3) the total rearing in the 
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inside four squares (centre rearing).  The social interactive behaviour for each pair of animals 
was the total time spent in social interaction (e.g. sniffing, grooming, mounting, and crawling 
over, crawling under or following the partner).  Because the behaviour of one animal affects 
that of the other, each pair of rats was treated as a unit (File & Seth, 2003) and only one score 
per pair was used for measures of social interaction behaviour.  Lower levels of social 
interaction are considered to be indices of higher anxiety (Baranvi et al., 2005).  
It has been suggested that the reciprocal neural circuits linking the PFC, the amygdala and 
hypothalamus are directly involved in fear and anxiety (Gonzalez, Rujano, Tucci, Paredes, 
Alba, & Hernandez, 2000; Voigt, Hortnagl, Rex, Van Hove, Bader, & Fink, 2005).  Since the 
introduction of benzodiazepines, 5-HT has been recognised as playing a crucial part in anxiety-
like behaviours (File & Seth, 2003).  The current view is that human anxiety is related to 
insufficient 5-HT.  Anxiety and drug abuse are inter-connected, possibly through the 
functioning of the 5-HT system (Gingrich & Hen, 2001).  One premise of the present study is 
that 5-HT connections to the immature PFC will cause a change in anxiety observed in 
adulthood.   
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Chapter 3: Statistical Analyses and Results 
Statistical analyses 
The major focus of this study was to examine longer-term outcomes following earlier exposure 
to either BZP or MA with the expectation that animals exposed to either BZP or MA in 
adolescence would subsequently demonstrate higher levels of anxiety (when in a drug-free 
state) than the control animals.  To facilitate interpretation, each response was subjected to a 
dose x sex ANOVA for each drug separately by means of the StatView programme for 
Macintosh computers, followed by Fisher PLSD post hoc tests (P<.05) when appropriate.  
These analyses were conducted for testing that occurred at each of the three testing periods 
(30-day washout, PND120, PND200) following treatment at PND31-40, PND41-50 and 
PND51-60.  Sex differences were taken into account because of the possibility that males and 
females may have differed in their responsiveness to the treatment (as has frequently been 
demonstrated with other treatments, Hughes, 2007). For the Y-maze, one-sample t-tests were 
also computed for % of novel time and % of novel entries compared with a mean expectancy 
of 50%. In view of the possibility that the use of Fisher post hoc tests may have increased the 
probability of Type 1 errors occurring, more rigorous Scheffe tests were also performed which 
confirmed the results of the original analyses.   
Results at 30 day wash-out period 
All animals were tested in the Y-maze, emergence box, EPM and Social Interaction test 30 
days after last administration of either saline, BZP or MA.  The 30 day wash-out period 
ensured that all animals were tested in a drug-free state. Full ANOVA results are included in 
Table 2 and significant sex effects are included in Table 3. 
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Table 2. F ratios for dose and sex effects for each measure recoded at three periods following treatment with BZP or MA at three stages of 
adolescence 
 
 BZP MA Sex (BZP) Sex (MA) 
30 day washout testing     
     
Treatment @ PND31-40     
   Y-maze percent novel arm entries F(3,72) = 1.03 F(3,72) = 2.28 F(1,72) = .66 F(1,72) = .06 
   Y-maze total arm entries F(3,72) = 5.19** F(3,72) = 1.76 F(1,72) = 20.14***  F(1,72) = 5.44** 
   Y-maze percent novel arm time F(3,72) = 1.73 F(3,72) = 3.57** F(1,72) = 1.28 F(1,72) = 1.90 
     
   Light/dark emergence F(3,72) = 1.43 F(3,72) = 3.67* F(1,72) = 1.28 F(1,72) = 2.86 
     
   EPM percent open arm entries F(3,72) = 5.04** F(3,72) = .49 F(1,72) = 4.27* F(1,72) = .18 
   EPM percent open arm time F(3,72) = 17.97*** F(3,72) = 1.62 F(1,72) = .20 F(1,72) = 2.83 
   EPM closed arm entries F(3,72) = .48 F(3,72) = 2.49 F(1,72) = 3.92 F(1,72) = 2.83 
     
   SI squares entered F(3,72) = 6.91*** F(3,72) = 2.36 F(1,72) = 15.38*** F(1,72) = 7.76** 
   SI outer rears F(3,72) = 4.08** F(3,72) = .96 F(1,72) = .54 F(1,72) = .48 
   SI centre rears F(3,72) = 2.29 F(3,72) = 1.11 F(1,72) = 1.84 F(1,72) = .36 
   SI interaction time F(3,36) = .51 F(3,36) = 1.55 F(1,36) = .60 F(1,36) = .24 
     
Treatment @ PND41-50     
   Y-maze percent novel arm entries F(3,72) = 2.23 F(3,72) = 1.72 F(1,72) = .11 F(1,72) = .87 
   Y-maze total arm entries§ F(3,72) = 9.34**** F(3,72) = 2.38 F(1,72) =  25.28**** F(1,72) = 25.36**** 
   Y-maze percent novel arm time F(3,72) = 3.93** F(3,72) = 2.07 F(1,72) = .01 F(1,72) = 1.60 
     
   Light/dark emergence F(3,72) = 4.26** F(3,72) = 2.66 F(1,72) = 13.70*** F(1,72) = 34.68**** 
     
   EPM percent open arm entries F(3,72) = 3.40* F(3,72) = 1.75 F(1,72) = .76 F(1,72) = 3.70 
   EPM percent open arm time F(3,72) = 7.60*** F(3,72) = 1.19 F(1,72) = 7.48** F(1,72) = 12.55*** 
   EPM closed arm entries F(3,72) = 1.04 F(3,72) = 2.53 F(1,72) = 13.86*** F(1,72) = 14.08*** 
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   SI squares entered F(3,72) = 2.29 F(3,72) = .35 F(1,72) = 22.99**** F(1,72) = 13.49**** 
   SI outer rears F(3,72) = .79 F(3,72) = 1.78 F(1,72) = .54 F(1,72) = 2.24 
   SI centre rears F(3,72) = 1.66 F(3,72) = 2.73 F(1,72) = .66 F(1,72) = 1.18 
   SI interaction time F(3,36) = .85 F(3,36) = .41 F(1,36) = .20 F(1,36) = .78 
     
Treatment @ PND51-60     
   Y-maze percent novel arm entries F(3,72) = 1.05 F(3,72) = .87 F(1,72) = 3.93 F(1,72) = 7.90** 
   Y-maze total arm entries F(3,72) = 42.91**** F(3,72) = 43.35**** F(1,72) = 31.88**** F(1,72) = 11.86*** 
   Y-maze percent novel arm time F(3,72) = 1.14 F(3,72) = 1.37 F(1,72) = 2.19 F(1,72) = 7.12** 
     
   Light/dark emergence F(3,72) = 2.43 F(3,72) = 2.59 F(1,72) = 16.95**** F(1,72) = 9.94** 
     
   EPM percent open arm entries§ F(3,72) = 5.76*** F(3,72) = 2.05 F(1,72) = 11.62*** F(1,72) = 12.92*** 
   EPM percent open arm time§ F(3,72) = 3.90** F(3,72) = 7.84**** F(1,72) = 10.38*** F(1,72) = 22.58*** 
   EPM closed arm entries F(3,72) = 1.47 F(3,72) = 2.18 F(1,72) = 7.29** F(1,72) = 10.52*** 
     
   SI squares entered F(3,72) = 3.75** F(3,72) = 5.49*** F(1,72) = 32.30**** F(1,72) = 13.43*** 
   SI outer rears F(3,72) = 3.67* F(3,72) = 4.34** F(1,72) = 1.75 F(1,72) = 3.32 
   SI centre rears F(3,72) = 2.14 F(3,72) = 1.24 F(1,72) = .12 F(1,72) = 1.16 
   SI interaction time F(3,36) = .16 F(3,36) = .79 F(1,36) = 6.51** F(1,36) = 8.51** 
     
Testing @ PND120     
     
Treatment @ PND31-40     
   Y-maze percent novel arm entries F(3,72) = 1.51 F(3,72) = .64 F(1,72) = .03 F(1,72) = 1.04 
   Y-maze total arm entries F(3,72) = 1.05 F(3,72) = 6.50*** F(1,72) =  64.79**** F(1,72) = 43.09**** 
   Y-maze percent novel arm time F(3,72) = 3.95** F(3,72) = .17 F(1,72) = .15 F(1,72) = 2.24 
     
   Light/dark emergence F(3,72) = 5.48*** F(3,72) = 5.34** F(1,72) = 29.25**** F(1,72) = 13.90*** 
     
   EPM percent open arm entries F(3,72) = 3.06* F(3,72) = 3.41* F(1,72) = .03 F(1,72) = 1.50 
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   EPM percent open arm time F(3,72) = 3.45* F(3,72) = 1.12 F(1,72) = .02 F(1,72) = 3.13 
   EPM closed arm entries F(3,72) = .26 F(3,72) = .88 F(1,72) = 26.47**** F(1,72) = 24.47*** 
     
   SI squares entered F(3,72) = 8.23**** F(3,72) = 7.95**** F(1,72) = 83.59**** F(1,72) = 54.18*** 
   SI outer rears F(3,72) = 5.80*** F(3,72) = 3.58** F(1,72) = 9.18** F(1,72) = 9.33** 
   SI centre rears F(3,72) = 8.22**** F(3,72) = 5.22*** F(1,72) = 2.33 F(1,72) = 2.54 
   SI interaction time F(3,36) = 1.02 F(3,36) = .45 F(1,36) = 4.30* F(1,36) = 7.88* 
     
Treatment @ PND41-50     
   Y-maze percent novel arm entries F(3,72) = 3.09* F(3,72) = 4.30** F(1,72) = .95 F(1,72) = 3.48 
   Y-maze total arm entries§ F(3,72) = 8.08**** F(3,72) = 16.17**** F(1,72) = 36.73****  F(1,72) = 24.81*** 
   Y-maze percent novel arm time F(3,72) = 2.51 F(3,72) = 2.84* F(1,72) = .02 F(1,72) = 3.65 
     
   Light/dark emergence F(3,72) = 13.44**** F(3,72) = 8.08**** F(1,72) = 6.85** F(1,72) = 14.75*** 
     
   EPM percent open arm entries F(3,72) = 1.35 F(3,72) = .62 F(1,72) = 2.59 F(1,72) = 3.85 
   EPM percent open arm time§ F(3,72) = 1.29 F(3,72) = .34 F(1,72) = 1.13 F(1,72) = 4.70* 
   EPM closed arm entries F(3,72) = .05 F(3,72) = 3.65* F(1,72) = 21.77**** F(1,72) = 23.75**** 
     
   SI squares entered F(3,72) = 1.78 F(3,72) = .18 F(1,72) = 83.89**** F(1,72) = 125.80**** 
   SI outer rears F(3,72) = .87 F(3,72) = .84 F(1,72) = 27.95**** F(1,72) = 30.06**** 
   SI centre rears F(3,72) = 2.43 F(3,72) = .21 F(1,72) = 4.66* F(1,72) = 2.16 
   SI interaction time F(3,36) = .40 F(3,36) = 1.54 F(1,36) = .36 F(1,36) = 1.29 
     
Treatment @ PND51-60     
   Y-maze percent novel arm entries F(3,72) = .72 F(3,72) = 1.05 F(1,72) = .29 F(1,72) = .30 
   Y-maze total arm entries F(3,72) = 5.70** F(3,72) = 14.59**** F(1,72) =  55.67**** F(1,72) = 24.38**** 
   Y-maze percent novel arm time§ F(3,72) = 1.42 F(3,72) = 1.37 F(1,72) = .20 F(1,72) = .96 
     
   Light/dark emergence F(3,72) = 4.64** F(3,72) = 1.67 F(1,72) = 3.19 F(1,72) = 10.27** 
     
   EPM percent open arm entries§ F(3,72) = 3.51* F(3,72) = 10.60**** F(1,72) = 3.42 F(1,72) = 9.40*** 
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   EPM percent open arm time F(3,72) = 3.10* F(3,72) = 6.93*** F(1,72) = 13.10*** F(1,72) = 17.68**** 
   EPM closed arm entries F(3,72) = .61 F(3,72) = 3.97** F(1,72) = 18.76**** F(1,72) = 13.51*** 
     
   SI squares entered F(3,72) = 5.41** F(3,72) = 2.54 F(1,72) = 18.59**** F(1,72) = 69.93**** 
   SI outer rears F(3,72) = 5.91** F(3,72) = 1.54 F(1,72) = 13.36*** F(1,72) = 18.11**** 
   SI centre rears F(3,72) = 3.61* F(3,72) = 1.45 F(1,72) = .30 F(1,72) = .52 
   SI interaction time F(3,36) = .57 F(3,36) = 1.92 F(1,36) = .25 F(1,36) = .01 
     
Testing @ PND200     
     
Treatment @ PND31-40     
   Y-maze percent novel arm entries F(3,72) = 5.22** F(3,72) = 1.13 F(1,72) = .03 F(1,72) = .03 
   Y-maze total arm entries F(3,72) = 2.60 F(3,72) = .03 F(1,72) = 83.55****  F(1,72) = 80.62**** 
   Y-maze percent novel arm time F(3,72) = 3.95* F(3,72) = .88 F(1,72) = .46 F(1,72) = .02 
     
   Light/dark emergence§ F(3,72) = 8.08**** F(3,72) = 6.95*** F(1,72) = 30.56**** F(1,72) = 18.25**** 
     
   EPM percent open arm entries F(3,72) = 3.71** F(3,72) = 2.13 F(1,72) = .77 F(1,72) = 11.48** 
   EPM percent open arm time F(3,72) = 3.32* F(3,72) = 4.86** F(1,72) = .15 F(1,72) = 9.75** 
   EPM closed arm entries F(3,72) = 6.21*** F(3,72) = 2.28 F(1,72) = 43.44**** F(1,72) = 29.56**** 
     
Treatment @ PND41-50     
   Y-maze percent novel arm entries F(3,72) = .24 F(3,72) = .58 F(1,72) = .95 F(1,72) = 3.47 
   Y-maze total arm entries F(3,72) = 3.27* F(3,72) = 8.79**** F(1,72) =  73.75**** F(1,72) = 40.78**** 
   Y-maze percent novel arm time F(3,72) = 2.35 F(3,72) = .71 F(1,72) = .43 F(1,72) = 1.25 
     
   Light/dark emergence F(3,72) = 20.96**** F(3,72) = 18.93**** F(1,72) = 13.28*** F(1,72) = 12.64*** 
     
   EPM percent open arm entries F(3,72) = 1.23 F(3,72) = 1.40 F(1,72) = 6.78** F(1,72) = 4.79* 
   EPM percent open arm time F(3,72) = 2.02** F(3,72) = 3.18* F(1,72) = 5.60* F(1,72) = 5.29* 
   EPM closed arm entries F(3,72) = .69 F(3,72) = 1.03 F(1,72) = 22.89**** F(1,72) = 3.10**** 
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Treatment @ PND51-60     
   Y-maze percent novel arm entries F(3,72) = 1.36 F(3,72) = 2.27 F(1,72) = 3.31 F(1,72) = 7.18** 
   Y-maze total arm entries§ F(3,72) = .03 F(3,72) = 8.72**** F(1,72) = 80.62****  F(1,72) = 53.85**** 
   Y-maze percent novel arm time F(3,72) = .55 F(3,72) = 2.50 F(1,72) = 6.70* F(1,72) = 3.51 
     
   Light/dark emergence F(3,72) = 9.06**** F(3,72) = 5.07** F(1,72) = 15.19*** F(1,72) = 14.56*** 
     
   EPM percent open arm entries§ F(3,72) = 1.09 F(3,72) = 4.74** F(1,72) = 6.64** F(1,72) = 19.96**** 
   EPM percent open arm time§ F(3,72) = .74 F(3,72) = 1.89 F(1,72) = 1.57 F(1,72) = 13.83*** 
   EPM closed arm entries F(3,72) = 3.81** F(3,72) = 4.98** F(1,72) = 39.20**** F(1,72) = 24.17**** 
 
§Dose x sex interaction significant (see text); *P<.05; **P<.01; ***P<.001: ****P<.0001.  
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Table 3: Means  ± SEMs for sex differences that were significant for each measure at three 
periods following treatment with BZP or MA during three stages of adolescence 
 
 
30 day washout testing 
 
Treatment @ PND31-40 BZP MA 
 Male Female Male Female 
Y-maze percent of novel arm entries ns ns ns ns 
Y-maze total arm entries 1.78 ± .14 2.58 ± .13 2.45 ± .18 3.04 ± .19 
Y-maze percent of novel arm time ns ns ns ns 
     
Light/dark emergence 124.54 ± .62 109.7 ± 3.08 ns ns 
     
EPM percent of open arm entries 36.33 ± 2.33 41.41 ± 1.18 ns ns 
EPM percent of open arm time ns ns ns ns 
EPM closed arm entries ns ns ns ns 
     
SI squares entered 105.62 ± 2.45 119.67 ± 2.32 106.93 ± 3.12 119.18 ± 3.10 
SI outer rears ns ns ns ns 
SI centre rears ns ns ns ns 
SI interaction time ns ns ns ns 
     
Treatment @ PND41-50     
     
Y-maze percent of novel arm entries ns ns ns ns 
Y-maze total arm entries 1.39 ± .12 2.28 ± .18 1.68 ± .16 2.86 ±.19 
Y-maze percent of novel arm time ns ns ns ns 
     
Light/dark emergence 146.64 ± 4.12 124.97 ± 4.67 143.1 ± 6.45 114.25 ± 5.93 
     
EPM percent of open arm entries ns ns ns ns 
EPM percent of open arm time 29.03 ± 2.61 37.85 ± 2.43 31.39 ± 2.94 44.83 ± 2.34 
EPM closed arm entries 5.87 ± .28 7.64 ± .38 5.26 ± .37 7.22 ± .40 
     
SI squares entered 92.07 ± 3.20 113.26 ± 3.13 101.78 ± 2.98 119.38 ± 3.64 
SI outer rears ns ns ns ns 
SI centre rears ns ns ns ns 
SI interaction time ns ns ns ns 
     
Treatment @ PND51-60     
     
Y-maze percent of novel arm entries ns ns 43.6 ±3.04 54.56 ± 2.48 
Y-maze total arm entries 1.87 ± .21 2.92 ± .22 1.89 ± .21 2.57 ± .25 
Y-maze percent of novel arm time ns ns 41.32 ± 3.19 52.86 ± 2.91 
     
Light/dark emergence 136.20 ± 4.25 107.69 ± 5.59 132.01 ± 4.77 121.53 ± 5.41 
     
EPM percent of open arm entries 34.98 ± 2.09 43.41 ± 1.73 39.01 ± 2.01 47.09 ± 1.26 
EPM percent of open arm time 28.75 ± 2.75 40.00 ± 2.44 34.95 ± 2.73 48.25 ± 1.87 
EPM closed arm entries 6.19 ± .39 7.38 ± .33 6.67 ± .32 8.18 ± .35 
     
SI squares entered 98.15 ± 3.44 121.22 ± 2.57 95.93 ± 3.34 112.7 ± 3.79 
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SI outer rears ns ns ns ns 
SI centre rears ns ns ns ns 
SI interaction time 116.45 ± 5.23 98.67 ± 4.36 120.3 ± 6.06 96.9 ± 6.96 
 
Testing @ PND120 
 
Treatment @ PND31-40 BZP MA 
 Male Female Male Female 
Y-maze percent of novel arm entries ns ns ns ns 
Y-maze total arm entries 3.51 ± .20 5.88 ± .22 2.95 ± .19 4.90 ± .21 
Y-maze percent of novel arm time ns ns ns ns 
     
Light/dark emergence 154.29 ± 7.07 117.51 ± 6.09 154.94 ± 4.64 130.99 ± 4.45 
     
EPM percent of open arm entries ns ns ns ns 
EPM percent of open arm time ns ns ns ns 
EPM closed arm entries 5.43 ± .30 7.64 ± .36 6.07 ± .28 8.08 ± .30 
     
SI squares entered 80.10 ± 2.37 110.35 ± 2.38 78.95 ± 3.29 110.67 ± 3.51 
SI outer rears 36.04 ± .88 40.42 ± 1.07 35.50 ± 1.12 40.67 ± 1.36 
SI centre rears ns ns ns ns 
SI interaction time 107.31 ± 4.36  91.83 ± 3.81 109.70 ± 6.37 88.05 ± 4.79 
     
Treatment @ PND41-50     
     
Y-maze percent of novel arm entries ns ns ns ns 
Y-maze total arm entries 3.15 ± .20 4.88 ± .25 2.96 ± .21 4.30 ± .28 
Y-maze percent of novel arm time ns ns ns ns 
     
Light/dark emergence 140.93 ± 6.67 121.53 ± 6.35 138.47 ± 4.61 108.84 ± 5.61 
     
EPM percent of open arm entries ns ns ns ns 
EPM percent of open arm time ns ns 41.88 ± 3.35 50.12 ± 2.01 
EPM closed arm entries 5.20 ± .31 7.30 ± .31 6.22 ± .37 8.69 ± .37 
     
SI squares entered 72.65 ± 3.21 113.36 ± 3.20 73.18 ± 2.90 122.57 ± 3.28 
SI outer rears 34.70 ± 1.27 44.41 ± 1.34 33.90 ± 1.35 44.62 ± 1.38 
SI centre rears 1.05 ± .27 2.13 ± .42 ns ns 
SI interaction time ns ns ns ns 
     
Treatment @ PND51-60     
     
Y-maze percent of novel arm entries ns ns ns ns 
Y-maze total arm entries 2.95 ± .19 5.10 ± .21 2.61 ± .20 3.87 ± .24 
Y-maze percent of novel arm time ns ns ns ns 
     
Light/dark emergence ns ns 138.27 ± 5.00 114.36 ± 5.63 
     
EPM percent of open arm entries ns ns 42.12 ± 2.02 48.22 ± 1.26 
EPM percent of open arm time 36.02 ± 2.55 47.45 ± 2.01 41.58 ± 2.47 525.67 ± 1.70 
EPM closed arm entries 6.27 ± .53 8.10 ± .44 6.27 ± .30 8.10 ± .28 
     
SI squares entered 80.55 ± 3.29 99.70 ±3.43 73.00 ± 2.54 108.60 ± 3.57 
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SI outer rears 35.88 ± 1.24 42.53 ± 1.57 33.12 ± 1.12 40.17 ± 1.21 
SI centre rears ns ns ns ns 
SI interaction time ns ns ns ns 
 
Testing @ PND200 
 
Treatment @ PND31-40 
BZP MA 
 Male Female Male Female 
Y-maze percent of novel arm entries ns ns ns ns 
Y-maze total arm entries 3.00 ± .16 5.28 ± .19 2.76 ± .17 5.10 ± .19 
Y-maze percent of novel arm time ns ns ns ns 
     
Light/dark emergence 155.33 ± 4.06 117.51 ± 7.26 155.78 ± 4.96 132.55 ± 7.09 
     
EPM percent of open arm entries ns ns 43.41 ± 2.53 49.09 ± 1.24 
EPM percent of open arm time ns ns 34.74 ± 2.99 45.97 ± 2.42 
EPM closed arm entries 4.98 ± .29 7.84 ± .37 5.36 ± .29 7.69 ± .32 
     
Treatment @ PND41-50     
     
Y-maze percent of novel arm entries ns ns ns ns 
Y-maze total arm entries 2.79 ± .17 5.00 ± .21 2.72 ± .18 4.31 ± .22 
Y-maze percent of novel arm time ns ns ns ns 
     
Light/dark emergence 115.09 ± 6.37 128.13 ± 6.89 149.35 ± 6.09 123.76 ± 7.11 
     
EPM percent of open arm entries 39.67 ± 2.75 47.40 ± 1.13 42.22 ± 2.24 47.90 ± 1.30 
EPM percent of open arm time 35.86 ± 3.40 47.90 ± 1.76 35.66 ± 3.26 44.70 ± 2.59 
EPM closed arm entries 5.70 ± .37 8.03 ± .3 5.50 ± .29 7.75 ± .27 
     
Treatment @ PND51-60     
     
Y-maze percent of novel arm entries ns ns 54.93 ± 2.65 63.30 ± 1.60 
Y-maze total arm entries 2.76 ± .19 5.1 ± .19 2.21 ± .14 3.83 ± .22 
Y-maze percent of novel arm time 46.69 ± 2.42 54.03 ± 1.40 ns ns 
     
Light/dark emergence 157.81 ± 4.47 130.38 ± 6.89 157.60 ± 4.59 129.79 ± 6.26 
     
EPM percent of open arm entries 41.96 ± 2.15 48.20 ± 1.15 40.58 ± 1.97 49.83 ± 1.34 
EPM percent of open arm time ns ns 38.71 ± 3.49 53.43 ± 2.30 
EPM closed arm entries 5.10 ± .18 7.41 ± .16 5.68 ± .29 7.89 ± .38 
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1. Y-Maze results  
Each animal was tested in the Y-maze four times and averages of the four trials were used in 
each of the analyses.  See Table 2 above for F ratios and Table 3 for significant sex differences, 
across the three testing periods.  
BZP and MA treated: Percentage of Entries of the Novel Arm of the Y-maze at 30 day 
wash-out period.  
 
Figure 3: Mean (±S. E. M.) percent of novel entries for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 20mg/kg) 
and MA (Dose 1 -0 .5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male and female rats.  † differs 
significantly (p<.05) from chance expectancy of 50% (one-sample t test). .  
Figure 3 illustrates that although the dose effect was not significant for either drug, rats treated 
with saline during PND31-40 displayed a significant preference for entering the novel arm over 
the familiar arm and rats treated during PND41-50 with 20 mg/kg BZP or 1.0 mg/kg MA 
displayed significant preference for entering the familiar rather than novel arm. There was one 
sex effect for treatment at PND51-60: female MA-treated rats made significantly more entries 
of the novel arm at than male MA-treated rats.   
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BZP and MA treated: Total Entries of both arms of the Y-maze at 30 day wash-out 
period.  
 
Figure 4: Mean (±S. E. M.) total entries of both arms for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 20mg/kg) 
and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male and female rats.  * 
significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
Figure 4 illustrates that PND31-40 BZP-treated rats made significantly fewer entries of both 
arms of the Y-maze than saline treated rats of the same age.  PND 41-50 and PND51-60 BZP-
treated rats made significantly fewer entries of both arms of the Y-maze than saline treated rats 
of the same age. For both PND41-50 and PND51-60 BZP-treated rats, there was a significant 
difference between the lowest and highest doses, indicating that as the BZP dose increased, 
treated rats became less active.   However, in the former case, a significant dose x sex 
interaction outlined in Figure 5 showed that the effect applied to female but not male rats. Only 
the PND51-60 MA-treated rats made significantly fewer entries of both arms of the Y-maze 
compared to saline-treated rats of the same age.  All treated female rats made significantly 
more total arm entries than similar treated male rats.  Overall, the pattern of results suggests 
that the as dose of BZP increased, regardless of administration age, animals became less 
mobile.  This outcome only typified rats treated with MA during later adolescence.     
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Drug x sex interaction for PND41-50 BZP treated rats: Total Entries of both arms of the 
Y-maze at 30 day wash-out period.  
 
 
Figure 5: Mean (±S. E. M.) total entries of both arms for control (Saline), BZP PND41-50 treated male and female rats.  * significantly 
different (p<.05) from saline for that particular sex. a,b difference between groups with superscript in common significant (p<.05) for 
that particular drug.   
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BZP and MA treated: Percentage of Time spent in the Novel Arm of the Y-maze at 30 
day wash-out period. 
Figure 6: Mean (±S. E. M.) percent of  time spent in the novel  arm of the Y-maze for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male 
and female rats.  † differs significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) 
from saline for that particular drug; a,b difference between groups with superscript in common significant (p<.05) for that particular 
drug.   
 Figure 6 shows that, at PND31-40 and PND41-50, saline-treated animals preferred to spend 
time in the novel arm of the Y-maze over the familiar arm, compared with a mean expectancy 
of 50%.  However, PND31-40 highest MA-treated and PND41-50 highest BZP-treated rats 
preferred to spend significantly more time in the familiar arms of the Y-maze, compared with a 
mean expectancy of 50%.  Rats treated with 2.0 mg/kg of MA at PND31-40 spent a 
significantly less percentage of time in the novel arm, compared to saline- treated rats.  At 
PND41-50, BZP-treated rats spent a significantly less percentage of time in the novel arm of 
the Y-maze compared with age matched controls.  There was one significant sex effect for 
MA-treated rats at PND51-60; females spent significantly more time in the novel arm of the Y-
maze than their male counterparts.  
Summary of Y-maze results for 30 day wash-out period.   
The Y-maze taps into rats’ innate tendency to explore novel areas (Hughes, 2001; Hughes & 
Neeson, 2003; Samyai, et al., 2000) and normal animals will enter the novel arm more than the 
familiar arm, whereas anxious animals will show less of a preference for novelty.  
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Additionally, the Y maze is a test of short-term spatial memory for brightness change (Gray & 
Hughes, 2015).  The results showed that there were systematic differences in measures of 
emotionally similar to Aitchison and Hughes (2006) research.  That is, as adults, the rats that 
had been exposed to BZP as adolescents displayed more emotionally than control rats.  This 
was most evident in the PND41-50 developmental period. However this may also be attributed 
to differences between male and female treated rats, with the female treated rats being more 
effected by dose increases in BZP compared to male rats. In regards to earlier MA 
administration, the results suggest that that administration of MA during the later 
developmental period of adolescence (PND51-60) affects male rats significantly more than 
females, with male rats possibly displaying more anxiety in the Y-maze than females.   Overall, 
the results of adult testing of adolescence BZP and MA administration imply that, 30 days after 
drug treatment, there are dose-related changes in Y-maze behaviour that could be indicative of 
changes in anxiety.     
2. Light/dark emergence results  
As each animal was tested in the light/dark apparatus seven times on each of the three different 
testing times, averages of the seven trials were used in each of the analyses.  See Table 2 above 
for F ratios and Table 3 for significant sex differences, across the three testing periods.  
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BZP and MA treated: Emergence latency time from the Light/dark apparatus at 30 day 
wash-out period.  
 
Figure 7:  Mean (±S. E. M.) emergence latency from the Light/dark box for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; 
Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female 
rats. † differs significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) from saline 
for that particular drug; a,b difference between groups with superscript in common significant (p<.05) for that particular drug.   
Figure 7 illustrates that at PND31-40, latencies to emerge from the dark following treatment 
with the two higher doses of MA were significantly different from same aged saline treated 
rats.  Additionally, there was a significant difference between the doses, with the higher MA 
dosed rats slower to emerge than those treated with the lowest dose. Similarly, PND41-50 rats 
administered both 10 mg/kg and 20 mg/kg BZP took longer than saline-treated matched 
controls to emerge from the dark compartment. Neither drug produced significant effects after 
treatment at PND51-60.   
There were five significant sex effects in the light/dark box at 30 day wash-out period, with 
female rats in all conditions being faster to emerge than male rats, with the exception of male 
and female rats treated with MA during PND31-40 which were comparative.      
Summary of Light/dark box emergence at 30 day wash-out period.  
The light/dark box is based on rodents' innate aversion to bright illuminated areas.  In response 
to stressors, that is, bright light and a novel environment, a rodent faces a natural conflict 
between the tendency to explore and the initial tendency to avoid the unfamiliar (Bourin & 
Hascoet, 2003).  As MA dose increased for PND 31-40 treated rats and BZP dose increased for 
PND 41-50 treated rodents, the rats were slower to emerge from the light/dark box, suggesting 
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an increase in anxiety for these conditions.  This implies differences in drug administered and 
adolescence developmental periods have different outcomes on latency to emerge from the 
light/dark box.  However, with the exception of PND 51-60, (which for both BZP and MA 
treated rats there was a longer latency to emerge, but no obvious dose-related pattern), both 
drugs administered during PND 31-40 and 41-50 showed increasing anxiety with increased 
doses.  Additionally, consistent with most research using both male and female rats: female 
rats generally are more active than male rats (Bridges & Starkey, 2004; Hughes & Neeson, 
2003; Palanza, 2001), which was supported in this measure. Female rats (in all conditions, 
except MA treatment administered during PND31-40) generally emerged faster than males.   
3.  EPM results  
Each animal was tested once at each of the three testing periods in the EPM, as research 
suggests the EPM can produce habitation effects if tested within two weeks after first trial 
(Bessa et al., 2005).   See Table 2 above for F ratios and Table 3 for significant sex differences, 
across the three testing periods.  
BZP and MA treated: Percentage of Entries of the open arms of the EPM at 30 day wash-
out period.  
 
Figure 8: Mean (±S. E. M.) percent of open arm entries for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 
20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats. . † 
differs significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) from saline for that 
particular drug; a,b difference between groups with superscript in common significant (p<.05) for that particular drug.   
Figure 8 illustrates that administration of BZP during PND31-40 significantly affected 
percentage of entries of the open arms of the EPM, with the highest dose significantly different 
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from saline and the two lower doses. Likewise, the highest BZP dose administered during 
PND41-50 was significantly different from saline controls, but not from the other two BZP 
doses. However, it was the lowest BZP dose administered during PND51-60 that was 
significantly different from control animals.  There are also differences between the doses of 
BZP administered during PND51-60, with the lowest dose (5 mg/kg) significantly different 
from the middle dose (10 mg/kg) and the middle BZP dosed animals significantly different 
from the highest BZP (20 mg/kg) treated rats in the percentage of entries of the open arms of 
the EPM.  With the exception of MA- treated females during PND31-40 and BZP and MA- 
treated during PND41-50 all other female treated rats made significantly more entries of the 
open arms of the EPM than similar treated male rats.   
A significant dose x sex interaction for PND51-60- MA-treated rats (F (1, 72) 2.92, P<.0397) 
outlined in Figure 9 revealed that the two lower doses of the drug increased this response for 
female but not male rats.  However, males treated with 1.0 mg/kg made fewer entries of the 
open arms than those treated with 0.5 mg/kg.  Female rats treated with 2 mg/kg scored lower 
on this response than those treated with 1 mg/kg. 
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Drug x sex interaction for PND51-60 MA treated rats: Percentage of Entries of the open 
arms of the EPM at 30 day wash-out period.  
 
Figure 9:  Mean (±S. E. M.) percentage of open arm entries  for control (Saline), MA  PND 51-60 treated male and female rats. * 
significantly different (p<.05) from saline for that particular sex. a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
BZP and MA treated: Percentage of time in the open arms of the EPM at 30 day wash-
out period.  
 
Figure 10:  Mean (±S. E. M.) percentage of time spent in the open arms of the EPM for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 
- 10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male 
and female rats.  † differs significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) 
from saline for that particular drug; a,b difference between groups with superscript in common significant (p<.05) for that particular 
drug.   
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Figure 10 illustrates that PND31-40 BZP treated rats spent significantly less percentage of time 
in the open arms of the EPM compared to saline controls and the 5 mg/kg and 10 mg/kg treated 
rats.  Rats from both the lowest and the highest PND41-50 BZP treatment groups were 
significantly different from controls, and 10 mg/kg BZP treated rats. For PND51-60 the BZP 
10 mg/kg treated rats spent significantly more time in the open arms of the EPM compared to 
the higher (20 mg/kg) and lower (5 mg/kg) treated rats, but results were not statistically 
different from control rats.  Although the lowest MA dosed rats (0.5 mg/kg) spent significantly 
more time in the open arms than control animals, and the two MA-treated groups, a significant 
dose x sex interaction (F (3,72) 4.51, P<.0059) outlined in Figure 11 revealed that this response 
was increased by the two lower doses for females only. Although no male group differed 
significantly from saline, both higher doses significantly reduced time in the open arms 
compared with the lowest dose.  
Similar to the results for total closed arm entries, there was a significant difference between the 
sexes for both BZP- and MA-treated PND41-50 and 51-60 rats, with female treated rats 
spending a significant longer percentage of time in the open arm, than male treated rats.   
Drug x sex interaction for PND51-60 MA treated rats: Percentage of time spent in the 
open arms of the EPM at 30 day wash-out period.  
 
Figure 11:  Mean (±S. E. M.) percentage of time spent in the open arms  for control (Saline), MA  PND 51-60 treated male and female 
rats.  * significantly different (p<.05) from saline for that particular sex. a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
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BZP and MA treated: Entries of the closed arms of the EPM at 30 day wash-out period.  
 
Figure 12: Mean (±S. E. M.) entries of the closed arms of the EPM for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 
3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats.   
Figure 12 illustrates that there were no significant dose effects for all treatment groups on 
entries of the closed arms in the EPM at the 30 day wash-out period. However, again there 
were sex effects for both BZP- and MA-treated rats at both PND41-50 and 51-60, with female 
treated rats making more closed arm entries than male treated rats.  
Summary of EPM results for 30 day wash-out period.  
The EPM is currently one of the most popular in vivo animal tests (Carobrez & Bertoglio, 
2005) and research suggests that rats prefer the closed arms of the maze to the open arms and 
this preference is caused by fear or anxiety (Pellow et al., 1985; Flint, 2003).  The pattern of 
results suggests that the highest dose of BZP administered during the PND31-40 and 41-50 
affected the rats’ tendency to enter and spend time in the open arms of the EPM. Inconsistent 
with a dose-related increase in avoidance of the open arms, the lowest BZP dose group 
administered during PND51-60 made significantly fewer entries of the open arms of the EPM.  
Consistent with the results found in the Y-Maze and light/dark emergence box, female rats 
were more active than male rats. However, this effect was only significant for animals treated 
during PND41-50 and 51-60.     
While there appears to be a general pattern of increased avoidance with escalating BZP dose, in 
the EPM for rats administered BZP during PND31-40 and 41-50, the results for BZP and MA 
administered during PND51-60 are not as clear.  The lowest MA dose administered at PND51-
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60 resulted in a significantly longer percentage of time spent in the open arms, indicative of 
decreased anxiety compared to saline treated rats.  PND51-60 female rats administered either 
0.5 mg/kg or 1.0 mg/kg MA made significantly more entries and spent a longer percentage of 
time in open arms compared to saline treated female rats.  Interestingly, the female rats 
administered the highest MA dose (2.0 mg/kg) were comparable to the saline treated female 
rats in percentage of entries, with the saline treated rats and MA 2.0 mg/kg female rats 
choosing to enter the open arms of the EPM 43 percent of the time.  Likewise, the saline 
treated female rats and MA 2.0 mg/kg spent a similar amount of time, 38 percent and 41 
percent retrospectively in the open arms.  It appears that female rats administered MA during 
PND51-60 may be less than or equally anxious to untreated animals.            
4. Social Interaction test.  
Each animal was paired with an unfamiliar animal of a similar weight (± 10 grams) and tested 
once at each of the two testing periods in the Social Interaction test.  As already mentioned, 
PND200 data was destroyed in the February 2011 Christchurch Earthquake. See Table 2 above 
for F ratios and Table 3 for significant sex differences, across the three testing periods.  
BZP and MA treated: Total squares entered in the Social Interaction test at 30 day wash-
out period.  
 
Figure 13:  Mean (±S. E. M.) total squares entered in the Social Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats. .  * significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.  .    
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Figure 13 illustrates that PND31-40 BZP (20 mg/kg) treated animals entered significantly more 
squares in the open field of the Social interaction test than saline, and other two BZP doses. 
Similarly, the highest dose of BZP administered during PND51-60 treated rats entered 
significantly more squares in the OF, compared to controls and were significantly different 
from the BZP- (10 mg/kg) treated rats. Conversely, the highest dose MA-treated rats entered 
significantly fewer squares than the same aged saline controls, and lowest MA-treated rats.  
There were sex effects for all treated rats in total squares entered in the open field of the Social 
Interaction test, with female rats entering significantly more squares than similar treated male 
rats.  
BZP and MA treated: Outer Rears in the Social Interaction test at 30 day wash-out 
period.  
 
Figure 14:  Mean (±S. E. M.) total outer rears  in the Social  Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male 
and female rats.  * significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.   
Figure 14 illustrates that the highest dose of BZP administered during PND31-40 and PND51-
60 animals made significantly more outer rears in the open field of the Social Interaction test, 
than same aged control animals, and the two lower BZP doses. However the highest dose of 
MA administered during PND51-60 animals made significantly less outer rears in the Social 
interaction test than saline controls, and the two lower MA dosed groups.  There were no 
significant sex effects.   
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BZP and MA treated: Centre Rears in the Social Interaction test at 30 day wash-out 
period.  
 
Figure 15:  Mean (±S. E. M.) total centre rears in the Social Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats.   
Figure 15 illustrates no significant results for any conditions in rearing in the middle of the 
open field of the Social Interaction test or any significant sex effects.  
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BZP and MA treated: Interaction time in the Social Interaction test at 30 day wash-out 
period.  
 
Figure 16: Mean (±S. E. M.) total interaction time  in the Social  Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats.   
Figure 16 illustrates no significant dose effect for interaction frequency in the Social 
interaction test. However, there was a significant sex effect for both BZP and MA administered 
during PND51-60.  PND51-60 BZP and MA male treated rats spent a significantly higher 
frequency of time in social interaction than PND51-60 BZP female treated rats.   
Summary of Social Interaction test results at 30 day wash-out period.  
After a 30-day wash-out period pairs of unfamiliar animals from the same treatment condition 
were tested once in the Social Interaction test, which is a test of anxiety and curiosity (Wills, et 
al., 1983). Total squares entered is a measure of locomotion similar to that recorded in the Y-
maze, Light/dark emergence Box and EPM.  For this, as for those recorded on the other types 
of apparatus, female rats typically engaged in more locomotor activity than male rats.  
However,  there was still a significant dose effect for the PND31-40 BZP treated animals, in 
that as the dose of BZP increased both male and females increased the amount of squares 
entered, with females making significantly more entries than male rats.   Only the highest dose 
of MA administered during PND51-60 decreased locomotor activity for both male and female 
rats, with female rats still entering significantly more squares than male rats.  The highest dose 
of BZP administered to PND31-40 increased rearing in the outer squares, whereas the highest 
dose of MA administered to PND51-60 decreased outer rearing compared to matched controls. 
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The significant results for the PND51-60 MA- and BZP- treated rats may be explained, to 
some extent, by the significantly more time spent in social interaction seen by the  male treated 
rats, whereas they were more interested in the unfamiliar peers than exploring the novel 
environment.   
 
Results at PND120 
All animals were tested in the Y-maze, light/dark box, EPM and Social Interaction test at PND 
120.  See Table 2 above for F ratios and Table 3 for significant sex differences, across the three 
testing periods.  
1. Y-Maze results  
As each animal was tested in the Y-maze four times the averages of the four trials were used in 
each of the analyses.   
BZP and MA treated: Percentage of Entries of the Novel Arm of the Y-maze at PND120.  
 
Figure 17: Mean (±S. E. M.) percent of novel entries for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 20mg/kg) 
and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats.  † differs 
significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) from saline for that 
particular drug.   
Figure 17 shows a significant dose effect for all three BZP and MA doses administered during 
PND41-50, that were significantly different from same aged control rats in the percentage of 
entries of the Y-maze. Although, there were no other significant dose effects, rats treated with 
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saline during PND31-40 and 51-60, and rats treated with BZP during PND31-40 or all three 
doses of MA, and all three doses of BZP and MA during PND41-50 or 10 mg/kg BZP or 1.0 
mg/kg MA during PND51-60 displayed significant preferences for entering the novel arm 
rather than the familiar arm.  There were no significant sex effects.    
BZP and MA treated: Total Entries of both arms of the Y-maze at PND120.  
 
Figure 18:  Mean (±S. E. M.) total entries of both arms for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 
20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats.   * 
significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
 Figure 18 illustrates that rats treated with 2.0 mg/kg of MA during PND31-40, and rats treated 
with all three BZP and MA doses at PND41-50, and rats treated with 10 mg/kg of BZP during 
PND51-60, or all three MA doses, made significantly fewer entries of both arms than saline-
treated rats. However, a significant dose x sex interaction (F (3, 72) 2.77, P< .048) for effects 
of MA treatment at PND41-50 (outlined in Figure 19) revealed that the treatment effect was 
only typical of female rats.  Rats treated with 10 mg/kg BZP during PND51-60 made 
significantly fewer entries of both arms than 5 mg/kg and 20 mg/kg rats.  
Similar to the 30 day wash-out period, there were significant sex effects for all treated rats, 
with female rats making significantly more entries of both arms than male treated rats.  
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Drug x sex interaction for PND41-50 MA treated rats: Total Entries of both arms of the 
Y-maze at PND120.  
.    
 
Figure 19:  Mean (±S. E. M.) total entries of both arms for control (Saline), MA PND41-50 treated male and female rats. * significantly 
different (p<.05) from saline for that particular sex. a,b difference between groups with superscript in common significant (p<.05) for 
that particular drug.   
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BZP and MA treated: Percentage of Time spent in the Novel Arm of the Y-maze at 
PND120. 
 
Figure 20:  Mean (±S. E. M.) percent of  time spent in the novel  arm of the Y-maze for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 
- 10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats.  † differs significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) 
from saline for that particular drug.   
Figure 20 shows a significant dose effect for 10 mg/kg and 20 mg/kg BZP doses administered 
during PND31-40, and all three MA doses administered during PND41-50, with the BZP- 
treated spending lesser percentage of time in the changed arm while the MA- treated rats spent 
a significantly higher percentage of time in them. Although, there were no other significant 
dose effects, rats treated with 5 mg/kg BZP or 0.5 and 1.0 MA during PND31-40, and rats 
treated with 20 mg/kg BZP or all three doses of MA during PND41-50, saline at PND51-60 
and 1.0 mg/kg MA during PND51-60 displayed significant preferences for spending time in 
the novel arm rather than the familiar arm.  There were no significant sex effects.   
Summary of Y-maze results at PND120 
The general pattern of results in the Y-maze at PND120 suggest that rats treated with MA 
during PND41-50 had a significant tendency to enter and spend time in the novel Y-maze arm.  
PND41-50 BZP treated rats preferred to enter the novel arm over the familiar arm also, but it 
appears that once they entered the novel arm they did not prefer to spend time in it.  It is 
therefore possible that the PND41-50 treated rats are more impulsive than saline-treated rats.  
Ueno et al. (2002) report impulsive behaviour to appear as increased time and entries in a novel 
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environment in relation to total arm entries. Total entries of both arms is a measure of general 
locomotor activity and female rats are consistently more active than male rats.  However, 
female rats treated with MA during PND41-50 showed a decrease in locomotor activity in a 
dose dependent manner. Overall, it appears that rats treated with both BZP and MA during 
PND41-50 had decreased anxiety or possible impulsivity when tested at PND120, which was 
not contaminated by locomotor activity.     
2. Light/dark emergence results  
As each animal was tested in the light/dark box seven times and averages of the seven trials 
were used in each of the analyses.   
BZP and MA treated: Emergence latency time from the Light/dark box at PND 120.  
 
Figure 21:  Mean (±S. E. M.) emergence latency from the Light/dark box for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 -0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male 
and female rats.  * significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.   
Figure 21 illustrates that rats treated during PND31-40 with 20 mg/kg BZP, or 1.0 mg/kg and 
2.0 mg/kg MA, and all rats treated during PND41-50, and rats treated with 5 mg/kg BZP, 
during PND51-60 took significantly longer to emerge from the dark than saline-treated rats. 
Rats treated with 20 mg/kg BZP during PND31-40 had a significantly longer latency to emerge 
than the other two BZP doses and rats treated with MA 1.0 mg/kg, during the same period were 
significantly different from rats treated with MA 0.5 mg/kg. Also, rats treated with 5 mg/kg or 
 80 
 
20 mg/kg of BZP during PND51-60 had a significantly longer latency to emerge compared to 
the 10 mg/kg BZP treated rats.        
There were significant sex effects for all groups except for the rats treated with BZP during 
PND51-60, with female rats having a faster latency to emerge than male rats.  
Summary of Light/dark emergence results at PND120 
The general pattern of results again suggest that rats treated with BZP or MA during PND41-
50 were significantly different from saline-treated rats.  However, whereas these rats possibly 
displayed decreased anxiety or impulsivity in the Y-maze, longer latencies to emerge from the 
darkened box into the illuminated arena are indicative of higher anxiety (Archer, 1975) 
suggesting that the treatment of BZP or MA during PND41-50, and highest dose BZP rats or 
1.0 and 2.0 mg/kg MA treated rats at PND31-40 or lowest dose BZP PND51-60 are more 
anxious compared to control rats.  
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3. EPM results  
As already mentioned, due to potential habituation effects, each animal was tested once in the 
EPM.   
BZP and MA treated: Percentage of Entries of the open arms of the EPM at PND120. 
  
Figure 22:  Mean (±S. E. M.) percent of open arm  entries for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 
20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats.  * 
significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
Figure 22 illustrates that rats treated with all three doses of BZP during PND31-40, and rats 
treated with 0.5 mg/kg and 2.0 mg/kg MA, during PND31-40 had a significantly lower 
percentage of entries of the open arms of the EPM than saline-treated rats.  Similarly, rats 
treated with 10 mg/kg and 20 mg/kg of BZP during PND51-60, and rats treated with 2.0 mg/kg 
MA, during the same developmental period had a significantly lower percentage of open arm 
entries that saline-treated rats.  Rats treated with 1.0 mg/kg of MA during PND31-40 and rats 
treated with 2.0 mg/kg of MA during PND51-60 were significantly different from those 
administered the other two doses of MA during the same period.      
There was one sex effect, with female rats treated with MA during PND 51-60 having a higher 
percentage of open arm entries than male treated rats. There was also a significant drug x sex 
interaction (F (3, 72), P<.05) which, as outlined below in Figure 23, revealed that the drug 
effect following treatment with MA at PND51-50 was most obvious with male rats.  
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Drug x sex interaction for PND51-60 MA treated rats: Percentage of Entries of the open 
arms of the EPM at PND120.  
 
Figure 23:  Mean (±S. E. M.) percentage of open arm entries for control (Saline), MA PND51-60 treated male and female rats.   * 
significantly different (p<.05) from saline for that particular sex. a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
This graph illustrates that both male and female rats treated with 2.0 mg/kg of MA during 
PND51-60 had a significantly lower percentage of entries of the open arms than saline-treated 
rats.  However it appears that as the dose of MA increased, male rats were more affected, with 
the rats treated with 2.0 mg/kg being significantly different from those treated with either 0.5 
mg/kg or 1.0 mg/kg.  
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BZP and MA treated: Percentage of time in the open arms of the EPM at PND120.  
 
Figure 24:  Mean (±S. E. M.) percentage of time spent in the open arms of the EPM for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 
- 10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats.  * significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.   
As depicted in Figure 24 rats treated with all three doses of BZP during PND31-40, 20 mg/kg 
of BZP during PND51-60, and rats treated with 2.0 mg/kg MA during PND51-60, spent a 
significantly lower percentage of time in the open arms of the EPM than saline-treated rats. 
The rats administered 2.0 mg/kg of MA during PND51-60 were significantly different from the 
other two doses of MA administered at that time.  However, as shown in Figure 25, a 
significant drug x sex interaction (F (3,72), P<.009) for rats treated with MA during PND 41-
50 was due to a significant decrease in open-arm entries with 1.0 mg/kg for females only.  
Similarly, for rats treated with MA during PND51-60 a significant dose x sex interaction (F (3, 
72), P<.0408) revealed that the differences that appeared in the significant main effect applied 
to males but not to females (see Figure 26).    
There was no significant sex effect for rats treated with either BZP or MA during PND31-40. 
However, female rats treated with MA during PND41-50, and Both BZP or MA during 
PND51-60 spent a significant percentage more time in the open arms that male treated rats  
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Drug x sex interaction for PND41-50 MA treated rats: Percentage of time spent in the 
open arms of the EPM at PND120.  
 
Figure 25:  Mean (±S. E. M.) percentage of time spent in the open arms for control (Saline), MA PND 41-50 treated male and female 
rats.  .   * significantly different (p<.05) from saline for that particular drug. 
Drug x sex interaction for PND 51-60 MA treated rats: Percentage of time spent in the 
open arms of the EPM at PND 120.  
 
Figure 26:  Mean (±S. E. M.) percentage of time spent in the open arms for control (Saline), MA  PND 51-60 treated male and female 
rats.   .  * significantly different (p<.05) from saline for that particular  sex; a,b difference between groups with superscript in common 
significant (p<.05) for that particular sex.   
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BZP and MA treated: Entries of the closed arms of the EPM at PND120.  
 
Figure 27:  Mean (±S. E. M.) entries of the closed arms of the EPM for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 
3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male and female rats.  
.   * significantly different (p<.05) from saline for that particular drug. 
As illustrated in Figure 27, rats treated with 0.5 mg/kg and 2.0 mg/kg of MA during PND41-50 
and rats treated with all three MA doses during PND51-60 made significantly more closed arm 
entries than saline-treated rats.    
There were significant sex effects for all treated rats’ at all three different stages of 
adolescence, with female treated rats making significantly more entries of the closed arms than 
male treated rats.   
Summary of EPM results at PND120 
Rats treated with BZP during PND31-40 displayed increased anxiety in the EPM as evidenced 
by decreased percentages of entries of and time spent in the open arms.  However, this may be 
attributable to general activity for female rats only, as there was no significant difference in 
entries of the closed arms for male rats compared with saline-treated rats.  Similarly rats treated 
with 0.5 and 2.0 mg/kg of MA during PND31-40 displayed increased anxiety as shown by a 
decrease in percentage of open arm entries.  However, the MA treated rats appeared to be less 
impulsive than the similar aged BZP treated rats as there was no significant difference in the 
percentage of time spent in the open arms, suggesting that although the PND31-40 MA rats 
have had a have heightened reluctance to enter the open arms, once on them they displayed a 
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similar response to saline-treated rats.  PND41-50 BZP and MA treated rats displayed 
emotional reactivity comparable to saline treated rats.  However, although the highest dose 
BZP-treated rats entered the open arms equally as often as the saline-treated rats, once actually 
on them they probably found them aversive and thus preferred to not occupy them. Rats treated 
with 0.5 and 2.0 mg/kg of MA were more active than control rats, suggesting that MA 
treatment at PND41-50 impacts on later locomotor behaviour, primarily only for male rats as 
observed by the sex-related effects.  Additionally, only the female rats treated with 1.0 mg/kg 
of MA during PND41-50 had a reduced percentage of time spent on the open arms of the EPM, 
suggesting increased emotionality for female rats treated with 1.0 mg/kg of MA compared with 
males and 0.5 and 2.0 mg/kg MA-treated females.  Rats treated with BZP (5 and 20 mg/kg) 
during PND51-60 displayed increased anxiety as observed by a reduced percentage of entries 
into the open arms, which was not related to general activity.  However only the high dose 
BZP-treated rats displayed increased anxiety in the percentage of time spent on the open arms 
and due to the significant sex effect, it is likely that male rats treated with BZP during PND51-
60 were more anxious than similar aged females and control rats.  Similarly, rats treated with 
the highest dose of MA (2.0 mg/kg) displayed increased anxiety as evidenced by reduced 
percentages of entries into and time spent on the open arms for both male and female rats.  
However, the male rats appeared more affected by the highest dose than the other two lower 
MA doses.  All three MA-treated groups made significantly more entries of the closed arms, 
with female rats making significantly more entries than males. This suggests that earlier MA 
treatment impacted on later locomotor activity as opposed to increased anxiety, with the 
exception of male rats treated with 2 mg/kg of MA during PND51-60 displaying increased 
anxiety over the EPM measures.  
4. Social Interaction test results  
Each animal was paired with an unfamiliar animal of a similar weight (± 10 grams) and tested 
once on the Social Interaction test.      
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BZP and MA treated: Total squares entered in the Social Interaction test at PND120.  
 
Figure 28:  Mean (±S. E. M.) total squares crossed in the Social Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats. * significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.    
As illustrated in Figure 28 rats treated with 20 mg/kg of BZP during PND31-40, or 0.5 mg/kg 
and 2.0 mg/kg of MA entered significantly more squares than saline-treated rats. Rats treated 
with 20 mg/kg were also significantly different from rats treated with 5 mg/kg and 10 mg/kg, 
during PND31-40.  Additionally, rats treated with 10 mg/kg and 20 mg/kg during PND51-60 
entered significantly more squares than saline-treated rats.    
There was a significant sex effect for all conditions, with female treated rats entering 
significantly more squares in the open field than similar treated male rats.  
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BZP and MA treated: Outer Rears in the Social Interaction test at PND120.  
 
Figure 29:  Mean (±S. E. M.) total outer rears in the Social Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - .5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male 
and female rats.  * significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.    
As illustrated in Figure 29 rats treated with 5 mg/kg and 20 mg/kg of BZP during PND31-40,  
or 0.5 mg/kg and 2.0 mg/kg of MA reared significantly more often than saline-treated rats in 
the outer squares of the OF. Rats treated with 10 mg/kg of BZP during PND31-40 were also 
significantly different from rats treated with 20 mg/kg of BZP.  Rats treated with 10 mg/kg and 
20 mg/kg of BZP during PND51-60 also reared significantly more often than saline-treated 
rats.     
For all conditions there was a significant sex effect, with female treated rats rearing more often 
than male treated rats on the outer squares of the OF in the Social Interaction test.   
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BZP and MA treated: Centre Rears in the Social Interaction test at PND120.  
 
Figure 30:  Mean (±S. E. M.) total inner rears in the Social Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats.  * significantly different (p<.05) from saline for that particular drug; a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.    
Figure 30 illustrates that rats treated with 20 mg/kg BZP or 2.0 mg/kg of MA during PND31-
40, and rats treated with 20 mg/kg of BZP during PND51-60, reared significantly more in the 
inner squares of the OF than saline-treated rats. Additionally, there was a significant difference 
between rats treated with 20 mg/kg of BZP and 2.0 mg/kg MA during PND31-40, and the 
other doses of BZP and MA.  Only the female rats treated with BZP during PND41-50 reared 
significantly more than comparative treated male rats in the centre of the open field.    
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BZP and MA treated: Interaction time in the Social Interaction test at PND120.  
 
Figure 31:  Mean (±S. E. M.) total interaction time  in the Social  Interaction test for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 
10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male 
and female rats.   
As illustrated in Figure 31, there was no significant dose effects for treated groups in 
interaction time, however male rats treated with BZP and MA during PND31-40 spent 
significantly more time in social interaction than BZP treated female rats.   
Summary of Social Interaction results at PND120 
With the exception of PND41-50 treated groups, and PND51-60 MA treated rats, the highest 
dose of either BZP or MA administered at either PND31-40 and BZP administered at PND51-
60 significantly affected outer and inner rearing.  This suggests that decreased anxiety 
increased vertical exploration, but may have also reflected increased locomotor activity, as 
evidenced by the treated animals entering more squares in the open field than saline treated 
rats. However female treated rats in all conditions had increased locomotor activity compared 
to male treated rats and a significantly higher frequency of rearing in the outer area of the open 
field than male treated rats, which may explain the differences found.  Alternatively, increased 
inner rearing in rats treated with BZP during PND31-40 and 51-60, and in rats treated with the 
highest dose of MA during PND31-40 may not have reflected decreased anxiety but rather 
indicated scanning for an exit from the aversive environment, thereby suggesting increased 
anxiety and reduced risk assessment. Interestingly, and against the general pattern of results 
was the treated male rats during PND31-40 increasing their time in social interaction compared 
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to female rats.  It is possible that for the male treated rats, the novelty of the unfamiliar peer 
was greater than the novelty of the testing apparatus, suggesting decreased anxiety.  
Results at PND200 
All animals were tested in the Y-maze, light/dark emergence box and EPM at PND200.  See 
Table 2 above for F ratios and Table 3 for significant sex differences, across the three testing 
periods. Unfortunately it was not possible to examine results of the social interaction test at this 
period because all video-recorded data for this test was destroyed in the devastating 
Christchurch earthquake of February 2011 before it could be analysed. 
1. Y-Maze results  
As each animal was tested in the Y-maze four times and the averages of the four trials were 
used in each of the analyses.   
BZP and MA treated: Percentage of Entries of the Novel Arm of the Y-maze at PND200.  
 
Figure 32: Mean (±S. E. M.) percent of novel entries for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 20mg/kg) 
and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats.  † differs 
significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) from saline for that 
particular drug;  a,b difference between groups with superscript in common significant (p<.05) for that particular drug.   
Figure 32 shows a significant dose effect for 5 mg/kg and 10 mg/kg of BZP during PND31-40.  
Rats treated with saline and 20 mg/kg of BZP during PND31-40, rats treated with saline and 10 
mg/kg and 20 mg/kg of BZP or 0.5 mg/kg and 1.0 mg/kg of MA during PND41-50, and rats 
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treated with 5 mg/kg and 10 mg/kg of BZP or all three doses of MA during PND51-60 
displayed significant preferences for entering the novel rather than the familiar arm. There was 
one significant sex effect, with female rats (mean = 63.305, SEM = 1.6) treated with MA 
during PND51-60 making a higher percentage of entries of the novel arm than male treated 
rats.   
BZP and MA treated: Total Entries of both arms of the Y-maze at PND200.  
 
Figure 33:  Mean (±S. E. M.) total entries of both arms for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 
20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats. * 
significantly different (p<.05) from saline for that particular drug.   
As depicted in Figure 33, rats treated with 5 mg/kg of BZP, or all three doses of MA, during 
PND41-50, and rats treated with 1.0 mg/kg and 2.0 mg/kg of MA, during PND51-60 made 
significantly fewer entries of both arms than saline-treated rats.  However, a significant dose x 
sex interaction (F (3, 72) 3.30, P<.025) outlined in Figure 34 showed this effect of MA to 
characterise female, but not male rats.  Additionally, all treated female rats made significantly 
more entries of both arms than male treated rats.  
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Drug x sex interaction for PND51-60 MA treated rats: Total Entries of both arms of the 
Y-maze at PND200.  
 
Figure 34:  Mean (±S. E. M.) total entries of both arms for control (Saline),  MA PND51-60 treated male and female rats.   * 
significantly different (p<.05) from saline for that particular sex;  a difference between groups with superscript in common significant 
(p<.05) for that particular sex.   
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BZP and MA treated: Percentage of Time spent in the Novel Arm of the Y-maze at 
PND200.  
 
Figure 35:  Mean (±S. E. M.) percent of  time spent in the novel  arm of the Y-maze for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 
- 10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male 
and female rats.  † differs significantly (p<.05) from chance expectancy of 50% (one-sample t test); .  * significantly different (p<.05) 
from saline for that particular drug. 
Figure 35 shows that rats treated with saline or .0.5 mg/kg of MA at PND31-40, and saline or 
0.5 mg/kg and 1.0 mg/kg of MA at PND41-50, and all three doses of MA administered during 
PND51-60 displayed significant preferences for occupying the novel rather than the familiar 
arm. Rats treated with 5 mg/kg and 10 mg/kg of BZP during PND31-40 spent significantly less 
time than saline treated rats in the novel arm. There was one sex effect, with female rats treated 
with BZP during PND51-60 spending significantly more time in the novel arm than male 
treated rats. 
Summary of Y-maze results at PND200 
Interestingly, the general pattern of results at PND200 in the Y-maze suggest that most treated 
rats prefer to enter and spend time in the changed arm over the familiar arm, which is not 
related to general activity for male rats only. Fairly consistent with the other two behavioural 
testing phases, there was significant sex differences in treated female rats displaying increased 
motor activity compared to male treated rats treated during PND31-40.  However, for rats 
treated during PND41-50 general locomotor activity was decreased and this may account for 
why only male rats made significantly fewer total entries of both arms than females.  In 
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contrast to female MA treated rats during PND51-60 who made significantly less entries of 
both arms of the Y-maze than male treated rats and BZP treated female rats who made 
significantly more entries of the changed arm than controls or male rats. However, female MA 
treated rats had a higher percentage of novel arm entries which as mentioned was not related to 
general locomotor activity.   
2. Light/dark emergence results  
As each animal was tested in the light/dark box seven times and the averages of the seven trials 
were used in each of the analyses.   
BZP and MA treated: Emergence latency time from the Light/dark box at PND200.  
 
Figure 36:  Mean (±S. E. M.) emergence latency from the light/dark box for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; 
Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female 
rats.  * significantly different (p<.05) from saline for that particular drug;  a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
Figure 36 illustrates that rats treated during PND31-40 with 10 mg/kg and 20 mg/kg of BZP, or 
all three doses of MA, and BZP and MA rats treated during PND41-50 and rats treated during 
PND51-60 with 5 mg/kg and 20 mg/kg of BZP, and all three doses of MA, took significantly 
longer to emerge from the dark than saline-treated rats. Rats treated with 20 mg/kg BZP during 
PND31-40 had a significantly longer latency to emerge than rats treated with 5 mg/kg of BZP.  
However, as revealed in a significant dose x sex interaction (F (3,72) 3.47, P<.0207) for rats 
treated with BZP at this age, the effect only applied to females (see Figure 37). Also rats 
treated with 5 mg/kg of BZP during PND51-60 had a significantly longer latency to emerge 
compared to the 10 mg/kg and 20 mg/kg BZP treated rats.       
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There were significant sex effects for all groups, with all female rats having a faster latency to 
emerge from the dark compartment of the light/dark box, than male rats.  
Drug x sex interaction for PND31-40 BZP treated rats: Emergence latency from 
Light/dark box at PND200.  
 
Figure 37:  Mean (±S. E. M.) emergence latency from light/dark box  for control (Saline),  BZP PND 31-40 treated male and female 
rats. * significantly different (p<.05) from saline for that particular sex.   
Summary of Light/dark emergence results at PND200 
Consistent with the other behavioural testing periods, female rats in all groups showed a 
significantly faster emergence time than male rats.  All treated groups with the exception of 
rats treated with BZP (10 mg/kg) during PND51-60 had a longer latency to emerge into the 
illuminated area compared to saline-treated rats.  Of interest is the significant sex x drug 
interaction for PND31-40 BZP treated rats, with female treated rats increasing their emergence 
time in a dose-dependent manner.    
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3. EPM results  
Each animal was tested once in the EPM.   
BZP and MA treated: Percentage of Entries of the open arms of the EPM at PND200.  
 
Figure 38:  Mean (±S. E. M.) percent of open arm entries for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 3 - 
20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats.  * 
significantly different (p<.05) from saline for that particular drug;  a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
Figure 38 illustrates that rats treated with 20 mg/kg of BZP during PND31-40, made a 
significantly lower percentage of entries of the open arms of the EPM than saline-treated rats. 
Alternatively, rats treated with 1.0 mg/kg of MA, during PND51-60 made a significantly 
higher percentage of entries of the open arms of the EPM than saline-treated rats.  However, a 
significant dose x sex interaction (F (3, 72) 5.77, P<.0014) for this latter result (illustrated in 
Figure 39) showed that this effect may be attributable to female rats treated with 1.0 and 2.0 
mg/kg MA spending a greater percentage of time in the open arms than 2.0 mg/kg male treated 
rats who spent a significantly lower percentage of time in the open arms than the other two 
MA- treated males. Additionally, rats treated with 20 mg/kg of BZP during PND31-40 were 
significantly different from rats treated with 5 mg/kg and 10 mg/kg.  Likewise, rats treated with 
1.0 mg/kg of MA during PND51-60 were significantly different from rats treated with 20 
mg/kg of MA.   
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With the exception of rats treated with BZP during PND31-40 there were significant sex 
effects for all other conditions, with female rats preferring to enter the open arms compared to 
male treated rats.    
Drug x sex interaction for PND51-60 MA treated rats: Percentage of Entries of the open 
arms of the EPM at PND200.  
 
 Figure 39: Mean (±S. E. M.) percentage of entries of the open arms of the EPM for control (Saline), MA PND 51-60 treated male and 
female rats. * significantly different (p<.05) from saline for that particular sex;  a,b difference between groups with superscript in 
common significant (p<.05) for that particular sex.   
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BZP and MA treated: Percentage of time in the open arms of the EPM at PND200.  
 
Figure 40:  Mean (±S. E. M.) percentage of time spent in the open arms of the EPM for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 
- 10mg/kg; Dose 3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND 31-40, 41-50 and 51-60 male 
and female rats.  * significantly different (p<.05) from saline for that particular drug;  a,b difference between groups with superscript 
in common significant (p<.05) for that particular drug.   
As depicted in Figure 40, rats treated with 20 mg/kg of BZP during PND31-40, and all three 
MA doses, 20 mg/kg of BZP during PND41-50, and rats treated with 0.5 mg/kg and 2.0 mg/kg 
of MA, spent significantly less time in the open arms of the EPM than saline-treated rats. The 
rats administered 20 mg/kg of BZP during PND31-40 were significantly different from the 
other two doses of BZP administered at that time.  Although there were no significant drug 
main effects for rats treated at PND51-60, a significant dose x sex interaction (F (3,72) 3.02, 
P<.0057) for MA-treated rats at this age showed that, for males alone, treatment with 2.0 
mg/kg significantly reduced this response following treatment with saline and both lower doses 
(see Figure 41).    
With the exception of BZP- treated rats during PND31-40 and PND51-60, female treated rats 
spent a significantly longer percentage of time in the open arms compared to male rats.  
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Drug x sex interaction for PND51-60 MA treated rats: Percentage of time spent in the 
open arms of the EPM at PND200.  
 
Figure 41:  Mean (±S. E. M.) percentage of time spent in the open arms for control (Saline), MA PND51-60 treated male and female 
rats. * significantly different (p<.05) from saline for that particular sex;  a,b difference between groups with superscript in common 
significant (p<.05) for that particular sex.     
BZP and MA treated: Entries of the closed arms of the EPM at PND200.  
 
Figure 42:  Mean (±S. E. M.) entries of the closed arms of the EPM for control (Saline), BZP (Dose 1 - 5mg/kg; Dose 2 - 10mg/kg; Dose 
3 - 20mg/kg) and MA (Dose 1 - 0.5mg/kg; Dose 2 - 1.0mg/kg; Dose 3 - 2.0mg/kg) for PND31-40, 41-50 and 51-60 male and female rats.  
* significantly different (p<.05) from saline for that particular drug;  a,b difference between groups with superscript in common 
significant (p<.05) for that particular drug.   
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As illustrated in Figure 42, rats treated with 20 mg/kg of BZP, during PND31-40 made 
significantly more entries of the closed arms than rats treated with 5 mg/kg, 10 mg/kg or saline.  
However, rats treated with 20 mg/kg of BZP during PND51-60 made significantly fewer 
entries of the closed arm than saline-treated rats.  Similarly, rats treated with 1.0 mg/kg of MA 
during PND51-60 made significantly fewer entries of the closed arms than saline-treated rats.  
Rats treated with 0.5 mg/kg of MA during PND51-60 made significantly more entries of the 
closed arms then rats treated with 1.0 mg/kg and 2.0 mg/kg of MA.   
Consistent with other testing periods and across behavioural measures, there was significant 
sex effect for all conditions, with female rats making significantly more entries of the closed 
arms than male rats.  
Summary of EPM results at PND200 
Rats treated with the highest dose of BZP during PND31-40 displayed increased emotionality 
in the EPM as evidenced by decreased percentage of entries into and time spent on the open 
arms.  However, this could be explained by a higher frequency of closed arms entries, 
suggesting that the 20 mg/kg BZP may have increased locomotor activity rather than 
emotionality, but only for females.  Rats treated with MA during PND31-40 spent less time in 
the open arms, with female rats making significantly more entries and spending more time in 
them than male treated rats.  Therefore, it is possible that, although male rats chose to enter the 
open arms, they did not prefer to spend time in them.  For the rats treated during PND41-50 
highest dose of BZP- and MA-treated rats (0.5 and 2.0 mg/kg) had reduced percentages of time 
spent in the open arms, which again could be attributed to male treated rats primarily, as female 
treated BZP and MA treated rats had a significantly higher percentage of entries and time spent 
in the open arms than male treated rats.  
Similar to other tests and behavioural testing times, the PND50-61 MA-treated rats displayed a 
complex behavioural profile.  The rats treated with 1.0 mg/kg of MA during PND50-61 had a 
significantly higher percentage of entries of the open arms than control rats. However the drug 
x sex interaction suggests that this may be accountable for the female 1.0mg/kg treated rats 
who made significantly more entries than the other two MA doses and saline-treated rats.  This 
was not due to general locomotor activity as observed in the decreased total entries of the 
closed arms for the 1.0 mg/kg treated rats.  This suggests that female rats treated with 1.0 
mg/kg MA during PND51-60 had decreased anxiety-like behaviour compared to males, 
females treated with 0.5 and 2.0 mg/kg of MA and saline matched controls. Additionally, the 
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male rats treated with 2 mg/kg of MA during PND51-60 spent a significantly lower percentage 
of time in the open arms than the other two lower MA dose and male controls and made fewer 
entries of the open arms than the other two doses, suggesting increased anxiety due to earlier 
MA treatment.        
 
Table 4: Summary of the significant effects of BZP or MA treatment for each measure at three 
periods, on responses emitted by male and female rats in the  Y-maze, Light/dark emergence, 
EPM and Social Interaction. 
 
 PND31-40 PND41-50 PND51-60 
30 day wash-out 
testing 
   
    
Y-maze percent novel 
arm entries 
No significant effects  No significant effects MA ♀  increased  
Y-maze total arm 
entries 
BZP dose 3 ↓, all 
treated ♀  ↑ 
BZP all doses ↓, ♀ 
only. MA ♀  ↑ 
BZP and MA all doses 
↓ and all treated ♀ ↑ 
Y-maze percent novel 
arm time 
MA dose 3 ↓ BZP all doses ↓  MA ♀  ↑ 
    
Light/dark emergence MA dose 2&3 longer 
emergence 
BZP  ♀  shorter 
emergence 
BZP dose 2 & 3 longer 
emergence 
BZP & MA ♀  shorter 
emergence 
BZP & MA ♀  shorter 
emergence 
    
EPM percent open arm 
entries 
BZP dose 3 ↓, BZP ♀  
↑ 
BZP dose 3 ↓ BZP dose 1 ↓, BZP & 
MA dose 1 & 2 ♀ ↑  
    
EPM percent open arm 
time 
BZP dose 3 ↓ BZP dose 1 & 3 ↓, BZP 
& MA ♀ ↑ 
MA dose 1 ↑, BZP & 
MA dose 1 & 2 ♀ ↑ 
EPM closed arm 
entries 
 
No significant effects BZP & MA ♀ ↑ BZP & MA ♀ ↑ 
SI squares entered BZP dose 3 ↑, BZP & 
MA ♀ ↑ 
BZP & MA ♀  ↑ BZP dose 3 ↑& MA 
dose 3 ↓. BZP & MA 
♀  ↑ 
SI outer rears BZP dose 3 ↑ No significant effects BZP dose 3 ↑and MA 
dose 3 ↓.  
SI centre rears No significant effects MA dose 3 
approaching 
significance (P<.0503) 
No significant effects 
SI interaction time No significant effects No significant effects BZP & MA ♂ ↑  
    
Testing at PND120    
    
Y-maze percent novel 
arm entries 
No significant effects All 3 BZP & MA doses 
↑ 
No significant effects 
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Y-maze total arm 
entries 
MA dose 3 ↓, BZP & 
MA ♀  ↑ 
All 3 BZP & MA doses 
↓, BZP ♀ ↑.  As MA 
dose ↑ ♀  ↓ 
BZP dose 2 and all 3 
MA ↓. BZP & MA ♀ ↑ 
Y-maze percent novel 
arm time 
BZP dose 2 & 3 ↓ All 3 MA ↑  No significant effects 
    
Light/dark emergence BZP dose 3 & MA 
dose 2 & 3 longer 
emergence, BZP & 
MA ♀  shorter 
emergence 
All 3 BZP & MA 
longer emergence, BZP 
& MA ♀  shorter 
emergence 
BZP dose 1 longer 
emergence, MA ♀ 
shorter emergence 
    
EPM percent open arm 
entries 
All 3 BZP & MA dose 
1 & 3 ↓ 
No significant effects BZP dose 2 & 3 & MA 
dose 3 ↓, MA♀  ↑, 
however only MA dose 
3  ♂  & ♀  
significantly different 
from other MA doses   
    
EPM percent open arm 
time 
All 3 BZP ↓ MA ♀ i↑, however 
only MA dose 2 ♀  ↓ 
compared to ♂ or other 
MA ♀ 
BZP & MA dose 3 ↓, 
BZP & MA ♀ ↑, 
however only MA dose 
3 ♂ impacted 
EPM closed arm 
entries 
BZP & MA ♀ ↑ MA dose 1 & 3 ↑, BZP 
& MA ♀ ↑ 
 
All 3 MA ↑, BZP & 
MA ♀ ↑  
SI squares entered BZP dose 3 & MA 
dose 1 & 3 ↑, BZP & 
MA ♀  ↑ 
BZP & MA ♀ ↑ BZP dose 2 & 3 ↑, 
BZP & MA ♀ ↑ 
SI outer rears BZP & MA dose 1 & 3 
↑, BZP & MA ♀ ↑ 
BZP & MA ♀  ↑ BZP dose 2 & 3 ↑, 
BZP & MA ♀ ↑ 
SI centre rears BZP & MA dose 3 ↑ BZP ♀  ↑ BZP dose 3 ↑  
SI interaction time BZP & MA ♂ ↑ No significant effects No significant effects 
 
 
Testing at PND200 
   
    
Y-maze percent novel 
arm entries 
BZP dose 1 & 2 ↓ No significant effects MA ♀ ↑ 
Y-maze total arm 
entries 
BZP & MA ♀ ↑ BZP dose 1 and all 3 
MA doses ↓, BZP & 
MA ♀  ↑ 
MA dose 2 & 3 ↓, 
however only for ♀, 
BZP ♀ ↑ 
Y-maze percent novel 
arm time 
BZP dose 1 & 2 ↓ No significant effects BZP ♀  ↑ 
    
Light/dark emergence BZP dose 2 & 3 & all 
3 MA doses longer 
emergence, MA ♀ 
shorter emergence & 
as BZP dose increased 
♀  had longer 
emergence 
All BZP & MA longer 
emergence, BZP & MA 
♀  shorter emergence 
BZP dose 1 & 3 & all 3 
MA longer emergence, 
BZP & MA ♀  shorter 
emergence 
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EPM percent open arm 
entries 
BZP dose 3 ↓, MA ♀  
↑ 
BZP & MA ♀  ↑ MA dose 2 ↑, 
accountable for ♀  
only, BZP ♀ ↑ 
    
EPM percent open arm 
time 
BZP dose 3 & all 3 
MA ↓, BZP & MA ♀ ↑ 
BZP dose 3 & MA 
dose 1 & 3 ↓, BZP & 
MA ♀  ↑  
 
MA dose 3 ♂ ↓ 
EPM closed arm 
entries 
BZP dose 3 ↑, BZP & 
MA ♀  ↑ 
BZP & MA ♀  ↑ BZP dose 3 & MA 
dose 2 ↓, BZP & MA 
♀  ↑ 
 
 
BZP dose 1 = 5 mg/kg; BZP dose 2 = 10 mg/kg; BZP dose 3 = 20 mg/kg, MA dose 1 = .05 mg/kg; MA dose 2 = 
1.0 mg/kg MA dose 3 = 2.0 mg/kg    ♂ = Male rats; ♀ = Female rats  ↑= increased  ↓ = decreased 
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Chapter 4: Discussion of Results 
In the present study, at three ages (PND 31-40, PND 41-50 and PND 51-60), adolescent rats 
were exposed to either saline, BZP (5 mg/kg, 10 mg/kg or 20 mg/kg) or MA (0.5 mg/kg, 1 
mg/kg or 2 mg/kg).  All groups received one daily i.p injection for ten consecutive days. The 
rats were subsequently tested on measures of emotionality after a thirty day washout period, 
and then at PND120 and PND200, to assess any long-term effects.  
Overall, it appears that early exposure to either BZP or MA affected later behaviour and this 
persisted over time.  However, although the general pattern of results is suggestive of increased 
emotionality the results are complicated by no clear dose response for either drug and 
compounded by sex differences.  See Table 4 for a summary of significant effects across the 
three periods of adolescence and three periods of behavioural testing.   
Summary of Results over the three testing phases 
1: PND31-40 
In the Y-maze, there were no significant effects of BZP on percentage of novel arm entries for 
the 30 day wash-out period or at PND120.  Although, there was no significant results for 
percentage of novel arm entries at PND120, BZP- treated rats (10 & 20 mg/kg) once in the 
novel arm preferred to spend less time in it, compared to control rats.  Rats treated with BZP (5 
& 10 mg/kg) made significantly fewer novel arm entries at PND200 and spent less time in the 
novel arm than control rats. MA- treated rats (2.0 mg/kg) spent a significantly lower percentage 
of time in the novel arms at the 30 day wash-out period and made less total arm entries at 
PND120.   
In the Light/dark emergence test, the general pattern of results were consistent over time, with 
rats treated with MA (1.0 & 2.0 mg/kg) having longer latencies to emerge from the dark 
compartment across all three testing periods. BZP- treated rats had longer latencies to emerge 
and by PND200 it was evident that as the dose of BZP increased treated rats decreased in their 
emergence from the dark compartment. All female treated rats emerged faster than comparable 
male treated rats.   
On the EPM, BZP- (20 mg/kg) treated rats had decreased percentage of open arm entries and 
decreased percentage of time spent in the open arms, across the three testing periods, compared 
to control rats.  However, at PND120 this could be explained by increased closed arm entries. 
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Additionally at PND120 rats treated with all three doses of BZP made fewer entries and spent a 
lower percentage of time in the open arms, similar to the and MA- treated rats (0.5 & 2.0 
mg/kg), who also made fewer entries of the open arms, but once on the open arms did not 
differ from control rats. However, at PND200 all MA- treated rats spent a significantly lower 
percentage of time in the open arms, compared to control rats. Additionally, the BZP- treated 
rats (20 mg/kg) spent a significantly lower percentage of time in the open arms, compared to 
control rats at PND200.   
On the SI test, rats treated with BZP (20 mg/kg) entered more squares of the OF, made more 
rears in the outer squares at the 30 day wash-out period and PND120 and significantly more 
centre rears at PND120.  Likewise, rats treated with MA (0.5 & 2.0 mg/kg) entered more 
squares, made more outer rears and the highest dose of MA- treated rats made more centre 
rears at PND120.  All treated female rats made significantly more outer rears at PND120, than 
male treated rats, however both drugs increased interaction time for male rats only at PND120. 
Overall, the general pattern of results suggests that rats treated with both drugs during PND31-
40 displayed more anxiety-related behaviour compared to control rats and this effect increased 
with drug dose, primarily for male- treated rats.  
For rats treated during PND31-40, female rats displayed greater locomotor activity, evidenced 
in the Y-maze total arm entries, EPM closed arm entries (with the exception of testing at the 30 
day wash-out period), and squares entered in the OF of the SI, compared to treated male rats, 
across the three testing periods.  
2: PND41-50 
In the Y-maze, there were no significant effects of BZP at the 30 day wash-out period and 
PND200 on percentage of novel arm entries, however both BZP- and MA- treated rats made 
significantly more novel arm entries at PND120, than control rats.  All BZP- treated rats spent 
a lower percentage of time in the novel arms at the 30 day wash-out period, and all three doses 
of MA increased the percentage of novel arm time at PND120.  
In the Light/dark emergence test, the general pattern of results was consistent over time, with 
all female rats having a shorter latency to emerge from the dark compartment, compared to 
male rats. At the 30 day wash-out period only the BZP - treated (10 & 20 mg/kg) rats had 
longer emergence than control rats.  However, all BZP- and MA- treated rats had longer 
emergence times at PND120 and PND200, than saline-treated animals.    
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On the EPM, similar to treated rats during PND31-40, BZP- (20 mg/kg) treated rats showed a 
decreased percentage of open arm entries and decreased percentage of time spent in the open 
arms, at the 30 day wash-out period, compared to control rats.  However, this could be 
explained by increased closed arm entries for BZP female treated rats. Additionally at PND200 
BZP- (20 mg/kg) and MA- treated (0.5 & 2.0 mg/kg) also had a decreased percentage of time 
spent in the open arms, compared to control rats. BZP and MA treated female rats spent a 
longer percent of time in the open arms compared to male rats at the 30 day wash-out period.  
Interestingly, at PND120, although there were significant sex effects for all MA- treated 
females who spent a longer percentage of time in the open arms, compared to male treated rats.  
The drug x sex interaction suggests that only female rats treated with MA (1.0mg/kg) spent a 
significantly decreased percentage of time in the open arms compared to the male treated and 
other MA female treated rats.  At PND200 all female treated rats made significantly more open 
arm entries and spent a longer percentage of time in the open arms than the male treated rats, 
however as already mentioned this may be accountable for female rats being generally more 
active than male treated rats as evidenced by the measures of locomotor activity.    
On the SI test, there were no significant drug effects for any of the four measures at the 30 day 
wash-out period and PND120 for BZP- and MA- treated rats. However, both drugs 
administered to both BZP- and MA- treated female rats resulted in increased outer rears at 
PND120 and only the BZP treated female rats displayed significantly more centre rears 
compared to male treated rats at PND120.  Overall, the general pattern of results over time, 
suggests that rats treated with both drugs during PND41-50 displayed increased anxiety-like 
behaviour compared to control rats and these effects again, were primarily for male-treated 
rats.  
For rats treated during PND41-50, female rats displayed greater locomotor activity, evidenced 
in the Y-maze total arm entries (MA- treated females only at 30 day wash-out period and as the 
dose of MA increased at PND 120 female treated rats decreased their total arm entries), EPM 
closed arm entries, and squares entered in the OF of the SI, compared to treated male rats, 
across all testing periods.   
3: PND51-60  
In the Y-maze, there were no significant drug effects for either BZP- or MA- treated rats on 
percentage of novel arm entries or percentage of time spent in the novel arms across the three 
different behavioural testing periods. However, of interest is the behaviour displayed by the 
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BZP- (10 mg/kg) and MA (1.0 mg/kg) treated rats, who preferred to enter the novel arm at 
PND120 over the familiar arm and this was significantly difference from chance.  Similarly, at 
PND200, rats treated with BZP (5 & 10 mg/kg) and all three doses of MA preferred to enter 
the novel arm over the familiar arm, however only the MA- treated rats (1.0 mg/kg at PND120 
and all 3 doses at PND200) preferred to spend time in it.  Although this would suggest they 
displayed decreased anxiety-like behaviour, it is more likely that once in the novel arm they 
froze as evidenced by decreased closed arm entries by the all the rats mentioned. This implies 
that they had no deficits in spatial memory as they remembered from the acquisition trail which 
arm had changed in brightness and were actively looking for a means of escape and once they 
realised there was no way out of the apparatus froze, suggestive of increased anxiety-like 
behaviour.    
In the Light/dark emergence test, the general pattern of results were consistent over time, with 
all treated female rats having a shorter latency to emerge from the dark compartment, 
compared to male rats, with the exception of BZP-treated rats at PND120, however this was 
approaching significance (P<.0781).   BZP-treated rats (5 mg/kg) displayed a longer latency to 
emerge at PND120 and PND200, and rats treated with BZP (20 mg/kg) or all three MA doses 
had a longer latency to emerge from dark compartment at PND200, compared to control rats.     
On the EPM, BZP- treated rats (5 mg/kg) displayed a decreased percentage of open arm entries 
at the 30 day wash-out period, compared to control rats, with all BZP-treated females 
displaying a higher percentage of open arm entries than males.  The drug x sex interactions 
illustrated that MA treated-females (0.5 & 1.0 mg/kg) made a higher percentage of entries and 
spent a longer percentage of time in the open arms of the EPM compared to male treated rats.   
At PND120, rats treated with BZP (10 & 20 mg/kg) or MA (2.0 mg/kg) made significantly 
fewer entries of the open arms and the sex x drug interaction suggests the both the male and 
female 2.0 mg/kg MA- treated rats made significantly fewer entries of the open arms, 
compared to controls or the other MA- treated male and female rats. However, the sex x drug 
interaction on percentage of time spent in the open arms illustrates that only the 2.0 mg/kg 
male MA- treated rats had a significantly less percentage of time spent on the open arms.  
These results suggest that the highest dose of MA treated male rats upon entering the open 
arms would flee significantly faster from the aversive environment back to the safety of the 
closed arms, compared with 0.5 and 1.0 mg/kg male and female MA-treated rats.  This reflects 
that the male rats treated with the highest dose of MA during PND51-60 displayed more 
anxiety-like behaviour on this measure at PND120.   At PND200, rats treated with MA (1.0 
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mg/kg) made significantly more entries of the open arms than control rats.  However, the sex x 
drug interaction illustrates that this interaction effect was due to the MA- (1.0 mg/kg) treated 
female rats only.  Although there were no significant dose effects for treated rats on percentage 
of open arm time, a sex x drug interaction illustrated that male rats treated with MA (2.0mg/kg) 
spent significantly less percentage of time in the open arms compared to the two smaller doses 
of MA- treated rats and female MA- treated rats. Both BZP- and MA- treated female rats made 
significantly more entries of the open arms than male treated rats.      
In the SI test, the highest BZP dose (20mg/kg) treated rats entered significantly more squares 
in the OF and made more outer rears, compared to saline treated rats, conversely, the highest 
dose of MA (2.0 mg/kg) treated rats entered significantly fewer squares in the OF and made 
significantly fewer outer rears than saline controls, at the 30 day wash-out period.  
Interestingly, at this first behavioural testing phase, male BZP- and MA- treated rats spent a 
significantly longer time in social interaction than similar treated female rats. Social interaction 
is proposed to measure decreased anxiety (File, 2003), however this does not appear to be 
consistent with the other behavioural measures and results displayed by male rats in the SI test.  
It is possible that the male-treated rats in this study found the novelty of the OF more aversive 
than interaction with another unfamiliar male rat.  At PND120, BZP- treated rats (10 & 20 
mg/kg) entered more squares in the OF, and made significantly more outer rears than saline- 
treated rats.  The highest dose of BZP- (20 mg/kg) treated rats made significantly more centre 
rears than saline controls and BZP-treated rats (10 & 20 mg/kg) made more outer rears at 
PND120 than control rats.  Overall, the general pattern of results is more complex than the 
other two adolescence periods, with MA- treated female rats displaying increased anxiety-like 
behaviours as the MA dose increases. And the highest doses of BZP administered to rats 
during PND51-60 displaying decreased emotionality, as evidenced by increased rearing 
behaviours, however this may be accounted for by an augmented need to scan the environment 
for an escape from the aversive novel environment.   
The sex effects for rats treated during PND51-60, are not as clear as observed at the other 
adolescent dosing periods, possibly due to a greater number of sex x dose interaction effects for 
the PND51-60 MA-treated rats. Both BZP- and MA- treated female rats displayed greater 
locomotor activity, as evidenced in the Y-maze total arm entries, EPM closed arm entries, and 
squares entered in the OF of the SI, compared to treated male rats, across all testing periods.  
There were, however significant differences for MA-treated female rats, with female rats 
administered MA (1.0 & 2.0 mg/kg) making fewer entries of both arms of the Y-maze 
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compared to male MA-treated rats and female rats treated with 0.5 mg/kg of MA at PND120.  
Additionally, female rats treated with 20 mg/kg of BZP or 1.0 mg/kg of MA made significantly 
fewer closed arm entries on the EPM compared to male treated rats at PND200.   
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Chapter 5: General Discussion 
The results indicate that there were systematic changes in measures of emotionality in the 
predicted direction, in almost all of the behavioural tests used.  That is, as adults, the rats that 
had been exposed to both BZP and MA as adolescents displayed more anxiety-like behaviour 
than control rats that persisted over time. This was most evident in the light/dark emergence 
test. However, the results for the other three measures (Y-maze, EPM and Social Interaction 
test) were generally more complicated, and depended to a greater extent on the drugs, the sex 
of the rats, the responses recorded and the age of testing.  
Similarities between BZP and Methamphetamine and differences between drug 
administration periods 
Overall, the results of the current research suggest that there are more similarities between BZP 
and MA adolescent treatment, on anxiety-like behaviours in adulthood, than differences.  BZP 
was introduced into New Zealand as a safe and legal alternative for the escalating MA problem 
that was occurring in the early 2000's (Bowden, 2004). However, there was no research to 
support this assumption.  In the 1970's Bye et al. (1973) and Campbell et al. (1973) reported 
that BZP had approximately 10 percent of the potency of dexamphetamine.  Therefore, the 
doses used in this study were based on the assumption that the same potency difference would 
also apply to MA and BZP.   
The general pattern of results however, is suggestive of more detrimental effects of earlier BZP 
treatment than MA treatment and this was observed over the three testing phases.  
Notwithstanding, MA- treated rats additionally differed significantly from controls, in the same 
direction.  However, whereas dose-related increases were observed for the BZP-treated rats, 
the behavioural profiles for MA-treated rats differed, with conflicting results for the three 
doses, at the different adolescent treatment phases, on the different measures and over time.  
For example, for the rats treated during PND51-60, 0.5 mg/kg MA- treated rats at the 30 day 
wash-out period spent more time on the open arms of the EPM, whereas the 1.0 mg/kg MA- 
treated rats spent more time on the open arms at PND200.  Similarly, all three MA treated rats 
during PND41-50 spent more time in the novel arm of the Y-maze at PND120, whereas there 
were no MA effects following treatment at PND31-40 or PND51-60 on this measure. On 
measures of general locomotor activity, MA- treated rats treated during PND31-40 with 2.0 
mg/kg of MA made fewer entries of both Y-maze arms, but more entries of squares in the SI 
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test at PND120. It seems that the lack of consistency in this study for MA- treated rats may 
have been due to male rats being more affected by their earlier drug exposure.  
Most sex x drug interactions occurred for rats treated during PND51-60 with MA. As 
mentioned above this treatment period was more sensitive for male rats and this was maybe 
due to the earlier maturation of the female brain compared with males. Therefore, it is possible 
that the female brain had matured enough that the vulnerability to long-lasting neuronal 
changes was less.  This may have been due to neurotransmitter systems approaching adult 
levels for female rats, whereas for males they were still very immature and thus more 
vulnerable to effects of MA.  Nevertheless, female rats administered MA during PND51-60 
still displayed some increased anxiety compared with control rats.      
Neurodevelopment 
Although, this research study was purely a behavioural teratological study without 
complimentary neurochemical assessments, the possibility of alterations to the 
neurodevelopment during adolescence will be briefly discussed.  During adolescence there are 
dramatic changes in the 5-HT neurotransmitter system, with the density of the 5-HT transporter 
(SERT) rising, and 5-HT levels in the CNS increasing between the juvenile period and puberty, 
followed by a decline in young-adult-hood.  Consequently, this developmental period may be 
especially sensitive to effects of exposure to a variety of drugs (Piper et al., 2005). Exposure to 
environmental variables that affect 5-HT during development might have caused 'miswiring' in 
the CNS (De Jong et al., 2006) that may have led to the increased anxiety-like behaviour seen 
in BZP- and MA- treated rats.   
One of the premises of the current research was that adolescent stimulant use would interfere 
with the 5-HT system, producing behavioural change displayed as anxiety in later age.  It was 
proposed that the 5-HT projections in the PFC would most likely be affected, as the PFC is the 
last brain region to mature (Olmstead, 2006).  Whether the different developmental stages of 
adolescence would produce differences in anxiety-like behaviour due to synaptic plasticity is 
not possible to ascertain from the present results.  All three adolescent developmental periods 
resulted in a change in behaviour in adulthood compared to control animals.  Olmstead (2006) 
administered cocaine to adolescent and adult rats and found on a PFC-mediated task (simple 
discrimination set-shifting task) that synaptic plasticity within the PFC was altered by cocaine 
only in adult animals.  They concluded that adolescence was a period where PFC mechanisms 
are protected against drug insult and that this protection may enhance the exploration of novel 
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environments, risk-taking and sensation seeking (typical of adolescent behaviours), which 
conversely may increase the likelihood of experimentation with substances. Whether or not the 
drug treated animals in this study had alterations to the PFC is unknown and will require 
further research.  
DA involvement in drug addiction is more likely mediated by the structural and functional 
changes in the circuits that are modulated by DA, including the PFC (Goldstein & Volkow, 
2002). Abnormalities in DA neurotransmission are also important factors contributing to wide 
range of psychiatric illnesses, including affective disorders (Rodriguiz, Chu, Caron & Wetsel, 
2004). DA also plays a pivotal role in psychostimulant reinforcement but contributions from 
the NE and the 5-HT systems are starting to be recognised (Pierce & Kumaresan, 2006).  
Brown and Molliver's (2000) found that mice that lack the DA transporter would self-
administer cocaine, thereby challenging the DA hypothesis of addiction.  They therefore 
concluded that 5-HT neurons may also contribute to the rewarding effects of stimulant drugs.   
However, Fone et al. (2002) and McGregor et al. (2003) observed persistent behavioural 
changes after MDMA administration in the absence of any detectable 5-HT depletion.  5-HT is 
of interest due to its effect on anxiety-like behaviours (which this study investigated).  
Although there is ample evidence for the effect of earlier administration of stimulant drugs on 
later DA functioning and effects of MDMA on the 5-HT system, there is limited information 
about the role of 5-HT after BZP treatment.  Reports of the mechanisms of action involved are 
conflicting.  For example, Baumann et al. (2005) found that BZP administration caused a rise 
in 5-HT dialysate levels in the nucleus accumbens of rats. However, Simmler et al. (2014) 
argued that BZP is an indirect DA and NE agonist without 5-HT properties.  Research is 
suggesting that 5-HT also plays a role in behavioural change after MA treatment (Cappon et 
al., 1997; Kokoshka et al., 2000; & Zombeck et al., 2010). However, there is only one 
published study to date looking at the long-term effects of MA administration during the 
adolescent phase on later affective behaviours. 
This one study involved assessments of long-term effects of adolescent MA treatment on later 
depressive behaviour in mice (Joca et al., 2014).  The subjects received 2 days of MA 
treatment (4 x 7.5 mg/kg in 2-hour intervals) during PND30-31 and then randomly assigned to 
one of two later testing groups, defined as late adolescent (PND41-52) or adult (PND62-73).  
MA treatment increased depression-like behaviour in the forced swim test in both late 
adolescent and adult treated male and female mice.  The authors suggested that their results 
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were due to something more than MA's effect on the DA transporters, possibly a dysregulation 
of the HPA axis affected primarily the male treated mice.   
The HPA axis is the central mechanism in the brain's neuroendocrine response to stress. The 
hypothalamus, when stimulated, secretes the corticotropin-releasing hormone (CRH), which 
stimulates the pituitary gland to secrete the andrenocorticotropic hormone (ACTH) into the 
bloodstream.  In order to prepare the body to meet a challenging situation, ACTH then causes 
the adrenal gland to release cortisol.  This system works on a feedback loop and it is reported 
that damage or disruption to this feedback loop can affect normal responses to stress and the 
ability to regulate emotions, such as anxiety or low mood (see Panagiotakopoulos & Neigh, 
2014 for a comprehensive review).   
McCormick (2010) investigated social instability stress in adolescence and the risk of later 
consumption of DOA.  Rats were confined to a small ventilated container for one hour a day, 
then paired with a new peer in a new cage during PND30 - PND45, to produce social 
instability.  Rats were then tested both for the immediate social interaction effects and HPA 
functioning effects (PND46-52) and again at PND70-76 to investigate any lasting effects.  
Additionally, rats were tested at both periods on locomotor activation to nicotine and AMP.  
Their results suggested that both male and female rats displayed increased anxiety-like 
behaviour and increased locomotor sensitisation to psychostimulants.  However the 
behavioural effects were greater for male rats whereas behavioural responses to DOAs were 
greater for females.  These effects continued into adulthood.  Overall, male rats appeared more 
affected from the earlier administration of both BZP and MA in the current study.  This may 
have been due to disruption of the HPA axis which is implicated in anxiety disorders.  
Anxiety and behavioural measures 
This research utilised a battery of behavioural measures of animal anxiety, which tapped into 
approach/avoid conflicts in rats.  However, Ramos (2008) argues that emotionality in rats is 
multidimensional and different tests may be measuring different aspects of anxiety. The current 
study results were consistent for the light-dark box, with all treated rats predominately 
displaying increased anxiety-like behaviour that was maintained over time.  However, the 
results of anxiety-like behaviours' displayed in the Y-maze, EPM and SI test were not as 
straightforward.    
The Y-maze involves rats choosing to enter a novel environment (the changed arm) rather than 
a familiar one. This response has been associated with increased DA levels within the nucleus 
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accumbens (Adriani, Chiarotti & Laviola, 1998). Novelty is believed to be rewarding for rats.  
However, an alternative interpretation is that rats may be avoiding the familiar arm as it was 
associated with stress-related aversion (inability to escape) due to the 6 minute acquisition 
trails prior to testing. For the treated rats that spent a more time in and made more entries into 
the changed arm (all three BZP and MA doses and all three MA doses respectively, treated 
during PND41-50 and tested at PND120) it is possible that they displayed decreased fear of 
novelty or were reacting to their prior confinement. It seems more likely that for these treated 
rats the latter explanation is most likely as evidenced by their behaviour on the other measures.  
In the EPM, it is known that rats prefer the secure closed arms of the maze to the more 
threatening open arms (Pellow et al., 1985; Flint, 2003) and this preference is greater in more 
anxious animals. Albrecht-Souza, Borelli and Brandao (2008) reported that performance of rats 
in the EPM differs between their first trial in the maze and subsequent trials.  They suggested 
that on the first trial, the response is typically based on an approach-avoidance conflict.  On 
subsequent trials, there is a qualitative shift in the emotional state of the rat with its behaviour 
being motivated more by the learned fear acquired from the initial trial.  Therefore, with 
repeated trials the rat actively avoids the open arms and no long seeks an escape route.  
However, the current study suggests that the rats treated with all three doses of BZP during 
PND31-40 showed significantly decreased open arm entries and time spent on the open arms 
over all three testing phases, which is inconsistent with Albrecht-Souza et al (2008) hypothesis.  
However, rats treated during PND41-50 with BZP displayed decreased open arm exploration at 
the 30 day wash-out period and no significant effects at PND120, which suggests for these rats 
that they may have been motivated more by the learned fear at the second testing period.  
Conversely, rats treated with BZP (5 mg/kg) during PND51-60 displayed decreased open arm 
entries whereas the 0.5 mg/kg dose of MA increased time spent in the open arms at the 30 day 
wash-out period.  At PND120 it was only the higher doses of both drugs that produced 
decreased open arm exploration with no significant drug effects at PD200.   
In the SI test, not only was the apparatus novel but the pairing of one rat with an unfamiliar 
peer would have added to the novelty.  With the exception of increased social interaction 
shown by male rats treated with both BZP and MA during PND51-60 and tested at the 30  day 
wash-out period, and male rats treated with both drugs during PND31-40 and tested at 
PND120, the general pattern of results suggested increased anxiety-related behaviour that was 
more pronounced at the second testing period.  Novel environments are rewarding (Cain, Smith 
& Bardo, 2004) so that rats prefer novel stimuli over familiar (Hughes 1992).  While novelty 
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preference can be explained as avoidance of familiar stimuli, it possible that the increased 
social interaction with an unfamiliar peer shown for male rats provided an alternative reinforce 
to exploration of the novel environment.  As male rats have been shown to have higher levels 
of harm avoidance compared to females rats (Ray & Hansen, 2005) it is possible that 
exploration of the novel environment could have been more aversive than interaction with 
another rat.  
Sex Differences 
Most research continues to examine the effects of drugs in male rats exclusively (Hughes, 
2007; Zucker & Beery, 2010).  Beery and Zucker (2011) investigated sex bias in studies from 
ten biological disciplines for 2009 and reported that male bias was evident in eight of these.  
They also reported that women are diagnosed with anxiety disorder 2.25 times more often than 
men, but the majority of animal studies of anxiety and anxiolytic drugs use male rats 
exclusively. However, both female and males individuals use stimulant drugs, for varying 
reasons and any study of long-term behavioural change due to earlier stimulant use needs to 
address sex differences.   
Females are twice more likely to be diagnosed with depression than men, and have more 
symptoms, higher symptom severity and more self-reported subjective distress (Seney & 
Sibille, 2014).  Anxiety symptoms are almost always co-morbid with depression for women, 
whereas men are more likely to have co-morbid substance abuse.  This suggests different 
coping strategies for females compared to males.  Most literature suggests that males start 
experimenting with substances for the positive reinforcement that receive from them whereas; 
females are more likely to take drugs to reduce stress or psychological distress (Becker, Perry 
& Westenbroak, 2012).   
In 2008, substance dependence or abuse among youth aged 12 to 17 was similar for males 
(8.0%) to that for females (8.1%) (Johnston, O’Malley, Bachman, & Schulenberg, 2008).  
Rates are also similar for stimulant use for those younger than 25.  Generally, women report 
using stimulant substances at an earlier age (Becker et al., 2012), progress through the stages of 
addiction more quickly and have shorter periods of abstinence before relapse than males 
(Cummings, Gowl, Westenbroek, Clinton, Akil & Becker, 2011).  Female rodents generally 
exhibit a higher motivation for cocaine than male rodents.  However it is only with low doses 
that a significant difference between the sexes emerges (Cummings et al., 2011).  
 117 
 
Female rats treated with both BZP and MA during the three different adolescent exposure 
periods displayed fewer anxiety-related responses and higher locomotion than males, and this 
sex difference endured over time.  This was possibly due to the different brain maturation rates 
of male and female adolescent rats (Andersen & Teicher, 2000). During adolescence there are 
dynamic changes in the brains of both male and females, with the magnitude of alterations 
being greater for males.  In the striatum, DA D1 and D2 receptors are overproduced during the 
juvenile and adolescent developmental period in the male rat’s brain and subsequently 
eliminated during early adulthood.  In the female rat’s brain, D1 and D2 receptor numbers 
gradually increase to adult levels during adolescence, with no subsequent elimination 
(Andersen et al., 1997; Koenig et al., 2005; McFadden, Yamamotot and Matuszewich, 2011).  
Therefore, it is likely that since the male brain undergoes more dramatic developmental 
changes in the DA system, males may be more vulnerable to the long-term effects of stimulant 
drugs during the adolescent stage compared to females.  
In humans, sensation-seeking, novelty-seeking, reactivity to novelty and impulsivity increase 
the likelihood of substance abuse (Cummings et al., 2011).  Novelty has positive incentive 
capacity and exposure to novel environments increases DA release in the NAc (Rebec, 
Christensen, Guerra, & Bardo, 1997). Accordingly, it is conceivable that the hypoactivity 
displayed by the female treated rats was due to decreased sensitivity to the rewarding aspects 
of exploring a novel environment.  On the other hand, novelty also has some aversive-stressful 
components (Bardo, Donohew & Harrington, 1996).  Nonetheless, it is well established that 
novelty-elicited behavioural activation is largely dependent on the mesolimbic DA system 
(Bardo et al., 1996) and that the level of behavioural responding is correlated with activity of 
the ventral tegmental area DA neurons (Marinelli and White, 2000).  Therefore, regardless of 
whether the treated rats were responding to a rewarding or stressful stimulus, it is likely that 
the reduced activity by male treated rats, in all mazes is an indication of deficits in the 
mesolimbic DA system resulting from earlier BZP and MA treatment.  
However, since female rats generally show more locomotor activity than males (Becker, 1999), 
there was an unexpected lack of sex differences among rats treated at PND31-40 with both 
BZP and MA.  At the 30 day wash-out period, for all measures there were only two significant 
sex differences for female rats treated at PND31-40 that were not confounded by locomotor 
activity. These differences occurred for rats treated with BZP i.e., females emerged faster in the 
light/dark box and made significantly more open arm entries in the EPM than males.   The lack 
of sex differences may have been due in part to the younger age of the PND31-40 treated rats 
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at the 30 day wash-out period (PND70), as the literature suggests that rats become less anxious 
and more exploratory up until approximately PND90 (Ray & Hansen, 2005).  There are 
relatively few sex differences reported in young rats.  Alternatively, the lack of sex differences 
may be explained by immaturity of glutamatergic and DA systems which are still developing 
until after PND40 (Pu, Broening & Vorhees, 1996) and may be thus less likely to be affected 
by early drug treatment. The general pattern of results at the 30 day wash-out period suggests 
that as the age of adolescence treatment increases male rats are more affected, as suggested by 
male rats displaying more anxiety-related behaviour that is not influenced by locomotor 
activity.  
At PND120, both BZP- and MA-treated females emerged faster and displayed more locomotor 
activity in the open field. This suggests that MA treatment during PND31-40 increases general 
activity in female rats.   Additionally, all doses of BZP and MA affected outer rearing at 
PND120, yet only the highest doses of BZP and MA affected inner rearing, with female rats 
rearing significantly more than male rats. Significant drug x sex interactions occurred at 
PND200, with female rats increasing their latency to emerge from the light/dark box as the 
dose of BZP increased.  However MA-treated female rats displayed decreased anxiety in the 
EPM as shown by increased entries into and time spent on the open arms. Therefore, it is 
hypothesised that the behavioural outcomes of MA administered to female rats during PND31-
40, initially decreased their locomotor response, but over time also decreased their 
emotionality.  
Conversely, female rats treated with MA during PND51-60 displayed decreased anxiety from 
the first testing period which was maintained over time.  However, this appeared to be limited 
to the two lower doses of MA, with the female rats treated with 1.0 mg/kg displaying the least 
emotionality.  For male rats treated with MA the general pattern of results suggests that as the 
dose of MA increases, male rats display more avoidance of the novel environments, suggestive 
of increased anxiety-like behaviour.     
Behaviours observed but not investigated  
Although not a focus of investigation, the serotonin behavioural syndrome (low body posture, 
splayed hind limbs and head weaving; Haberzettl, Bert, Fink & Fox, 2013) was observed in 
three female rats (PND51-60) administered the highest dose of BZP on the eighth day of 
dosing.  Research suggests that this syndrome appears to result from the release of both 5-HT 
and DA and the blockade of the 5-HT transporter (Bull et al., 2003).  This is important as Gee 
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et al. (2005) reported human equivalents of this behaviour (seizures, severe respiratory and 
metabolic acidosis) in his work at Christchurch Hospitals Emergency Department, in which he 
collected data from 61 patients admitted to hospital with BZP toxicity.  Gee et al. (2005) stated 
that female patients had more severe effects than male patients. Similarly, Baumann et al. 
(2004) found administration of BZP and TFMPP (10 mg/kg) caused seizures in five out of 
seven rats that were treated with the combination of the two psychoactive substances. 
Although, there were no significant effects on weights for any of the treated rats compared to 
controls, the rats treated with BZP had constant diarrhoea, which was more evident in the 
higher doses and became more pronounced over time.  After drug administration the MA-
treated rats displayed some stereotypical behaviour, e.g. sniffing, rearing and grooming 
(Kitanka et al., 2010), in their home cage, which again was observed to be more evident in the 
higher doses of MA, however this behaviour decreased over the ten days. Another casual 
observation was that, by day three, a number of treated female rats were agitated (as reflected 
in their increased locomotor activity in home cage and hanging from the top of their home 
cages) when the researcher came to administer either BZP or MA.  On the other hand, over the 
course of 10 days, male rats displayed avoidant behaviours, such as remaining huddled in the 
corner of their home cages.  
Consistent and Inconsistent Findings 
As already mentioned, very few studies have been devoted to the particular issues explored in 
this study, and any studies to date examining the effect of adolescent psychostimulant exposure 
on later anxiety-like behaviours are scarce and largely ambiguous.   One of the few efforts in 
this regard has been the work of the current researchers. We administered 10 mg/kg (BZP) over 
10 consecutive days during PND45-55 to male and female rats.  Seventeen days later, the 
subjects were evaluated for anxiety-like responses emitted in the Y-maze, light/dark box and a 
social interaction test.  We reported evidence for the development of anxiety-like responses 
following BZP treatment in all three behavioural tests. Although the results of our 2006 study 
were generally consistent with the BZP results of the present investigation, they administered 
BZP during a later age period (PND45-55), which in the current study encompassed two 
different developmental periods (PND41-50 and PND51-60).  In addition, the present study 
utilised the experimental procedure of Vorhees et al. (2005) on the assumption that, as per 
these authors, PND41-50 would be a critical period of drug administration for later behaviour 
change.  In the present study BZP or MA administration during each of the three different 
stages of adolescent development affected later anxiety-like behaviour (albeit to different 
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degrees).  This contrasts with Vorhees et al. (2005) who concluded that MA-treated rats during 
PND41-50 showed impaired cognitive functioning at a 30 day wash-out period unlike those 
treated at PND21-30, PND31-40 or PND 51-60. However, as the study of Vorhees et al. (2005) 
was a dose-response experiment which assessed earlier MA toxicity on later cognitive 
functioning, it is possible that the mechanisms of action were different, or that their 
behavioural apparatus assessed different effects. 
 Findings of this study support other research suggesting earlier stimulant drug use affects later 
behaviour.  Regardless of the differences in drug or apparatus used or the abstinent period, 
similar increased anxiety-like behaviour has been found with cocaine (Estelles et al., 2007; 
Santucci & Maderia, 2008; and Santucci & Rosario, 2010), MDMA (Bull et al., 2004; Cox et 
al., 2014; Gurtman et al., 2002; Fone et al., 2002; Kolyaduke & Hughes, 2013[males only]; 
McGregor et al., 2003 and Morley et al., 2001), MP (Bolanos et al., 2003; Crawford et al., 
2013; Vendruscolo et al., 2008), MA (Joca et al., 2014) and BZP (Aitchison & Hughes).  
 
Other research has provided conflicting results.  For example, Labonte et al. (2012) reported 
decreased anxiety in AMP-treated adolescent rats as displayed in the EPM and Piper and 
Meyer (2004) showed decreased anxiety in the EPM after adolescent MDMA treatment.  
However, Modi, Yang, Swann and Dafnyl. (2006), report many animal studies correlating 
earlier MDMA use with lasting cognitive and behavioural deficits, including impairments in 
spatial memory and learning, increased anxiety-like behaviour and a weakened ability to react 
to stress as adults.  Similarly, Estelles et al. (2007) found the same results for adolescent 
cocaine-treated mice. Untangling these conflicting results is complicated and as no 
neurochemical analysis was used in the present study, inferences about causation must be 
tentative and drawn from previous work in which both behavioural and neurochemical data 
were reported.  
 
One area of research that can be tentatively related to the current study, is the impact of 
adolescent stress on later adult behaviours.  Drug use could be considered a stressor, as 
adolescence is a critical developmental period where life experiences can shape brain 
development either positively or negatively.  For example, Adriani, Deroche-Gamonet, Le 
Moal, Laviola and Piazza (2006) found environmental enrichment can reverse the detrimental 
effects of early life stressors.  However, most research suggests that early life stressors lead to 
increased anxiety in adulthood (McCormick, Mathews, Thomas & Walters, 2010).  For 
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example, Avital and Richter-Levin (2005) exposed male Wistar rats (PND26-28) to an elevated 
platform and then measured their locomotor activity at PND90 and found decreased activity, 
which they accounted for as enhanced anxiety at adulthood, evidenced by decreased open field 
activity and an increased startle response.  Schmidt et al. (2007) exposed PND28-84 CD1 male 
mice to group housing (four mice) changed twice weekly and found decreased OF activity at 
PND80. A similar result was reported by Sterlemann et al. (2008) with PND28-77 CD1 male 
mice, investigated in the OF at PND45, suggesting that effects of induced anxiety by early life 
stress can be maintained over time.   
Results utilising rats’ supports the above finding with mice.  Wright, Herbert and Perrot-sinal 
(2008) exposed male and female Long Evans rats to predator odour on PND40, 41, 44, 47 and 
48 and found decreased OF activity at PND60 and 61.  However, Toth, Avital, Leshem, 
Richter-Levin and Braun (2008) found rats exposed to 23 hour food restriction, an acute swim 
test (forced to swim for 10 minutes) and an elevated platform (PND 30 and 90) did not differ 
from controls at PND90 on the OF test.   Additionally, Ulys et al. (2006) found increased 
rearing in Sprague Dawley male rats that had been stressed at PND28, 35 and 60, when tested 
in the OF at PND68, and Toth et al. (2008) found decreased time in social interaction in a SI 
test, but no effect on number of encounters.  .   
There are some similarities to this previous research in effects of earlier drug administration on 
behaviour in the OF.  In the current research, rats treated with BZP (20 mg/kg) at PND31-40 
displayed more rearing behaviour at the 30 day wash-out period and PND120.  Likewise both 
BZP and MA treated PND41-50 rats displayed more rearing behaviour at PND120, however 
only the PND51-60 BZP- treated rats demonstrated this effect at the first testing period and 
conversely, the  MA- treated rats (2.0 mg/kg) made significantly fewer rears in the OF  at the 
30 day wash-out period. Female rats in all these conditions displayed significantly more 
rearing behaviour than similarly treated male rats.  However, with the exception of Wright et 
al. (2008), the researchers mentioned above used male rats exclusively. In contrast, with the 
exception of rats treated during PND41-50, treated rats in the present study displayed increased 
OF activity compared to saline controls.  Female rats again were more active than male rats in 
these conditions thereby supporting similar observations by Wright et al. (2008).   
In the EPM, Schmidt et al. (2007) described decreased time spent on the open arms and 
Sterlemann et al (2008) reported decreased open arm entries by CD1 male mice.  Ulys et al. 
(2007) found increased rearing in the EPM, in rats, supporting a similar result they obtained in 
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the OF.  Pohl, Olmstead, Wynne-Edwards, Harkness and Menard (2007) exposed Long Evans 
male and female rats to either chronic mild stress or severe sporadic stress during PND23-51, 
and investigated their behaviour on the EPM at PND70-91.  Males in the severe stress group 
showed exaggerated anxiety-like behaviour (e.g., jumping off the open arms), whereas females 
in the severe condition displayed other types of behaviour related to depression, such as 
decreased sucrose consumption.  For the mild stress condition, only the female rats showed 
signs of anxiety or depression in the form of reduced burying behaviour, decreased sucrose 
consumption and an exaggerated corticosterone response to cold-water immersion stress. 
However, McCormick, Smith and Mathews (2008) found that female rats that were stressed by 
daily 1 hour isolation, followed by housing with a new peer in a new cage) during PND30-45 
displayed increased anxiety on the EPM (time on open arms and open arm entries) at PND90 
only when in diestrus, whereas male stressed rats were observed to exhibit increased anxiety-
like behaviour continuously.   
The results from the current study support the above-mentioned research in terms of entries 
into and time spent in the open arms of the EPM for all three adolescent developmental ages at 
the 30 day washout period, although this seemed to primarily characterise BZP- treated 
subjects.  Rats treated with 0.5 mg/kg of MA during PND51-60 spent more time in the open 
arms than saline controls. At PND120, all three doses of BZP administered during PND31-40 
decreased entries into and time spent in the open arms. There were no significant dose effects 
for rats treated with either BZP or MA during PND41-50 on percentage of entries or time spent 
on the open arms. However, for rats treated with both BZP and MA during PND51-60 the 
results suggested that, as the dose of each drug increased, treated rats displayed more anxiety-
like behaviour.  Similar results were observed at PND200.   
Overall, there is a very limited amount of published research with which to compare the results 
of the present study.  And only assumptions can be made about what central processes might 
have been involved in the modification of brain development induced by adolescent exposure 
to the two drugs that led to long-lasting increases in anxiety-related behaviour.  In this latter 
respect, the present study supports and significantly extends the earlier findings of Aitchison 
and Hughes (2006) with BZP- treated rats, and of Joca et al. (2014) research with MA-treated 
mice.      
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Methodological Limitations 
The use of an animal model for the present research is confounded by the fact that the drugs 
were administered by the researcher and not self-administered by the animal.  As substance 
seeking is a key component of addiction this research did not address this and the 
neurobiological effects of BZP and MA may vary depending on whether the animal chooses to 
take the drug or not (Robinson & Kolb, 2004).  As mentioned above, there is a difference 
between an animal seeking the drug (Andersen, et al., 2002) and actually being given it 
(Brandon, et al., 2001).  However, in some brain regions both self-administration and 
experimenter administration produce the same changes.  For example, AMP administered 
either way increases the spine density in the NAc and PFC (Robinson & Kolb, 2004), 
therefore, affecting behaviour in a similar manner. Studies have demonstrated a difference 
between the two methods of delivery in different behavioural and neurobiological effects. 
However, Joffe et al. (2014) argue that not all the effects of substances are dependent on 
contingent administration and both methods have been utilised in addiction research.    
Another concern is the administration of both BZP and MA by way of intraperitoneal (i.p) 
injection.  Human users of BZP typically take the dose orally; MA is initially smoked before 
individuals’ progress in their addiction to intravenous injecting.  In this study voluntary oral 
administration of both drugs, as with other DOA, would be the optimal route of administration 
(Carlezon & Konradi, 2004), but there is no research to suggest that rats will orally take BZP.  
However, studies indicate that there is no protective effect of oral, as opposed to other routes of 
administration, and the effects of i.p. administration of AMP are similar to the effects of oral 
administration in rats (MacCann & Ricutre, 2004).  Moreover, i.p. administration is a relatively 
slow and gradual process similar to oral administration (Blanchard & Blanchard, 1999).  It 
must be stressed that all groups experienced i.p. exposure to either saline, BZP or MA and 
therefore the results cannot be attributed to differences in experimental procedure, but rather to 
the drugs themselves.   
A potential issue is the question of whether the behaviour that was observed was anxiety or 
something else. A current issue with animal tests of anxiety is that they are rarely validated, 
other than pharmacologically. The reason for this is that animal models of anxiety are 
complicated by no single behavioural or physiological measure reflecting anxiety alone 
(Pellow et al., 1985).  We cannot ask the rat whether it is anxious or afraid.  The results of this 
research were assumed to be assessing anxiety in the adult rat after adolescent MA or BZP 
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administration.  However, anxiety as a subjective component had to be inferred from 
behavioural measures.   
Other researchers utilising similar behavioural models report that animals experience stress, 
fearfulness, emotionality, suffering, reduced wellbeing or anxiety (Ramos & Mormede, 1998).  
The current research exposed the adult animal to psychologically aversive stimuli (novel 
environments, strongly illuminated areas, open spaces, social interactions) as opposed to 
physically aversive stimuli (electric shocks, food deprivation, submersion in water, extreme 
temperatures).  Some measures (Y-maze, EPM and light-dark box) allowed the animal to avoid 
the aversive stimulus.  The results of this study indicate that increased anxiety-like behaviour 
in adult rats followed BZP and MA exposure during the rat’s equivalent period of adolescence. 
The behavioural measures used for this study utilised the natural approach/avoidance conflict 
that rats display (File & Seth, 2003).  That is, a natural conflict between curiosity about a novel 
environment and avoidance of a potentially threatening environment.  However, whether or not 
this type of conflict is relevant to humans is uncertain. One study that throws some light on this 
concern is that of Blanchard et al. (2001), in which 161 male and female undergraduate 
students were interviewed.  The participants read a set of 12 scenarios based on defensive 
responding in rodents (e.g. magnitude of threat, the need to escape the situation, distance 
between the threat and the subject, ambiguity of the threat stimulus and the presence of a 
hiding place).  The authors concluded that the patterns of defensive behaviour and emotional 
responding were similar for rodents and humans (Blanchard, Hynd, Minke, Minemoto, & 
Blanchard, 2001) with no significant differences between males and females.  That is, humans 
(both males and females) will react in a similar way as rats to a present or potentially 
threatening conspecific or environment. This study was replicated by Shuama et al. (2008) 
utilising 324 medicine and psychology students of both genders and the authors supported the 
view that defensive behaviour is similar for humans and non-human mammals. Therefore, it is 
possible that the use of the animal model in this research can be extrapolated back to the 
human population namely, that the administration of BZP and/or MA during earlier 
development can impact on later anxiety-like behaviours.      
This research was based on evidence that adolescent brain development is a critical 
developmental period in which drugs can have long-term behavioural consequences that persist 
into adulthood. However, the conflicting results of this study suggest that there are differences 
in outcome, dependent on exactly what stage a substance is administered.  Future research 
assessing earlier stimulant use on later behaviour would benefit from neurochemical analyses. 
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Due to the inclusion of different treatment ages in the experimental design, the first testing 
period (after a 30 days washout period) inevitably meant that the rats were tested at slightly 
different ages.  Therefore, it is difficult to conclusively determine if the results obtained at this 
period were due to the age of testing or to the drugs’ effects. However, Vorhees et al. (2005) 
provide a sound rationale for adopting this approach namely, that after PND50, behavioural 
testing does not markedly differ as a result of age. The fact that the results for the different 
groups of animals remained largely consistent over time supported this rationale.  
Another potential limitation of this study is the issue of handling.  In the course of completing 
the present research, the author conducted a total of 16,380 trials, with each rat being handled 
(prior to and after trial) 39 times.  It is well-established that prior handling has anxiolytic 
effects in several testing situations (Hogg, 1996). There is also the possibility that repeated 
testing may have reduced the anxiety-inducing effects of the test environments.  However, as 
the control rats were exposed to the same experimental procedure it is unlikely that handling or 
repeated testing contributed significantly to the results.  
Methodological Strengths 
In humans, it is likely that a combination of experiences may lead to the development of 
psychopathologies, therefore making it difficult to establish causality.  Therefore, animal 
models represent a useful strategy to understand how early life events may affect the 
functioning of the central nervous system in adulthood, in terms of behaviour and its 
underlying mechanisms (Neto et al., 2012).   Furthermore, human studies are often 
retrospective and correlational (Wilkin et al., 2012).  Human users may often self-administer 
other drugs in addition to party pills. In many human studies there is little control over the 
amount of drug used, the purity of it and any polydrug habits of the subjects. As BZP was the 
main base drug in most party pills the present research provides a starting point for further 
research involving different drug combinations. Therefore, this study addressed the long-term 
effects of BZP and MA in a way that avoids the complex issues of polydrug use, drug purity 
and any pre-drug psychopathology that can possibly compromise human drug research 
(Koenig, et al., 2005). The animal model used in this study controls for the history, experiences 
and environmental conditions of the subject. As it is usually impossible to control for all of 
these in humans, this study provides an example of relatively uncontaminated BZP and MA 
effects. 
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An advantage of this study in measuring behaviour is that, because rats develop rapidly; the 
thirty days between the last exposures to BZP or MA and rats reaching adulthood was 
sufficient time to ensure that there was no residual direct drug action still affecting their 
performance (Snyder et al., 1998). In addition, the increased anxiety-like behaviour that was 
displayed from the twelve treated groups was unlikely to be due to the handling, weighing or 
experimental procedures because the control animals were treated in exactly the same way. 
 
Although direct extrapolation of findings from the present research to humans must be 
approached cautiously, many former animal models have been useful in predicting long-term 
responses in humans For example, Andersen et al. (2002) showed that chronic treatment with 
typical neuroleptic medications can induce brain morphological changes that are similar in 
rodents and humans (Andersen et al., 2002). One study of the metabolism of BZP in male 
Wister rats found that the same identified metabolites were found in the rats’ urine as was 
found in human urine (Staack, & Maurer, 2005). Notwithstanding, the half-life of MA in 
humans is 8 to 12 hours, but in rats it is closer to 1 hour.  Therefore if a person takes MA daily, 
the concentrations in plasma will gradually increase, however the same is not true for rats.  
Larger effects may have been displayed if the animals had received BZP or MA several times a 
day.  Nonetheless, the results obtained in this study may be applicable to a human population, 
bearing in mind that they concern subsequent effects of BZP and MA specifically, and do not 
include effects of other drugs that human users might also take. 
 
Although, this study did not use large doses or extended dosing regimens, this protocol was not 
intended to exactly replicate human consumption situations; rather it was intended to capture 
some of the aspects of regular dosing of three escalating doses of BZP and MA, during a 
critical period of adolescent brain development. A dose of 1.0mg/kg of MA is considered to 
slightly increase locomotor activity, whereas 3.0 mg/kg of MA produces much higher levels of 
motor activity without causing toxicity (Milesi-Halle et al., 2005).  Davison et al. (2001) 
reported that research conducted in both human and non-human primates showered long-term 
loses in DA and 5-HT function after chronic MA administration, and this was found in adult 
brains, so it goes without saying that because the adolescent brain is still developing, the 
administration of a non-toxic dosing regimen may have impacted in similar ways on both DA 
and 5-HT activity.   Notwithstanding, this research provides a valuable starting point for future 
research. 
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Additionally the purity of the drugs used in this study is a methodological strength.  In real life 
scenarios it is rare to find a pure form of a drug as many recreational drugs are made with 
ingredients that are easy to procure. As already stated, in New Zealand MA can be synthesised 
from general household products and BZP is often combined with other psychoactive 
substances.  The current study used pure research-grade BZP purchased from ABRC Gmbh & 
Co, Karlesruhe, Germany and pure crystal form MA donated by Environmental Science & 
Research Limited (ESR, Wellington, New Zealand).  
 
Implications 
This research did not address potential cross-sensitization and the implications of this could be 
far reaching.  Cross-sensitization is the increased response to a different drug due to early 
exposure to another drug (Landa et al., 2014). It is possible that the cohort of individuals who 
consumed what they considered to be legal highs may be more prone to the development of 
substance use disorders in later life.    
There is little empirical information on how stimulant exposure during the developmentally 
critical period of adolescence influences adult functioning, following extended periods of 
abstinence.  This is vitally important as a relapse can occur despite individuals maintaining 
long periods of abstinence and the fact that adolescent stimulant use has risen significantly in 
the last two decades.   The general consensus is that stimulant exposure during adolescence 
represents a greater risk factor for addiction (Schramm-Sapyta, Pratt & Winder, 2004) than 
exposure during adulthood and this leads to a greater possibility of the development of 
psychosocial dysfunctions and psychiatric symptoms. For example, King et al. (2010) found 
that adolescents who had been abstinent from MA for an average of 4-11 months had increased 
social anxiety and depression, following an average of 2-3 years of MA use.  Females under 
the age of seventeen years had scores significantly higher on the Symptom Checklist-90R 
(SCL-90) compared to female controls.  Therefore, the authors concluded that young female 
MA users may be more susceptible to, and stressed by social situations.  This is important as 
stress can further induce MA craving and use, followed by relapse after a period of abstinence.  
The implications of this study for the greater population could be far-reaching, regardless of 
whether or not there is full agreement about the validity of animal models in studying drug-
induced anxiety. The results support temporal ordering (i.e., substance abuse can precede mood 
disorders) and neuronal imprinting (i.e., effects of the drug are long-term) theories. BZP and 
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MA may interfere with the brain’s ability to reorganize neural circuits and earlier drug 
exposure could interfere with the cognitive advances that are made through development 
(Robinson & Kolb, 2004). This is critical as alterations in cognitive functioning may interfere 
with quality of life (Carlezon & Konradi, 2004), possibly because of difficulties in social 
cognition and decision-making (Rogers et al., 1999). For example, in a clinical investigation, 
the decision-making of 18 AMP and 13 opiate abusers, 20 patients with PFC damage and 26 
controls (matched for age and intelligence) was compared. They were assessed on decision-
making behaviour. The results included increased deliberation times to make a choice in the 
AMP, opiate and PFC damaged patients, and poorer quality of decision-making by PFC-
damaged patients and AMP abusers compared with controls. For the AMP abusers this was not 
due to increases in deliberation times, but was instead correlated negatively with the number of 
years of abuse. Interestingly, tryptophan depletion in the control group produced the same 
outcomes as shown by the AMP and PFC groups. Because tryptophan depletion reduces 
central 5-HT activity, the authors concluded that AMP abusers and patients with damage to the 
PFC were similarly affected, possibly because of deficits in the neuromodulation of 5-HT and 
its inter-connected systems (Rogers et al., 1999). 
 
The ability to quickly respond to objects, events and threats in the environment is essential for 
the survival of humans and animals alike (Gawronski & Cesario, 2013).  Although fear and 
anxiety are behaviourally very similar, anxiety is defined as a long-lasting state of 
apprehension that can become pathological if it becomes extreme, whereas, fear is prompted by 
imminent and potential real danger and serves to activate the individual to respond.  Anxiety is 
a future-oriented mood state that is associated with arousal and vigilance (Davis et al., 2010) 
and behavioural avoidance is a central feature of anxiety disorders.  In rats, anxiety induces 
avoidance behaviour that can reflect fear of novelty, whereas approach behaviour (e.g. 
exploration) reflects motivation to explore novelty. In the current research, the conflict between 
approach and avoidance was exploited.  However, it is possible that they do not represent ends 
of a continuum, but instead exert independent biological functions (Green et al., 2012).   
 Commencing early in life, anxiety disorders are among the most common mental disorders 
with an estimated one in fourteen people meeting diagnostic criteria at any one point in time 
(Baxter et al., 2012). No single brain structure or neurotransmitter controls the anxiety response 
system.  Instead, several interrelated systems operate together in complex ways to induce 
anxiety.  As discussed, the HPA axis and the limbic system (particularly the amygdala) act as a 
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mediator between the brain stem and the cortex, the PFC and other cortical and subcortical 
structures to evoke behavioural responses to potential threats and fear (Chaby et al., 2015).  
Adolescent treated rats in this study may have undergone an alteration to the HPA which led to 
increased anxiety when adult.  
Anxiety and cognition interact in a fundamental way, and several studies suggest that cognitive 
dysfunctions may be the primary presenting feature of anxiety (Ohl, 2003). There is also 
considerable research that suggests that the mechanisms that are involved in emotion are also 
involved in learning and memory (Conrad, Jackson, Wieczorek, Baran, Harman, Wright, Ryan 
and Korol, 2004; Wolf, Sun, Mangiavacchi, & Chao, 2004). As the results of this study suggest 
an increase in anxiety, the interrelationship between anxiety, cognition, learning and memory 
may lead to adolescent BZP and MA users experiencing more seriously adverse outcomes 
because their brain is not fully developed. Vorhees et al. (2005), found that when rats were 
treated with MA during PND41-50 they developed deficits in spatial learning/reference 
memory and sequential learning, whereas those treated before PND41 or after PND50 did not. 
Although, memory and learning were not directly measured in this study, DA and 5-HT are 
involved in emotion as well as learning and memory thereby suggesting some comparability 
with the findings of Vorhees et al. (2005) with respect to effects of MA, but also BZP.  
 
In conclusion, evidence provided in this thesis for increased anxiety-related behaviour 
following adolescent exposure to MA or BZP illustrates that alterations in emotionality are 
among the long-term effects of both of these drugs.  In particular, these results add to the 
limited literature indicating that stimulant exposure during adolescence has detrimental 
consequences for behaviour that extend and are maintained for long periods of time, possibly 
for the remainder of the rat’s life span.  
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Chapter 6: Future Directions 
This study highlights some important issues worthy of further investigation. For example, does 
the use of BZP during adolescence predispose the individual to later experimentation with 
other drugs?  In other words, are there young adults who starting using BZP as adolescents 
now using the very drug (MA) that BZP was supposed to reduce the harm of.   The neuronal 
imprinting theory was supported in this study, suggesting that early exposure to BZP leads to 
subsequent changes in adult behaviour. However, the alternative self-medication hypothesis 
was not examined. To fully examine the long-term effect of the administration of BZP in 
adolescence, investigations are needed with individuals who experience underlying mood 
disorders and who are possibly self-medicating with substances to alleviate negative emotions 
they might be experiencing. Finally, the ordering of dual diagnosis or temporal ordering of 
what precedes what, needs to be addressed. This study supports the theory that substance use 
precedes psychiatric disorder. However, the animals used were not genetically bred for 
underlying mood disorders, so testing for the possibility that a mood disorder leads to self-
medication was not possible. Additionally aggression has been associated with stimulant drug 
use (Kirilly, Benko, Ferrington, Ando, Kelly & Bagdy, 2006).  Aggression, impulsivity and 
risk-taking are all related to 5-HT depletion in the PFC and interrelated systems (Dawe & 
Loxton, 2004; Wills, Wesley, Moore & Sisemore, 1983). To examine whether the increased 
anxiety-like behaviour displayed by rats in this study is possibly connected also to aggression a 
resident-intruder test could be conducted.  For example, Homberg, Fattil, Janssen, Ronken, De 
Boer, Schoffelmeer and Cuppen (2007) found that homozygous SERT knockout rats displayed 
reduced aggression in the resident-intruder test.  Likewise, Centenaro, Vieira, Zimmermann, 
Miczek, Lucion and Martins de Almeida (2008) found a decrease in aggressiveness in a 
resident-intruder test, after microinjections of 5-HT1ᴀ and 5-HT1ᴃ receptor agonists into the 
PFC.  This suggests a possible relationship between anxiety and aggression and maybe due to 
the animals heightened state of arousal, involving the fight flight response (Cancela et al., 
2001).    
 
BZP was introduced into New Zealand under the harm reduction umbrella, yet there was no 
evidence to support this premise. It is possible that BZP may be useful for MA addicted 
individuals as the “agonist substitution” therapy involves administering substances that are less 
potent and less addictive than the DOA. This can be described as “normalisation” therapy, in 
which the administration of a less potent substance normalises deregulated neurochemistry 
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provoked by the DOA (Rothman & Baumann, 2003). However, the possibility that individuals 
will substitute MA for BZP needs to be further explored, possibly with a counter-balanced 
conditioned place preference design. Nonetheless, the results of this research suggest that both 
substances are potentially harmful for development of anxiety-like behaviour long after the 
drugs are removed from the system.  Yet, Hashimoto et al. (1992) suggest that BZP inhibits the 
reuptake of 5-HT which has been implicated in the rewarding properties of stimulant-like 
drugs, normalization therapy may work as a substitute for MA-dependent individuals. 
 
There is growing clinical evidence that the period of adolescence is a period of heightened 
vulnerability to the addictive properties of both legal and illegal drugs (Chambers et al., 2003). 
The results of this study support the idea of vulnerability to DOA during adolescence and, 
further research needs to continue to utilise adolescent male and female animals to answer 
questions that this research has raised.  For example, the lack of sex effects for female rats 
treated with BZP or MA during PND31-40 or the conflicting seemingly protective effect of 
MA administration to female rats treated during PND51-60.  Additionally, to assess cross-
sensitisation or the possibility that individuals who consumed BZP during adolescence, are 
more vulnerable to other stimulant use in later adulthood, a conditioned place preference may 
again help in answering some questions this research has raised (Bardo & Bevins, 2000).  
 
By using a counter-balanced conditioned place preference, the stage theory of addiction may be 
further examined. This could shed some light whether BZP may act as a gateway drug for 
further experimentation, with other DOA.  Secondly, will animals with underlying initial 
anxiety prefer to spent time in chamber associated with either BZP or MA, to alleviate negative 
emotions? This would address the self-medication hypothesis. Thirdly, as mentioned above, 
will MA dependent animals prefer BZP as a substitute for MA? This would test the assumption 
that BZP can act as a replacement drug for MA dependence, thereby, supporting normalization 
therapy. Finally the lack of neurochemical analyses in this study needs to be addressed. This 
would help clarify whether or not the increased emotionality displayed by the animals in this 
research was due to 5-HT or 5-HTT modification in the brain, especially the undeveloped PFC. 
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Chapter 7: Conclusions 
Substance use is a reality (Resnicow, Smith, Harrison, & Drucker, 1999) and no amount of 
research into the detrimental effects of drugs can prevent this actuality. However, this study 
opens the way for future understanding of the undesirable effects that could be observed in the 
next generation of individuals reaching adulthood. The administration of BZP or MA during 
this period may have caused a functional change in DA and 5-HT levels by altering modulation 
of the neurotransmitter release and/or altering the functional development of the PFC input, 
thereby leading to an increased risk of higher anxiety during adulthood. This higher anxiety 
during adulthood may lead to self-medication with illegal drugs, or worse still, dependence on 
these substances. Therefore, these ontogenetic changes, along with the fact that adolescence is 
the period of development when drug use is initiated, provide a compelling reason for future 
research into the long-term effects of adolescent BZP and MA use. The main limitation of the 
present study is clearly the lack of neurochemical analyses of the brains of the rats exposed to 
both drugs. While it is hypothesised that the observed effects on anxiety relate to the 
neurotoxic action of BZP and MA on the brain’s 5-HT systems, conclusive proof of this is 
lacking. Notwithstanding the lack of neurochemical analyses, and possible conflicting 
behavioural profiles displayed by the treated rats in different anxiety measures and over time, 
the general results of the present study are strikingly clear. Rats treated with BZP or MA in 
adolescence show increased anxiety-like behaviours in adulthood compared with untreated 
controls. 
 
The results of this research conclude that BZP and MA administered during adolescence 
affects later emotional behaviour, supporting the neuronal imprinting theory.  Due to New 
Zealand’s geographical separation and distinctive drug taking practices (limited access to well-
known DOA, for example cocaine, thereby resulting in individuals procuring substances with 
general household products), it appears that policy makers are playing an endless ‘cat-and-
mouse’ game with manufactures and users.  In that, as one new drug appears and becomes 
subject to legal controls, a new unrecognised and uncontrolled alternative substance is 
produced.  New Zealand’s clandestine chemists and manufacturers appear to be one step ahead 
of both the forensic scientists and the law, pushing further and further into the realm of untried 
and untested drugs. Collins (2007) summed up the consumption of BZP adequately, by 
reporting that 20% of the general population of New Zealand were "lab rats" for substances 
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that were not regulated, for which there had been no animal or clinical trials, and which are 
readily available at local corner stores and petrol stations.   
 Finally, this research provides further information that may assist in understanding the 
potential links from early substance use to later psychiatric and addiction problems.  Mental 
health and addiction treatment providers will need to screen and comprehensively assess earlier 
substance use, including earlier use of so-called legal substance to inform their treatment 
options and provide effective management of individuals with SUD.  
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